Master Question List for COVID-19 (caused by SARS-CoV-2)

Weekly Report

17 November 2020

For comments or questions related to the contents of this document, please contact the DHS S&T Hazard Awareness & Characterization Technology Center at HACTechnologyCenter@hq.dhs.gov.

Homeland Security

Science and Technology

CLEARED FOR PUBLIC RELEASE

FOREWORD

The Department of Homeland Security (DHS) is paying close attention to the evolving Coronavirus Infectious Disease (COVID-19) situation in order to protect our nation. DHS is working very closely with the Centers for Disease Control and Prevention (CDC), other federal agencies, and public health officials to implement public health control measures related to travelers and materials crossing our borders from the affected regions.

Based on the response to a similar product generated in 2014 in response to the Ebolavirus outbreak in West Africa, the DHS Science and Technology Directorate (DHS S&T) developed the following "master question list" that quickly summarizes what is known, what additional information is needed, and who may be working to address such fundamental questions as, "What is the infectious dose?" and "How long does the virus persist in the environment?" The Master Question List (MQL) is intended to quickly present the current state of available information to government decision makers in the operational response to COVID-19 and allow structured and scientifically guided discussions across the federal government without burdening them with the need to review scientific reports, and to prevent duplication of efforts by highlighting and coordinating research.

The information contained in the following table has been assembled and evaluated by experts from publicly available sources to include reports and articles found in scientific and technical journals, selected sources on the internet, and various media reports. It is intended to serve as a "quick reference" tool and should not be regarded as comprehensive source of information, nor as necessarily representing the official policies, either expressed or implied, of the DHS or the U.S. Government. DHS does not endorse any products or commercial services mentioned in this document. All sources of the information provided are cited so that individual users of this document may independently evaluate the source of that information and its suitability for any particular use. This document is a "living document" that will be updated as needed when new information becomes available.

The Department of Homeland Security Science and Technology Directorate is committed to providing access to our web pages for individuals with disabilities, both members of the public and federal employees. If the format of any elements or content within this document interferes with your ability to access the information, as defined in the Rehabilitation Act, please contact the Hazard Awareness & Characterization Technology Center for assistance by emailing HACTechnologyCenter@hq.dhs.gov. A member of our team will contact you within 5 business days. To enable us to respond in a manner most helpful to you, please indicate the nature of your accessibility problem, the preferred format in which to receive the material, the web address (https://www.dhs.gov/publication/st-master-question-list-covid-19) or name of the document of the material (Master Question List for COVID-19) with which you are having difficulty, and your contact information.

Table of Contents

Infectious Dose – How much agent will make a healthy individual ill?

What do we know?

The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. Based on experimental studies with humans exposed to other coronaviruses and animals exposed to SARS-CoV-2, the dose at which 50% of humans become infected is likely between 10 and 1,000 plaque-forming units (PFU).

- The UK plans to conduct human exposure trials in January 2021 to identify the infectious dose of SARS-CoV-2.[79]

Non-human primates

- A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (10^6 $TCID_{50}$ total dose).[578]
- Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of $4.75x10^6$ PFU (delivered through several routes), while marmosets developed mild infections when exposed to $1x10^6$ PFU intranasally.[425]
- Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (10^6 $TCID_{50}$).[169] Rhesus macaques infected with 2,600,000 $TCID_{50}$ of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.[474] A small study infected Rhesus macaques via ocular inoculation ($1x10^6$ $TCID_{50}$), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission. Interpretation is limited due to the small scale.[168]
- African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes),[730] mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU),[284] and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.[76]
- Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.[327]
- Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.[424]

Rodents and other animal models

- Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.[464]
- Golden Syrian hamsters exposed to 80,000 $TCID_{50}$ (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).[613] In a separate study, immunosuppressed Golden Syrian hamsters showed severe clinical symptoms (including death) after exposure to 100-10,000 PFU via intranasal challenge.[88]
- Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies,[123] and were also capable of infecting individuals in separate cages. In another study, older hamsters had more severe symptoms and developed fewer neutralizing antibodies than younger hamsters.[508]
- Mice genetically modified to express the human ACE2 receptor (transgenic hACE2 mice) were inoculated intranasally with 100,000 $TCID_{50}$ (~70,000 PFU), and all mice developed pathological symptoms consistent with COVID-19.[59]
- Transgenic (hACE2) mice became infected after timed aerosol exposure (36 $TCID_{50}$/minute) to between 900 and 1080 $TCID_{50}$ (~630-756 PFU). All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 $TCID_{50}$, ~504 PFU).[60] This paper has methodological caveats (e.g., particle size).
- Transgenic (hACE2) mice exposed intranasally to 400,000 PFU of SARS-CoV-2 develop typical human symptoms.[634]
- Ferrets infected with 316,000 $TCID_{50}$[343] or 600,000 $TCID_{50}$[571] of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.[343, 571] Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.[343] In one study, direct contact was required to transfer infection between ferrets,[343] however, transmission without direct contact was found in another study.[571] In a separate ferret study, 1 in 6 individuals exposed to 10^2 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to $>10^4$ PFU became infected.[588]
- Domestic cats exposed to 100,000 PFU of SARS-CoV-2 via the intranasal route developed severe pathological symptoms including lesions in the nose, throat, and lungs.[611] Even without symptoms, cats were able to transmit to other cats.[80]

Related Coronaviruses

- Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections,[97] with a plausible intranasal ID_{50} of 10 $TCID_{50}$ (~7 PFU).[84, 481] The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
- The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).[159, 162]
- Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection. Infection with higher doses result in severe syndromes.[24, 144, 391, 765]

What do we need to know?

We need to know the infectious dose for humans by all possible exposure routes in order to inform models, develop diagnostics and countermeasures, and inform disinfection efforts.

- Human infectious dose by aerosol, surface contact (fomite), fecal-oral routes, and other potential routes of exposure
- Most appropriate animal model(s) to estimate the human infectious dose for SARS-CoV-2
- Does exposure dose determine disease severity?

Transmissibility – How does it spread from one host to another? How easily is it spread?

What do we know?

SARS-CoV-2 is passed easily between humans (R_0 = 2.2-3.1, k = 0.2-0.7), through close contact and aerosol transmission.[39, 89, 270, 469] Vertical transmission from mother to fetus is possible[198, 680] but rare.[648]

- As of 11/17/2020, pandemic COVID-19 has caused at least 55,192,409 infections and 1,330,205 deaths globally.[323] In the US, there have been 11,214,231 confirmed COVID-19 cases and 247,356 confirmed deaths,[323] though both cases[36] and fatalities are underestimates.[499, 729] Estimates of human transmissibility (R_0) range from 2.2 to 3.1.[434, 516, 575, 739, 764]
- The US CDC and WHO acknowledge that SARS-CoV-2 can spread via aerosol or "airborne" transmission beyond 6 ft in certain situations[722] such as enclosed spaces with inadequate ventilation.[112] The CDC advises that most SARS-CoV-2 transmission is spread by larger respiratory droplets, not by small-particle aerosols,[112] though the distinction is loose.[699] Infectious virus aerosols have been found at varying concentrations (6 to 74 $TCID_{50}/L$[381] or 9 to 219 RNA copies/m^3[772]).
- The US CDC defines "close contact" as a combined total of 15 minutes within 6 feet of an infected person in a 24-hour period, regardless of whether either person was wearing a mask (e.g., cloth face covering, KN95 or N95 respirator).[109]
- Exhaled breath may emit 10^5-10^7 genome copies per person per hour;[431] the amount of infectious virus remains unknown.
- The risk of infection from fomites is believed to be low, though estimating contact hazard risk from estimated genome copies on surfaces (e.g., 2.5-105 copies/cm^2) is subject to considerable uncertainty.[285]

Individuals can transmit SARS-CoV-2 to others while asymptomatic or pre-symptomatic.

- Individuals may be infectious for 1-3 days prior to symptom onset.[48, 705] Pre-symptomatic[77, 349, 621, 631, 744, 768] or asymptomatic[56, 301, 430] patients can transmit SARS-CoV-2.[419] At least 12% of all cases are estimated to be due to asymptomatic transmission.[185] Approximately 40%[566] (between 15-56%) of infections may be caused by pre-symptomatic transmission.[101, 288, 416, 763] Individuals are most infectious before symptoms begin and within 5 days of symptom onset.[130]
- Asymptomatic individuals can transmit disease as soon as 2 days after infection.[630] There is some evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals,[92, 641] and asymptomatic children may have substantially lower levels of virus in their upper respiratory tracts than symptomatic children.[346]

Household transmission is rapid, but clusters from social settings are larger than those occurring in households.[20]

- Meta-analysis indicates that approximately 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the "attack rate"), with higher attack rates for symptomatic index cases, spouses of index cases, and adults.[347] In the US, symptomatic index cases resulted in transmission to approximately 53% of household members, regardless of index patient age.[267] This is higher than prior estimates,[347] likely due to intense follow-up reporting.[267] 75% of household infections occurred within 5 days of illness onset in the index case.[267] Attack rates are lower for non-household contacts.[483]
- SARS-CoV-2 may be spread by conversation and exhalation[14, 389, 595, 623] in indoor areas such as restaurants;[399] positive SARS-CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants[226] or worked in an office.[221] Clusters are often associated with large indoor gatherings,[380, 517] including bars, restaurants,[755] and gyms.[126]

Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.

- The majority of new infections come from relatively few infectious individuals (overdispersion parameter k = 0.2-0.5),[19, 193, 374, 378, 691] though estimates vary.[286] Phylogenetics shows the importance of SSEs early in the COVID-19 outbreak.[691]

Rates of transmission on public transit are unclear but appear low,[256] but the US CDC recommends masks during travel.[609]

- Several studies have identified plausible transmission on airplanes.[55, 137, 291, 339, 476] Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters (emission rate, infectious dose) remain uncertain.[614] Testing for this study assumed that mask wearing is continuous, the number of infected passengers is low, and passengers only face forward. The testing did not consider passenger movement, passenger conversations, or infected flight attendants.[614]
- On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.[297] Outbreaks have also occurred on public buses.[429]

The role of children in disease transmission is not well-understood, but confirmed pediatric cases in the US are increasing.[15]

- A large meta-analysis estimates that children are 44% less susceptible to COVID-19 than adults,[678] though modeling suggests that susceptibility does not differ substantially by age.[500] During April to May 2020 in the US, adults who worked in childcare centers acquired COVID-19 at rates similar to those without childcare exposure.[252] Adults in the UK living with children did not have elevated risk of COVID-19 infection,[235] though schools were closed for much of this time period (February-August).[2]
- Extensive contact tracing in India suggests that children readily transmit SARS-CoV-2 to other children.[378] In a Georgia summer camp, 260 of 344 tested attendees (campers and staff) tested positive for SARS-CoV-2 RNA.[636]

Undetected cases play a major role in transmission,[394] and most cases are not reported.[326, 585, 615]

Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.[407, 747]

What do we need to know?

We need to know the relative contribution of different routes of transmission (e.g., fomites, aerosols, droplets).

- How common is transmission from bodily fluids like semen,[390] urine,[632] and feces?[668]
- How infectious are young children compared to adults?
- What is the emission rate of infectious SARS-CoV-2 particles while breathing, talking, coughing, singing, or exercising, taking into account variation in viral load in the upper and lower respiratory tract?

Host Range – How many species does it infect? Can it transfer from species to species?

What do we know?

SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.[397, 411, 413] Current evidence suggests a direct jump from bats to humans is plausible.[78]

- Early genomic analysis indicates similarity to SARS-CoV-1,[773] with a suggested bat origin.[146, 773]
- Positive samples from the South China Seafood Market strongly suggests a wildlife source,[116] though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.[65, 147, 742, 754]
- Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago,[365] and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.[396] However, a survey of 334 pangolins did not identify coronavirus nucleic acid in 'upstream' market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network. These data suggest that pangolins are incidental hosts of coronaviruses.[383]

SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.

- Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1,[733] potentially explaining its high transmissibility.
- Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.[451]
- Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.[155]

Animals can transmit SARS-CoV-2 to humans.

- Infected mink have been linked to human infections in workers at mink farms.[509]

Several animal species are susceptible to SARS-CoV-2 infection.

- Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.[123, 343] In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.[1] SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.[368]
- Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques,[578] African green monkeys,[730] and Rhesus macaques.[425]
- Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (10^5 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.[238]
- Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route[611] or a combination of routes[277]), and can transmit the virus to other cats via droplet or short-distance aerosol.[611]
- Wild cats (tigers and lions)[703] can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.[436, 760] Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.[64] Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.[106]
- Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (10^4 or 10^5 $TCID_{50}$)[199] and are able to transmit virus to uninfected deer mice through direct contact.[264] Their capacity as a reservoir species is unknown.
- Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens[611], 100,000 PFU for pigs[611], ~70,000 PFU for pigs and chickens[596] all via intranasal route).[611] When pigs were inoculated by the oronasal route (10^6 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.[534]
- Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.[629]
- Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.[477]
- Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.[663]
- Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies[81] but exhibited no clinical symptoms.[611, 619]

What do we need to know?

We need to know the best animal model for replicating human infection by various exposure routes.

- What is the intermediate host(s) (if any)?
- Which animal species can transmit SARS-CoV-2 to humans?
- Can SARS-CoV-2 circulate in animal reservoir populations, potentially leading to future spillover events?

Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?

What do we know?

On average, symptoms develop 5 days after exposure with a range of 2-14 days. Incubating individuals can transmit disease for several days before symptom onset. Some individuals never develop symptoms but can still transmit disease.

- By general consensus, the incubation period of COVID-19 is between 5[375] and 6[706] days.[748] Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.[375] However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.[545] This could mean that 5-10% of individuals undergoing a 14-day quarantine are still infectious at the end.[545]
- There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U-shaped relationship between incubation period length and patient age[350] while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.[402]
- Individuals can test positive for COVID-19 even if they lack clinical symptoms.[56, 122, 271, 647, 768]
- Individuals can be infectious while asymptomatic,[113, 582, 647, 768] and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.[48, 341, 778]
- Peak infectiousness may be during the incubation period, one day before symptoms develop.[288] Infectious virus has been cultured in patients up to 6 days before the development of symptoms.[48]

It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.

- While the amount of virus needed to infect another individual is unknown, mild-moderate COVID-19 cases appear to be infectious for no longer than 10 days after symptom onset, while severely ill or immunocompromised patients may be infectious for 20-70[52] days after symptom onset; individuals can also transmit infection before symptoms appear.[685]
- Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.[298]

The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.

- On average, there are approximately 4[185] to 7.5[392] days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval). Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.[184, 550, 748]
- The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation,[29] meaning individuals tend to transmit virus for less time.

Individuals can shed virus for several weeks, though it is not necessarily infectious.

- Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).[428]
- Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.[384]
- Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.[706]
- Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.[684] The duration of the infectious period is unknown,[684] though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.[684]
- Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.[772]

What do we need to know?

We need to know the incubation duration and length of infectivity in different patient populations.

- What is the average infectious period during which individuals can transmit the disease?
- How soon can asymptomatic patients transmit infection after exposure?
- Does the incubation period correlate with disease severity or exposure dose?

Clinical Presentation – What are the signs and symptoms of an infected person?

What do we know?

Most symptomatic cases are mild, but severe disease can be found in any age group.[10] Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.[506] Fever is most often the first symptom.

- COVID-19 generally begins with fever, then cough and malaise.[369] In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.[752] Only 20% of emergency department patients testing positive for COVID-19 had fevers >100°F.[677]
- Most symptomatic COVID-19 cases are mild (81%).[647, 723] Initial COVID-19 symptoms include fever (87.9%),[46, 271] cough (67.7%),[271] fatigue, and shortness of breath.[114, 127, 299] Initial cough without fever may precede mild/moderate illness.[400] Chills, muscle pain,[475] sore throat, and loss of taste or smell[119, 524, 745] are also possible COVID-19 symptoms.[114] Gastrointestinal symptoms are present in approximately 9% of patients.[580] Neurological symptoms occur in up to 82% of individuals hospitalized with COVID-19.[406] Headaches are common, may persist for weeks, and may be associated with shorter disease duration.[100]
- Approximately 15% of hospitalized patients are classified as severe,[271, 647] and approximately 5% of patients are admitted to the ICU.[271, 647] Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.[432, 713]
- SARS-CoV-2 may attack blood vessels in the lung,[94] leading to clotting complications and ARDS.[18, 671] Clotting affects multiple organs[554] and is present in 15-27% of cases.[427] Other complications include pneumonia,[513] cardiac injury (20%),[612] secondary infection, kidney damage,[47, 628] pancreatitis,[34] arrhythmia, sepsis, stroke (1.6% of hospitalized patients),[453] other respiratory complications,[665] and shock.[271, 299, 687, 770] COVID-19 may increase stroke complications.[530]
- COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks[646] to months[99] after initial onset. Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.[272] This presentation may be distinct from acute COVID-19, and has been tentatively termed chronic COVID syndrome.[57]
- Adults can experience adverse inflammatory conditions[472] that increase disease severity and mortality.[704]
- Kidney disease prior to COVID-19 infection may increase COVID-19 disease severity.[495]
- Critically ill patients have consistently high viral loads in blood samples, indicating an inability to clear the virus.[129]
- Approximately 18.1% of COVID-19 patients have been diagnosed with a psychiatric condition (e.g., anxiety, insomnia, dementia) within three months of COVID-19 illness.[643]
- Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.[376]

Between 16% and 76% of cases are asymptomatic throughout the course of their infection.[92, 95, 366, 377, 384, 460, 489, 505, 637, 656]

The case fatality rate is unknown, but individuals >60 and those with comorbidities are at elevated risk of death.[647, 770]

- Cardiovascular disease, obesity,[21, 532] hypertension,[758] diabetes, and respiratory conditions all increase the CFR.[647, 770]
- The CFR increases with age (data from China and Italy): 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.[503]
- In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.[273] An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.[75]
- Smoking appears to be statistically associated with a higher likelihood of COVID-19 progressing to more severe disease.[521]

Minority populations are disproportionately affected by COVID-19.[468]

- Black, Asian, and Minority Ethnic populations acquire SARS-CoV-2 infection at higher rates than other groups[230, 263, 512, 542] and are hospitalized[246, 544] and die disproportionately.[293, 454] Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.[732] Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).[74] Social vulnerability, particularly in non-urban areas, is associated with greater SARS-CoV-2 transmission risk.[156]
- Pregnant women with COVID-19 appear to require ICU care more often than non-pregnant women,[537] have higher rates of preterm delivery,[728] and are less likely to present with fever and myalgia.[31] Severity in pregnant women may be associated with underlying conditions such as obesity,[31] and symptom severity may be predicted early.[462] Preterm births are more likely in symptomatic patients.[164] Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.[23]

Children are susceptible to COVID-19,[181] though generally show milder[128, 426] or no symptoms.

- Between 21-28% of children (<19 years old) may be asymptomatic.[426, 519, 546] Most symptomatic children present with mild or moderate symptoms,[262, 519] with few exhibiting severe or clinical illness.[738] In the US, 33% of children hospitalized with COVID-19 required ICU care, though the CFR was low (1.8%).[340] Severe symptoms in children[415] and infants[91, 426] are possible, and more likely in those with complex medical histories.[607]
- WHO[721] and US CDC[322] have issued definitions for a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C)[254] linked to COVID-19 infection.[576] The prevalence of this condition is unknown. Children with both severe and moderate initial symptoms can progress to MIS-C,[253] though it may be more likely to be preceded by fever.[752]

What do we need to know?

We need to know the true case fatality rate, as well as the duration and prevalence of debilitating symptoms.

- How does the asymptomatic fraction vary across age groups?
- How long, on average, are affected individuals unable to perform normal jobs and responsibilities?
- We need to understand the mechanism and clinical implication of recurrent, "long-haul" COVID-19.

Protective Immunity – How long does the immune response provide protection from reinfection?

What do we know?

Infected patients show productive immune responses, but the duration of any protection is unknown.[33, 718] Reinfection is possible. The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.

- Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.[216, 273, 577, 579] Mild COVID-19 infections can induce detectable immune responses for at least 3 months.[579] Antibody levels increase with disease severity[653] and are largely unaffected by patient age.[216] A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.[702]
- Neutralizing antibody responses are present within 8-19 days after symptom onset[418, 635] and can persist for months.[683] Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.[601] The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.[248] Asymptomatic cases generate weaker antibody responses to SARS-CoV-2.[136]
- Specific components of the immune response, such as IgG, may stimulate clotting factors that affect severity.[780]
- Strong, early inflammatory immune responses are associated with more severe clinical presentation.[165] There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.[473] A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.[473]
- Some patients do not develop detectable antibody responses,[642, 736] and their future protection is unknown. A small study (n=4) identified that children (<3 years) can seroconvert after asymptomatic infection, but level of protection is unknown.[334]
- SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.[497] T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.[779] While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA). [241, 610]
- In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.[190] Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.[96, 740]

Reinfection with SARS-CoV-2 is possible, but the frequency of reinfection is unknown.

- Researchers in Hong Kong[355] and the US[652] have identified COVID-19 reinfections. Reinfections have been either less[355] or more severe[652] than the initial infection. The infectiousness of re-infected individuals is unknown.
- Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days[170] or 35 days[125] after initial exposure resulting in no clinical symptoms. Ferrets infected with 10^2-10^4 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.[588]

The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.[482]

- Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.[440] Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.[485] Cross-reactivity from seasonal coronaviruses also enhances the immune response toward the S2 unit of the SARS-CoV-2 Spike protein.[485]
- Two studies identified key components of the adaptive immune system ($CD4^+$ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.[86, 266] These studies also identified Spike protein responses in $CD4^+$ T cells of ~30-40% of unexposed patients,[266] suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.[86, 266] Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross-reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.[379]
- Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.[602] Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2,[541] though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.[658]

Immune responses appear to differ by sex and age and may contribute to differences in symptom severity.

- The immune responses of females differs from males, namely through a stronger T-cell response and lower levels of some inflammatory cytokines.[639] Additionally, antibody levels may differ between males and females, supporting the notion that greater inflammatory responses in males contribute to their elevated disease severity.[355]
- Symptom severity in adults does not appear to be due to a lack of an adaptive immune response; rather, early action of the innate immune response may affect disease severity in both adult and pediatric/adolescent cases.[535] Children and adults have different immunological responses to SARS-CoV-2; adults with more severe symptoms develop stronger neutralizing antibody responses than those with milder symptoms, and this severity-dependence is not observed in children.[708] Additionally, children do not develop robust antibody (IgG) responses to the SARS-CoV-2 nucleocapsid (N) protein.[708]

What do we need to know?

We need to know the frequency and severity of reinfection, as well as the protective effects of immune components.

- How do different components of the immune response contribute to long-term protection?
- How does initial disease severity affect the type, magnitude, and timing of any protective immune response?

Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?

What do we know?

Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals. Screening solely by temperature or other symptoms is unreliable.

- The US CDC recommends that anyone, including those without symptoms, who has been in contact with a positive COVID-19 case should be tested (as of 9/18/2020).[120] The CDC advises that recovered patients need not be tested for SARS-COV-2 again within 3 months of recovery unless symptoms re-develop; this advice does not imply protection from re-infection.[115]
- The timing of diagnostic PCR tests impacts results. The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.[360] Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.[410]
- The duration of PCR-detectable viral samples is longer in the lower than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.[437] After 10 days post-infection, alternative testing methods (e.g., lower respiratory samples) may be necessary.[437]
- Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened),[180] and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.[387]
- Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid,[694] although evidence is mixed.[724] Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.[766] Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.[93] Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR,[587] and other work examining breath-based samplers is ongoing.[605]
- Diagnostic test results from at-home, mid-nasal swabs were comparable to clinician-conducted nasopharyngeal swabs, though false-negatives were observed in individuals with low viral titer.[443]
- Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.[283]
- Asymptomatic individuals have a higher likelihood of testing negative for a specific antibody (IgG) compared to symptomatic patients, potentially due to lower viral loads (as measured by RT-PCR).[711]
- Tests from the US CDC are available to states.[104, 113] Rapid test kits have been produced by universities and industry.[68, 72, 154, 208, 675] The CRISPR-Cas12a system is being used to develop fluorescence-based COVID-19 diagnostic tests.[178, 303, 692] India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.[5]
- Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.[455]
- Immunological indicators[53, 192, 237, 245, 287, 302, 536, 633, 688, 757] fasting blood glucose levels,[693] and oxygen levels[345] can identify future severe cases,[138] and decision-support tools for diagnosing severe infections exist.[444, 617, 737]
- As of 20 October, the FDA has approved 281 tests under EUAs, including 219 molecular, 56 antibody, and 6 antigen tests,[233] including one for detecting neutralizing antibodies from prior SARS-CoV-2 infection.[200]
- Pooling samples and conducting RT-PCR tests may expand testing capability.[457]
- Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.[543]
- High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.[531] A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.[82, 234]
- Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.[188]
- Artificial intelligence is being used to differentiate COVID-19 from other respiratory ailments via patient coughs.[363]
- Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.[478]

Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.

- Repeated serological testing is necessary to identify asymptomatic[540] and other undetected patients.[592] Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.[627]
- Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.[371, 714] Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.[408] The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.[206]
- SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance,[25] and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.[525] Wastewater sampling for SARS-CoV-2 should use ultrafiltration methods, rather than adsorption-extraction techniques.[319]

What do we need to know?

We need to identify additional factors that affect the accuracy of serological or PCR-based diagnostic tests.

- How long do antibody targets of serological assays persist, and after what point are they not informative for prevalence?
- What is the relationship between disease severity and the timing of positive serological assays?

Medical Treatments – Are there effective treatments?

What do we know?

There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.

- There is some evidence that earlier intubation of COVID-19 patients reduces mortality,[306] but results are mixed.[441]

Remdesivir may reduce symptom duration in hospitalized patients, but there is no evidence that it reduces mortality.

- Remdesivir may reduce the duration of symptoms in infected individuals, from 15 days to 10 days on average.[67] The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older,[211] with an Emergency Use Authorization for other patient groups.[202, 487] Remdesivir with anti-coronavirus immunoglobulin (ITAC) is being investigated in clinical trial.[488]
- A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.[514] An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.[700]

Hydroxychloroquine provides limited to no clinical benefit.[218, 600]

- Hydroxychloroquine does not prevent infection as either pre-[17, 250, 551] or post-exposure prophylaxis,[83, 458] does not benefit mild-moderate COVID-19 cases,[103] was associated with adverse cardiac events in severely ill patients,[336] does not reduce mortality,[3] and increases mortality when combined with azithromycin.[218] The FDA revoked its EUA on 6/15/20.[201]

Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.[655]

- Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen,[295] and no benefits in patients who did not need oxygen or ventilation.[295]
- A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.[626] Four separate, smaller trials of corticosteroids (n<152) were stopped early.[42, 173, 393, 654]
- The benefits of glucocorticoids may depend heavily on patient inflammation.[335] In several studies, high doses of steroids were associated with elevated mortality,[409, 466] though low-moderate doses can reduce mortality in patients with ARDS.[735]

Convalescent plasma treatment is safe and appears to be effective when administered early, though evidence is mixed.[523]

- A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.[307, 329] Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission,[591] and donor plasma with higher antibody levels appears more effective.[330, 438, 555]
- On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.[212]

Anticoagulants may reduce COVID-19 mortality in hospitalized patients.

- Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.[479] Anticoagulant use was associated with lower mortality in the severely ill,[515] but the correct dose is critical to avoid complications.[315] A small Phase II clinical trial found that enoxaparin significantly reduced the need for mechanical ventilation when used therapeutically.[385]

The benefits of tocilizumab are unclear.

- While tocilizumab appears to show a 12% reduction in mortality in treated patients,[435] a randomized clinical trial found no effects on mortality,[289] and other evidence suggests that it may be beneficial only in certain circumstances.[290, 463, 480]

Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.

- Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.[404] Regeneron's REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.[561] However, preliminary data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients[405] or those with high oxygen requirements.[559] Regeneron has applied for Emergency Use Authorization for its therapy.[560] Other antibody products are being tested in humans and appear safe,[681] including CT-P59 from Celltrion, which reduced patient recovery time.[118]
- Several interferon-based treatments show promise, including beta-1b,[304, 549] beta-1a,[158] alpha-2b,[528] and kappa.[239] A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity,[465] though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.[514]
- Anakinra has shown clinical benefits in small observational studies.[102, 141] Favipiravir may reduce the duration of clinical symptoms[179] and reduce the time for viral clearance.[240] Bradykinin inhibitors are being investigated as COVID-19 treatments,[666] due to the potential role of bradykinins in disease.[247] Statins[439, 589] and RAAS inhibitors[697] (for hypertension) do not appear to elevate COVID-19 risk.[565, 622] Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients,[640] and elderly COVID-19 patients who had taken vitamin D supplements in the year before infection showed less severe COVID-19 symptoms.[44] Acalabrutinib may improve patient oxygenation,[581] and is being included in large clinical trials (SOLIDARITY).[362] Colchicine may reduce rates of intubation and mortality.[593] Fluvoxamine may reduce clinical symptoms.[386] There is no clinical benefit from combination ritonavir/lopinavir.[98, 244, 265, 401]
- Androgen levels have been suggested as a factor in disease severity in men,[260, 467, 686] and treatment options are in trial.[261, 442]

What do we need to know?

We need clear, randomized trials for treatment efficacy in patients with both severe and mild/moderate illness.

- Does time to viral clearance correlate with symptom severity or time to symptom resolution?
- What treatment, or combination of treatments, is most effective for different disease severities and patient demographics?

Vaccines – Are there effective vaccines?

What do we know?

Work is ongoing to develop and produce a SARS-CoV-2 vaccine, and early Phase III trial results are promising.

Phase III Trials (testing for efficacy):

- Preliminary results for the mRNA candidate BNT162b2 (from BioNTech and Pfizer) show greater than 90% efficacy at the first Phase III interim endpoint (94 confirmed infections). The study, which targets 44,000 people, will continue, and Pfizer plans to submit an Emergency Use Authorization application to the US FDA in the coming weeks.[533]
- Moderna released interim results from the Phase III trial of their mRNA vaccine candidate (mRNA-1273), showing 94.5% efficacy in 95 COVID-19 positive volunteers (90 from placebo group, 5 from vaccine group).[461]
- University of Oxford and AstraZeneca's adenovirus candidate (now called AZD1222) has begun Phase II/III human trials.[510]
- Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.[618]
- Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates, one by the Wuhan Institute of Biological Products and the other by Beijing Institute of Biological Products.[63]
- Janssen, with Johnson and Johnson, has begun a Phase III clinical trial with 60,000 participants for their adenovirus Ad26.COV2.S candidate.[320]
- Russia's Gamaleya will begin a Phase III clinical trial for its adenovirus-based vaccine candidate (COVID-Vac-Lyo).[243, 558]
- CanSino's Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.[774]
- Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.[491]
- Baharat will begin a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people[557] in India.[645]
- Medicago, with GlaxoSmithKline, have announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).[268]

Phase II Trials (initial testing for efficacy, continued testing for safety, continued dose-finding):

- Inovio has begun a Phase II trial of their INO-4800 DNA vaccine candidate.[311]
- Imperial College London has begun Phase I/II trials of their RNA vaccine candidate, LNP-nCoVsnRNA.[493]
- Phase I/II trials have begun for vaccine candidates from Zydus Cadila (ZyCoV-D, DNA plasmid)[781] and Baharat (Covaxin, inactivated rabies virus used as carrier for SARS-CoV-2 proteins).[197]
- Anhui Zhifei has registered a Phase II clinical trial for their RBD-Dimer vaccine candidate.[43]
- Novavax has begun Phase II tests of its NVX-CoV2373 recombinant subunit vaccine candidate.[7]
- CureVac has begun a Phase II trial of their mRNA candidate CVnCoV.[153]
- Based on unpublished Phase I/II results, Russia has approved a second COVID-19 vaccine, EpiVacCorona.[143]
- Merck has initiated Phase I/II clinical trials for their modified measles vaccine (V591).[452]
- Biological E Limited (with Baylor College of Medicine and Dynavax) launched a Phase I/II trial of their vaccine candidate.[189]

Phase I Trials (initial testing for safety):

- mRNA vaccines: Chinese Academy of Military Sciences (ARCoV),[166] Arcturus (ARCT-021),[45] and Thailand's Chula Vaccine Research Center (ChulaCov19).[140]
- Adenovirus-based vaccines: ReiThera (GRAd-COV2),[563] Vaxart (oral vaccine, VXA-CoV2-1),[672] and ImmunityBio (hAd5).[310]
- Inactivated vaccines: Chinese Academy of Medical Sciences,[599] Immunitor LLC (V-Sars),[449] Kazakhstan's Research Institute for Biological Safety Programs (QazCOVID),[569] Shenzhen Kangtai,[332] Russia's Chumakov Center,[644] and ERUCOV-VAC.[361]
- Recombinant subunit vaccines: Vaxine Pty (Covax-19),[673] Clover Biopharmaceuticals (SCB-2019),[448] the Chinese Academy of Sciences (RBD-Dimer),[421] Medigen Vaccine Biologics (MVC-COV1901),[450] the University of Queensland (UQ),[547] the Finlay Vaccine Institute (Soverana 01),[502] Sichuan University,[743] Sanofi Pasteur,[594] and the Jiangsu Province CDC (Sf9).[324]
- DNA vaccines: Genexine (GX-19),[251] AnGes (AG0301-COVID19),[41] Entos (VAX-001),[194] and OncoSec (CORVax12).[501]
- Other vaccine platforms: lentiviral vectors (LV-SMENP-DC),[446] oral bacTRL-Spike candidates,[445] dendritic cells (DC-ATA by Aivita),[447] plant-derived virus-like particles (Kentucky BioProcessing[71]), measles vectors,[452, 520] baculovirus vectors,[22] mixed protein/peptide candidates,[674] influenza virus vector vaccine nasal spray (DelNS1-2019-nCoV-RBD-OPT1),[701] peptide based vaccines (UB-612[151] and pVAC[659]), vaccinia virus vectors (MVA-SARS-2-S),[278] vesiculovirus vectors,[318, 712] tetanus fusion vaccines (Sovereign 2),[217] and synthetic, mutated SARS-CoV-2 virus (COVI-VAC).[145]

Globally, there are 6 vaccine candidates that have received broad use approval or Emergency Use Authorization.

- CanSino's Ad5-nCoV vaccine has been approved for use in the Chinese military,[624] Gamelaya[9] and the Vector Institute[143] have been given conditional approval in Russia, SinoVac's CoronaVac candidate has been approved in China for limited emergency use,[11] and two of Sinopharm's vaccine candidates have been approved for use in the United Arab Emirates.[167]
- The US FDA has guidance for vaccine sponsors regarding the data needed to support Emergency Use Authorization.[207] In the US, vaccines must achieve 50% efficacy (e.g. reduction of viral shedding, risk of illness) for 6 months for approval.[203]

What do we need to know?

We need published results from Phase I-III trials in humans to assess vaccine efficacy and safety, and length of immunity.

- Safety and efficacy of vaccine candidates in humans, particularly from Phase III trials.

Non-pharmaceutical Interventions (NPIs) – Are public health control measures effective at reducing spread?

What do we know?

Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously. Public health notifications increase adherence to policies.[225]

- Social distancing and other policies are estimated to have reduced COVID-19 spread by 44% in Hong Kong[152] and reduced spread throughout China,[356, 359, 364, 422, 433, 690] Europe,[249, 333] and the US.[353] In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.[183] In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.[751] Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.[398]
- US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.[604] Modeling suggests that widespread use of facemasks is effective at reducing transmission[484] even when individual mask efficiency is low,[191] though their benefits are maximized when most of the population wears masks.[227]
- In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.[149] School closures and cancellation of large gatherings had smaller effects.[149] Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.[331] Adherence to social distancing policies depends on income.[707] Telework policies may reduce new cases.[221]
- Mobility[228, 370] and physical contact rates[321] decline after public health control measures are implemented. Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.[54, 282] Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.[471]
- A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.[215, 351] School closures alone appear insufficient,[317, 364] though likely reduced mortality in the UK[570] and the US.[51]
- Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.[126] Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.[337]
- Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies,[275] and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.[305] In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.[507]

Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.[524]

- Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.[182]
- Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.[294]
- The US CDC has indicated that face masks inhibit transmission by both reducing the number of exhaled particles from infectious individuals, as well as reducing the number of inhaled particles when worn by uninfected individuals.[111]

Due to the importance of superspreading events in COVID-19 transmission, particular focus should be placed on minimizing large gatherings where superspreading events are more likely.[725]

- Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.[121]
- There are multiple types of superspreading events, and different policies are required to mitigate risks from each.[32]

Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.

- In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.[631] Contact tracing and high levels of testing and physical distancing[358] may limit COVID-19 resurgence.[27, 219]
- Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.[242]
- Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.[657] Testing is critical to balancing public health and economic costs.[657] Rolling interventions may be necessary.[749] Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.[280]
- Quarantining whole households may increase the efficiency of testing.[28]
- Synchronizing public health interventions across US state lines may reduce the total number of required interventions.[583]
- Modeling indicates that COVID-19 is likely to become endemic in the US population, with regular, periodic outbreaks, and that additional social or physical distancing measures may be required for several years to keep cases below critical care capacity in absence of a vaccine or effective therapeutic.[344] Results depend on the duration of immunity after exposure.[344]

What do we need to know?

We need to understand measures that will limit spread in the winter, particularly in indoor environments.

- How effective are school closures when COVID-19 prevalence in the community is high? Low?
- How will holiday travel from colleges and universities impact COVID-19 case growth?

Environmental Stability – How long does the agent live in the environment?

What do we know?

SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity. Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.

Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.

- Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).[73] Persistence is reduced with warmer temperatures (37°C), and enhanced at colder temperatures (4°C).[281]
- SARS-CoV-2 was shown to be stable up to 7 days (25-27°C; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.[417] At 22°C, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.[281]
- SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22°C.[135] After 3 hours (22°C, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.[135]
- At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).[8, 312, 603]
- SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23°C, 40% RH)[669] and infectious virus can be recovered from a surgical mask after 7 days (22°C, 65% RH).[135]
- SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.[470]
- It is estimated that at least 1,000 viral particles per 25 cm^2 are needed to detect SARS-CoV-2 RNA on surfaces.[518]

In the absence of sunlight, SARS-CoV-2 can persist on surfaces for weeks.

- In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20°C and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.[574] This value is longer than other stability estimates,[134, 574, 669] potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.[574] In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.[556]
- The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.[176]

Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.

- It does not appear that pollen or air particulates are carriers of SARS-CoV-2,[187] despite some country-level associations.[61]

SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.

- DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.[175] Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.[767]
- Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 µm mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).[598] In dark conditions, the half-life of aerosolized SARS-CoV-2 is approximately 86 minutes in simulated saliva matrix.[598] Humidity alone had no significant impact on aerosolized virus survival.[598]
- SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 µm, tested at 21-23°C and 65% RH),[669] retaining infectivity for up to 16 hours in appropriate conditions (23°C, 53% RH, no sunlight).[213]

Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.

- RNA in clinical samples collected in viral transport medium is stable at 18-25°C or 2-8°C for up to 21 days without impacting real-time RT-PCR results.[620] RNA in clinical samples is also stable at 4°C for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL). Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25°C) resulted in unstable sample concentrations.[527]

There is currently no evidence that SARS-CoV-2 is transmitted to people through food.

- There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections,[314, 716] though several outbreaks have a hypothesized food origin.[279] Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.[567]
- SARS-CoV-2 is susceptible to heat treatment (70°C) but can persist for at least two weeks at refrigerated temperatures (4°C).[134, 553] SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20°C.[224]

What do we need to know?

We need to quantify the duration of SARS-CoV-2 infectivity on surfaces, not simply the presence of RNA.

- We need to determine the concentration of viral particles per area needed to detect SARS-CoV-2 RNA on surfaces.
- It is unclear how viability of SARS-CoV-2 is affected across the food supply chain.

Decontamination – What are effective methods to kill the agent in the environment?

What do we know?

Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.

- Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.[357]
- Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.[133]
- EPA has released a list of SARS-CoV-2 disinfectants that have been tested against SARS-CoV-2 specifically.[195]
- Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.[504] Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.[342] Chlorhexidine digluconate may be ineffective.[50]
- Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).[69]
- Efforts are ongoing to create paint-on surfaces that can rapidly inactivate SARS-CoV-2.[66]
- Under an emergency exemption, the US EPA permitted Texas and American Airlines to use a product manufactured by Applied BioScience as a surface coating capable of inactivating SARS-CoV-2 within 2 hours, for up to 7 days.[196]
- Iodine-based antiseptics may be able to decontaminate nasal passages, though any influence on transmission is unknown.[236]
- A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme®) effectively inactivated SARS-CoV-2 *in vitro*; additional tests are necessary to determine any clinical benefit.[274]
- Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.[590]
- Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).[26, 660]
- In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity;[625] Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.[715]
- Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.[85]
- Masks with laser-induced graphene have previously shown antibacterial properties,[300] and may facilitate mask decontamination, particularly when masks are exposed to sunlight.[30]

Several methods exist for decontaminating N95 respirators[494] and other PPE.

- Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor): UV radiation, heating to 70°C, and vaporized hydrogen peroxide (VHP).[223] Ethanol (70%) was associated with loss of physical integrity.[223] Dry heat and UV decontamination can also be used under certain conditions.[222]
- Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.[572] Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.[204]
- The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals,[87] though fit failure after reuse remains a concern.[403]
- Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.[526] Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.[13] Stacking respirators may increase decontamination rates without compromising efficiency.[586] Peracetic acid may be effective in combination with VHP.[325]
- Pulsed xenon ultraviolet light was able to decontaminate SARS-CoV-2 on respirators with 1-5 minute exposures.[616]
- Wet heat (65°C for 30 minutes) in a multicooker can decontaminate N95 respirators inoculated with SARS-CoV-2.[177]
- Methylene blue (in combination with visible light) is being investigated for decontamination of N95 respirators.[664]
- Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.[750]
- Heat treatment (56°C) is sufficient to kill coronaviruses (not SARS-CoV-2 explicitly),[548, 769] though effectiveness depends partly on protein in the sample.[548] Coronaviruses may be resistant to heat inactivation for up to 7 days when stabilized in stool.[649-650] Coronaviruses are more stable in matrixes such as respiratory sputum.[186] Dry heat (100°C, 5% RH for 50 minutes) was able to decontaminate N95 respirators inoculated with several viruses, but has not been tested on SARS-CoV-2.[498]
- Forced air ozone reactors may be able to decontaminate surgical gowns, though SARS-CoV-2 tests are needed.[142, 414]

What do we need to know?

We need additional SARS-CoV-2 decontamination studies, particularly with regard to PPE and other items in short supply.

- Does contamination with human fluids/waste alter disinfectant efficacy profiles?
- How effective is air filtration at reducing transmission in healthcare, airplanes, and public spaces?
- We need to know how to efficiently and effectively decontaminate whole rooms and large spaces.

PPE – What PPE is effective, and who should be using it?

What do we know?

Face masks appear effective at reducing infections from SARS-CoV-2. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.

- Healthcare worker illnesses[647] demonstrates human-to-human transmission despite isolation, PPE, and infection control.[597] Risk of transmission to healthcare workers is high.[564] Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.[696] Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.[573] Universal masking policies also reduced the rate of new healthcare worker infections.[695, 776] Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.[486]
- A modeling study suggests that healthcare workers are primarily at risk from droplet and inhalation exposure (compared to contact with fomites), with greater risk while in closer proximity to patients.[328]
- "Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield)."[108] WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.[719] PPE that covers all skin may reduce exposure to pathogens.[214, 710]
- Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.[720] Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.[90]
- A small observational study found no COVID-19 cases in 25 healthcare workers exposed to an infected patient while conducting aerosol-generating procedures, despite differences in the mask types (N95 respirator vs. 3-ply surgical mask) worn by the workers.[354] There is still insufficient evidence to recommend surgical masks as alternatives to N95s.
- KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.[205] On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.[210]
- A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.[522]
- Particular care should be taken with "duckbill" N95 respirators, which may fail fit tests after repeated doffing.[163] Dome-shaped N95 respirators also failed fit tests after extended use.[163]
- The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.[209]
- Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.[662]
- Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.[161]

Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.[6, 12]

- On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.[110] The CDC recommends masks without exhalation vents or valves,[105] as masks with valves can allow particles to pass through unfiltered.[676] The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.[717] Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.[698]
- A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission,[139] with N95 respirators more effective than surgical masks.[139] In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.[496] N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.[496]
- Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.[157, 388, 667] Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 µm).[388] Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer's face.[679]
- Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3µm,[348] while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).[689] Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.[756] Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.[220] Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.[49]

What do we need to know?

We need to continue assessing PPE effectiveness with specific regard to SARS-CoV-2 instead of surrogates.

- When and how do N95 respirators and other face coverings fail?
- How effective are homemade masks at reducing SARS-CoV-2 transmission?

Forensics – Natural vs intentional use? Tests to be used for attribution.

What do we know?

All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.

- New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate 'mixing' host.[78] Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.[78] Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.[78] These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
- Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from *Rhinolophus* (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country,[372] though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.[231]
- Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by "recombination" with other circulating strains of coronavirus.[38, 773]
- Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.[411, 413] The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.[423] The rest of the genome is more closely related to two separate bat coronaviruses[423] and coronaviruses found in pangolins.[413]
- Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.[276] These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.[276]
- Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.[727] Additional whole-genome sequencing in humans would help to confirm this finding.
- Genomic data support at least two plausible origins of SARS-CoV-2: "(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer."[38] Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
- Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses,[726] and data suggest that pangolins may be a natural host for beta-coronaviruses.[411, 413] Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.[395, 741] Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.[761] Additional research is needed.
- There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.[38, 395, 412, 761] These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor. Additional research is needed.
- A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).[150]
- A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein. While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.[771]
- Additionally, "[…] SARS-CoV-2 is not derived from any previously used virus backbone," reducing the likelihood of laboratory origination,[38] and "[…] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin."[38]
- Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.[160]
- A report claiming a laboratory origin of SARS-CoV-2[746] has been heavily disputed by scientists at Johns Hopkins University.[4]

What do we need to know?

We need to know whether there was an intermediate host species between bats and humans.

- What tests for attribution exist for coronavirus emergence?
- What is the identity of the intermediate species?
- Are there closely related circulating coronaviruses in bats or other animals with the novel PRRA cleavage site found in SARS-CoV-2?

Genomics – How does the disease agent compare to previous strains?

What do we know?

Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.

- There have been no documented cases of SARS-CoV-2 prior to December 2019. Preliminary genomic analyses, however, suggest that the first human cases of SARS-CoV-2 emerged between 10/19/2019 – 12/17/2019.[40, 65, 552]
- Analysis of more than 7,000 SARS-CoV-2 genome samples provides an estimated mutation rate of $6x10^{-4}$ nucleotides per genome per year.[670] The same analysis estimates the emergence of SARS-CoV-2 in humans between October and December 2019.[670] This aligns with the first known human cases in China in early December 2019, in Europe in late December 2019,[174] circulation in the US (Washington State) in February 2020,[731] and circulation in Mexico in March 2020.[638] In both California[171] and New York City,[258] evidence supports multiple introductions of SARS-CoV-2 from inside and outside the US.
- SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).[734] Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts,[734] and that additional jumps into humans may occur.
- In 94 COVID-19 patients, there was no association between viral genotype and clinical severity.[762] However, a 382 base pair deletion in the SARS-CoV-2 genome has been linked to milder clinical illness (n=39),[753] though the same size was small.

At least one mutation has been associated with greater viral transmission, but virulence appears unchanged.

- Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission,[682] but no change in clinical severity in infected patients.[352] An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation,[352, 420, 538, 759] though it is possible that founder effects contributed to its prevalence.
- The D614G mutation increased viral loads in experimentally infected hamsters in the nose and throat,[538] and hastened transmission (evidence of spread between hamsters after 2 days for D614G mutants vs. 4 days for wild-type virus).[296] The D614G mutation showed a competitive advantage within hamster hosts, meaning it increased in frequency *in vitro* compared to wild-type virus.[539] The mutation did increase viral replication in human cell lines.[538, 759]
- The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.[709] Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.[382]

A second SARS-CoV-2 variant is being assessed for its ability to evade the human immune system.

- A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies. This may affect the ability of vaccines and therapeutics that target this region.[651] As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.[651]

Associations between human blood type and COVID-19 severity are unclear, but certain human genome regions are associated with more severe disease.

- Several human genomic regions have been associated with increased risk of COVID-19 infection and severe disease.[37] Some of these are linked to human blood type,[255] where there is evidence of slightly increased prevalence[35, 62, 257] and moderately increased severity in those with type A blood,[292] though early evidence was mixed.[373] In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.[777] Non-O-type blood has been associated with clotting issues.[172]
- Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation,[255] as well as those with severe disease.[511]

There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.

- Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.[568] The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.[313] The stability of these changes and to what extent they would be affected by vaccine or treatment options in progress are unclear.
- The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.[148] There is no evidence that Y453F is more or less transmissible in humans than other wild-type viruses, though transmissibility in mink is high.[148]
- Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.[58]
- Researchers have identified a number of human proteins associated with COVID-19 severity, which could be used as a screening tool for designing appropriate treatment regimens.[775]

What do we need to know?

We need to link genotypes to phenotypes (e.g., disease severity) in infected patients.

- Are there similar genomic differences in the progression of coronavirus strains from bat to intermediate species to human?
- Are there different strains or clades of circulating virus? If so, do they differ in virulence or transmissibility?
- What are the mutations in SARS-CoV-2 that allowed human infection and transmission?
- How do viral mutations affect the long-term efficacy of specific vaccines?

Forecasting – What forecasting models and methods exist?

What do we know?

The US CDC provides ensemble forecasts based on the arithmetic mean of participating groups.[107]

- Columbia University Model: Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.[584]
- Institute of Health Metrics and Evaluation (IHME): Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.[308] Also provides global forecasts.[309]
- Los Alamos National Laboratory: Forecasts of state-level cases and deaths based on statistical growth model fit to reported data. Implicitly accounts for effects of social distancing and other control measures.[367]
- Massachusetts Institute of Technology: Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths. Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).[456]
- Northeastern University: Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.[490]
- Notre Dame University: Agent-based model forecasting cases and deaths for Midwest states. Includes effectiveness of control measures like social distancing.[529]
- University of California, Los Angeles: Mechanistic SIR model with statistical optimization to find best-fitting parameter values. Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.[661]
- University of Chicago: Age-structured SEIR model that accounts for asymptomatic individuals and the effectiveness of social distancing policies. Forecasts only for Illinois.[132]
- University of Geneva: Country-level forecasts of cases, deaths, and transmissibility (R_0). Uses statistical models fit to reported data, not mechanistic models.[229]
- University of Massachusetts, Amherst: Aggregation of state and national forecasts to create ensemble model.[562]
- Youyang Gu: Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values. Forecasts deaths and infections at the state and national level, including 60 non-US countries. Includes effects of public health control efforts.[269]
- CovidSim: SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).[131]
- Google/Harvard University: Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.[259]

Other forecasting efforts:

- Results from multiple independent modeling groups can be aggregated to capture additional risk and minimize group-specific biases associated with COVID-19 forecasts.[606]
- The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R_0), serial interval, generation time, and fatality rate.[70]
- University of Georgia: Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., "nowcasts"). Available at the state and national level for the US.[117]
- Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.[316]
- COVID Act Now: State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds). Fundamentally uses an SEIR model fit to observed data.[492]
- Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, R_{eff} or R_t).[16]
- Georgia Tech Applied Bioinformatics Laboratory: Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.[124]
- MITRE: Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning. Uses combinations of SEIR models and curve-fitting approaches.[459]
- Covasim: Agent-based model for testing effects of intervention measures, also available as Python library.[338]
- Florez and Singh: Global and country-level forecasts of cases and fatalities, simple statistical projection of future growth.[232]
- Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.[608]

What do we need to know?

We need to know how different forecasting methods have fared when compared to real data and develop an understanding of which model features contribute most to accurate and inaccurate forecasts.

- Additionally, we need to know how vaccine efficacy, uptake, and deployment will alter COVID-19 progression.

Table 1. Definitions of commonly used acronyms

Acronym/Term	Definition	Description
ACE2	Angiotensin-converting enzyme 2	Acts as a receptor for SARS-CoV and SARS-CoV-2, allowing entry into human cells
Airborne transmission	Aerosolization of infectious particles	Aerosolized particles can spread for long distances (e.g., between hospital rooms via HVAC systems). Particles generally <5 µm.
ARDS	Acute respiratory distress syndrome	Leakage of fluid into the lungs which inhibits respiration and leads to death
Attack rate	Proportion of "at-risk" individuals who develop infection	Defined in terms of "at-risk" population such as schools or households, defines the proportion of individuals in those populations who become infected after contact with an infectious individual
CCV	Canine coronavirus	Canine coronavirus
CFR	Case Fatality Rate	Number of deaths divided by confirmed patients
CoV	Coronavirus	Virus typified by crown-like structures when viewed under electron microscope
COVID-19	Coronavirus disease 19	Official name for the disease caused by the SARS-CoV-2 virus.
Droplet transmission	Sneezing, coughing	Transmission via droplets requires relatively close contact (e.g., within 6 feet)
ELISA	Enzyme-linked immunosorbent assay	Method for serological testing of antibodies
Fomite	Inanimate vector of disease	Surfaces such as hospital beds, doorknobs, healthcare worker gowns, faucets, etc.
HCW	Healthcare worker	Doctors, nurses, technicians dealing with patients or samples
Incubation period	Time between infection and symptom onset	Time between infection and onset of symptoms typically establishes guidelines for isolating patients before transmission is possible
Infectious period	Length of time an individual can transmit infection to others	Reducing the infectious period is a key method of reducing overall transmission; hospitalization, isolation, and quarantine are all effective methods
Intranasal	Agent deposited into external nares of subject	Simulates inhalation exposure by depositing liquid solution of pathogen/virus into the nose of a test animal, where it is then taken up by the respiratory system.
MERS	Middle East Respiratory Syndrome	Coronavirus with over 2,000 cases in regional outbreak since 2012
MHV	Mouse hepatitis virus	Coronavirus surrogate
Nosocomial	Healthcare- or hospital-associated infections	Characteristic of SARS and MERS outbreaks, lead to refinement of infection control procedures
NPI	Non-pharmaceutical intervention	Public health control measures designed to reduce transmission, such as social distancing, movement restrictions, and face mask requirements.
PCR	Polymerase chain reaction	PCR (or real-time [RT] or quantitative [Q] PCR) is a method of increasing the amount of genetic material in a sample, which is then used for diagnostic testing to confirm the presence of SARS-CoV-2.
PFU	Plaque forming unit	Measurement of the number of infectious virus particles as determined by plaque forming assay. A measurement of sample infectivity.

Acronym/Term	Definition	Description
PPE	Personal protective equipment	Gowns, masks, gloves, and any other measures used to prevent spread between individuals
R_0	Basic reproduction number	A measure of transmissibility. Specifically, the average number of new infections caused by a typical infectious individual in a wholly susceptible population.
SARS	Severe Acute Respiratory Syndrome	Coronavirus with over 8,000 cases in global 2002-2003 outbreak
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2	Official name for the virus previously known as 2019-nCoV.
SEIR	Susceptible (S), exposed (E), infected (I), and resistant (R)	A type of modeling that incorporates the flow of people between the following states: susceptible (S), exposed (E), infected (I), and resistant (R), and is being used for SARS-CoV-2 forecasting
Serial interval	Length of time between symptom onset of successive cases in a transmission chain	The serial interval can be used to estimate R_0, and is useful for estimating the rate of outbreak spread
SIR	Susceptible (S), infected (I), and resistant (R)	A type of modeling that incorporates the flow of people between the following states: susceptible (S), infected (I), and resistant (R), and is being used for SARS-CoV-2 forecasting
$TCID_{50}$	50% Tissue Culture Infectious Dose	The number of infectious units which will infect 50% of tissue culture monolayers. A measurement of sample infectivity.
Transgenic	Genetically modified	In this case, animal models modified to be more susceptible to MERS and/or SARS by adding proteins or receptors necessary for infection
Vertical transmission	Transmission from mother to fetus	Generally understood as intrauterine transmission via blood or placenta. Not the same as transmission during or after birth.

Literature Cited:

1. Coronavirus diagnosed at mink farms in North Brabant. *NOS* 2020. https://nos.nl/artikel/2331784-coronavirus-vastgesteld-bij-nertsenfokkerijen-in-noord-brabant.html
2. *Covid-19 Curriculum Watch: Education Policy in the first 3 months of the pandemic*; Cambridge Assessment Research Division: 2020. https://www.cambridgeassessment.org.uk/insights/uk-education-policy-during-covid-19-pandemic-topic-one/
3. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2022926
4. *In Response: Yan et al. Preprint Examinations of the Origin of SARS-CoV-2*; Johns Hopkins Bloomberg School of Public Health, Center for Health Security: 2020. https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/200921-in-response-yan.pdf
5. India's new paper Covid-19 test could be a 'game changer'. *BBC* 2020. https://www.bbc.com/news/world-asia-india-54338864
6. Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings. *Annals of Internal Medicine 0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-3213
7. Novavax begins Phase II part of Covid-19 vaccine trial. *Clinical Trials Arena* 2020. https://www.clinicaltrialsarena.com/news/novavax-covid-vaccine-phaseii/
8. Research Shows Virus Undetectable on Five Highly Circulated Library Materials After Three Days. Institute for Library and Museum Services: 2020. https://www.imls.gov/news/research-shows-virus-undetectable-five-highly-circulated-library-materials-after-three-days
9. Russia Approves First COVID-19 Vaccine. *FDA News* 2020. https://www.fdanews.com/articles/198492-russia-approves-first-covid-19-vaccine
10. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. . *MMWR* **2020**. https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm?s_cid=mm6912e2_w#suggestedcitation
11. Sinovac's Covid-19 vaccine gets emergency use approval in China. *Pharmaceutical Technology* 2020. https://www.pharmaceutical-technology.com/news/sinovac-vaccine-emergency-use/
12. Update Alert: Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings. *Annals of Internal Medicine 0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/L20-0948
13. 3M, *Decontamination of 3M Filtering Facepiece Respirators, such as N95 Respirators, in the United States - Considerations*; 3M: 2020. https://multimedia.3m.com/mws/media/1824869O/decontamination-methods-for-3m-filtering-facepiece-respirators-technical-bulletin.pdf
14. AAAS, You may be able to spread coronavirus just by breathing, new report finds. *Science* 2 April, 2020. https://www.sciencemag.org/news/2020/04/you-may-be-able-spread-coronavirus-just-breathing-new-report-finds
15. AAP, Children and COVID-19: State-Level Data Report. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/ (accessed 8/31/2020).
16. Abbott, S.; Hellewell, J.; Thompson, R.; Sherratt, K.; Gibbs, H.; Bosse, N.; Munday, J.; Meakin, S.; Doughty, E.; Chun, J.; Chan, Y.; Finger, F.; Campbell, P.; Endo, A.; Pearson, C.; Gimma, A.; Russell, T.; null, n.; Flasche, S.; Kucharski, A.; Eggo, R.; Funk, S., Estimating the time-varying reproduction number of SARS-CoV-2 using national and subnational case counts [version 1; peer review: awaiting peer review]. *Wellcome Open Research* **2020,** *5* (112). https://wellcomeopenresearch.org/articles/5-112/v1
17. Abella, B. S.; Jolkovsky, E. L.; Biney, B. T.; Uspal, J. E.; Hyman, M. C.; Frank, I.; Hensley, S. E.; Gill, S.; Vogl, D. T.; Maillard, I.; Babushok, D. V.; Huang, A. C.; Nasta, S. D.; Walsh, J. C.; Wiletyo, E. P.; Gimotty, P.

A.; Milone, M. C.; Amaravadi, R. K., Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. *JAMA Intern Med* **2020**.
18. Ackermann, M.; Verleden, S. E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; Li, W. W.; Li, V. W.; Mentzer, S. J.; Jonigk, D., Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2015432
19. Adam, D.; Wu, P.; Wong, J.; Lau, E.; Tsang, T.; Cauchemez, S.; Leung, G.; Cowling, B., Clustering and superspreading potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Hong Kong. **2020**.
20. Adam, D. C.; Wu, P.; Wong, J. Y.; Lau, E. H. Y.; Tsang, T. K.; Cauchemez, S.; Leung, G. M.; Cowling, B. J., Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-1092-0
21. Adams, M.; Katz, D.; Grandpre, J., Updated Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. *Emerging Infectious Disease journal* **2020,** *26* (9). https://wwwnc.cdc.gov/eid/article/26/9/20-2117_article
22. Adimmune, A Study to Evaluate the Safety and Immunogenicity of AdimrSC-2f Vaccine. https://clinicaltrials.gov/ct2/show/NCT04522089.
23. Afshar, Y.; Gaw, S. L.; Flaherman, V. J.; Chambers, B. D.; Krakow, D.; Berghella, V.; Shamshirsaz, A. A.; Boatin, A. A.; Aldrovandi, G.; Greiner, A.; Riley, L.; Boscardin, W. J.; Jamieson, D. J.; Jacoby, V. L., Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People. *Obstetrics & Gynecology* **9900,** *Latest Articles*, 10.1097/AOG.0000000000004178. https://journals.lww.com/greenjournal/Fulltext/9900/Clinical_Presentation_of_Coronavirus_Disease_2019.2.aspx
24. Agrawal, A. S.; Garron, T.; Tao, X.; Peng, B. H.; Wakamiya, M.; Chan, T. S.; Couch, R. B.; Tseng, C. T., Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. *J Virol* **2015,** *89* (7), 3659-70. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403411/pdf/zjv3659.pdf
25. Ahmed, W.; Bertsch, P. M.; Bibby, K.; Haramoto, E.; Hewitt, J.; Huygens, F.; Gyawali, P.; Korajkic, A.; Riddell, S.; Sherchan, S. P.; Simpson, S. L.; Sirikanchana, K.; Symonds, E. M.; Verhagen, R.; Vasan, S. S.; Kitajima, M.; Bivins, A., Decay of SARS-CoV-2 and surrogate murine hepatitis virus RNA in untreated wastewater to inform application in wastewater-based epidemiology. *Environmental Research* **2020**, 110092. http://www.sciencedirect.com/science/article/pii/S0013935120309890
26. Airora, The development, testing and verification of Airora's patented biocidal technology. https://www.airora.com/verification.html (accessed 19 Oct 2020).
27. Aleta, A.; Martin-Corral, D.; Pastore y Piontti, A.; Ajelli, M.; Litivinova, M.; Chinazzi, M.; Dean, N.; Halloran, M. E.; Longini, I.; Merler, S.; Pentland, A.; Vespignani, A.; Moro, E.; Moreno, Y., Modeling the impact of social distancing, testing, contact tracing and household quarantine on second-wave scenarios of the COVID-19 epidemic. *Preprint* **2020**. https://www.mobs-lab.org/uploads/6/7/8/7/6787877/tracing_main_may4.pdf
28. Aleta, A.; Martín-Corral, D.; Pastore y Piontti, A.; Ajelli, M.; Litvinova, M.; Chinazzi, M.; Dean, N. E.; Halloran, M. E.; Longini Jr, I. M.; Merler, S.; Pentland, A.; Vespignani, A.; Moro, E.; Moreno, Y., Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. *Nature Human Behaviour* **2020**. https://doi.org/10.1038/s41562-020-0931-9
29. Ali, S. T.; Wang, L.; Lau, E. H. Y.; Xu, X.-K.; Du, Z.; Wu, Y.; Leung, G. M.; Cowling, B. J., Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions. *Science* **2020**, eabc9004. https://science.sciencemag.org/content/sci/early/2020/07/20/science.abc9004.full.pdf

30. Allen, D., Graphene Face Masks Set to Boost Coronavirus Protection. http://emag.medicalexpo.com/graphene-face-masks-set-to-boost-coronavirus-protection/ (accessed 16 Nov 2020).
31. Allotey, J.; Stallings, E.; Bonet, M.; Yap, M.; Chatterjee, S.; Kew, T.; Debenham, L.; Llavall, A. C.; Dixit, A.; Zhou, D.; Balaji, R.; Lee, S. I.; Qiu, X.; Yuan, M.; Coomar, D.; van Wely, M.; van Leeuwen, E.; Kostova, E.; Kunst, H.; Khalil, A.; Tiberi, S.; Brizuela, V.; Broutet, N.; Kara, E.; Kim, C. R.; Thorson, A.; Oladapo, O. T.; Mofenson, L.; Zamora, J.; Thangaratinam, S., Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* **2020,** *370*, m3320. https://www.bmj.com/content/bmj/370/bmj.m3320.full.pdf
32. Althouse, B. M.; Wenger, E. A.; Miller, J. C.; Scarpino, S. V.; Allard, A.; Hébert-Dufresne, L.; Hu, H., Superspreading events in the transmission dynamics of SARS-CoV-2: Opportunities for interventions and control. *PLOS Biology* **2020,** *18* (11), e3000897. https://doi.org/10.1371/journal.pbio.3000897
33. Altmann, D. M.; Douek, D. C.; Boyton, R. J., What policy makers need to know about COVID-19 protective immunity. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)30985-5
34. Alves, A. M.; Yvamoto, E. Y.; Marzinotto, M. A. N.; Teixeira, A. C. d. S.; Carrilho, F. J., SARS-CoV-2 leading to acute pancreatitis: an unusual presentation. *The Brazilian Journal of Infectious Diseases* **2020**. http://www.sciencedirect.com/science/article/pii/S1413867020301392
35. Amoroso, A.; Magistroni, P.; Vespasiano, F.; Bella, A.; Bellino, S.; Puoti, F.; Alizzi, S.; Vaisitti, T.; Boros, S.; Grossi, P. A.; Trapani, S.; Lombardini, L.; Pezzotti, P.; Deaglio, S.; Brusaferro, S.; Cardillo, M., HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity. *Transplantation* **2020**.
36. Anand, S.; Montez-Rath, M.; Han, J.; Bozeman, J.; Kerschmann, R.; Beyer, P.; Parsonnet, J.; Chertow, G. M., Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)32009-2
37. Anastassopoulou, C.; Gkizarioti, Z.; Patrinos, G. P.; Tsakris, A., Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. *Hum Genomics* **2020,** *14* (1), 40.
38. Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0820-9
39. Anderson, E. L.; Turnham, P.; Griffin, J. R.; Clarke, C. C., Consideration of the Aerosol Transmission for COVID-19 and Public Health. *Risk Analysis* **2020,** *40* (5), 902-907. https://onlinelibrary.wiley.com/doi/abs/10.1111/risa.13500
40. Anderson, K., Estimates of the clock and TMRCA for 2019-nCoV based on 27 genomes. http://virological.org/t/clock-and-tmrca-based-on-27-genomes/347 (accessed 01/26/2020).
41. AnGes, Study of COVID-19 DNA Vaccine (AG0301-COVID19). https://clinicaltrials.gov/ct2/show/NCT04463472?term=NCT04463472&draw=2&rank=1.
42. Angus, D. C.; Derde, L.; Al-Beidh, F.; Annane, D.; Arabi, Y.; Beane, A.; van Bentum-Puijk, W.; Berry, L.; Bhimani, Z.; Bonten, M.; Bradbury, C.; Brunkhorst, F.; Buxton, M.; Buzgau, A.; Cheng, A. C.; de Jong, M.; Detry, M.; Estcourt, L.; Fitzgerald, M.; Goossens, H.; Green, C.; Haniffa, R.; Higgins, A. M.; Horvat, C.; Hullegie, S. J.; Kruger, P.; Lamontagne, F.; Lawler, P. R.; Linstrum, K.; Litton, E.; Lorenzi, E.; Marshall, J.; McAuley, D.; McGlothin, A.; McGuinness, S.; McVerry, B.; Montgomery, S.; Mouncey, P.; Murthy, S.; Nichol, A.; Parke, R.; Parker, J.; Rowan, K.; Sanil, A.; Santos, M.; Saunders, C.; Seymour, C.; Turner, A.; van de Veerdonk, F.; Venkatesh, B.; Zarychanski, R.; Berry, S.; Lewis, R. J.; McArthur, C.; Webb, S. A.; Gordon, A. C., Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. *Jama* **2020**. https://jamanetwork.com/journals/jama/fullarticle/2770278
43. Anhui, Clinical Study of Recombinant Novel Coronavirus Vaccine. https://clinicaltrials.gov/ct2/show/NCT04466085.

44. Annweiler, G.; Corvaisier, M.; Gautier, J.; Dubée, V.; Legrand, E.; Sacco, G.; Annweiler, C., Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study. *Nutrients* **2020,** *12* (11).
45. Arcturus, Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects. https://clinicaltrials.gov/ct2/show/NCT04480957?term=vaccine&cond=covid-19&draw=10.
46. Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F. X.; Chong, M.; Lee, M., Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.4326
47. Argenziano, M. G.; Bruce, S. L.; Slater, C. L.; Tiao, J. R.; Baldwin, M. R.; Barr, R. G.; Chang, B. P.; Chau, K. H.; Choi, J. J.; Gavin, N.; Goyal, P.; Mills, A. M.; Patel, A. A.; Romney, M.-L. S.; Safford, M. M.; Schluger, N. W.; Sengupta, S.; Sobieszczyk, M. E.; Zucker, J. E.; Asadourian, P. A.; Bell, F. M.; Boyd, R.; Cohen, M. F.; Colquhoun, M. I.; Colville, L. A.; de Jonge, J. H.; Dershowitz, L. B.; Dey, S. A.; Eiseman, K. A.; Girvin, Z. P.; Goni, D. T.; Harb, A. A.; Herzik, N.; Householder, S.; Karaaslan, L. E.; Lee, H.; Lieberman, E.; Ling, A.; Lu, R.; Shou, A. Y.; Sisti, A. C.; Snow, Z. E.; Sperring, C. P.; Xiong, Y.; Zhou, H. W.; Natarajan, K.; Hripcsak, G.; Chen, R., Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series. *medRxiv* **2020**, 2020.04.20.20072116. https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.20.20072116.full.pdf
48. Arons, M. M.; Hatfield, K. M.; Reddy, S. C.; Kimball, A.; James, A.; Jacobs, J. R.; Taylor, J.; Spicer, K.; Bardossy, A. C.; Oakley, L. P.; Tanwar, S.; Dyal, J. W.; Harney, J.; Chisty, Z.; Bell, J. M.; Methner, M.; Paul, P.; Carlson, C. M.; McLaughlin, H. P.; Thornburg, N.; Tong, S.; Tamin, A.; Tao, Y.; Uehara, A.; Harcourt, J.; Clark, S.; Brostrom-Smith, C.; Page, L. C.; Kay, M.; Lewis, J.; Montgomery, P.; Stone, N. D.; Clark, T. A.; Honein, M. A.; Duchin, J. S.; Jernigan, J. A., Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2008457
49. Asadi, S.; Cappa, C. D.; Barreda, S.; Wexler, A. S.; Bouvier, N. M.; Ristenpart, W. D., Efficacy of masks and face coverings in controlling outward aerosol particle emission from expiratory activities. *Scientific Reports* **2020,** *10* (1), 15665. https://doi.org/10.1038/s41598-020-72798-7
50. Assis, M. S.; Araújo, R.; Lopes, A. M. M., Safety alert for hospital environments and health professional: chlorhexidine is ineffective for coronavirus. *Rev Assoc Med Bras (1992)* **2020,** *66Suppl 2* (Suppl 2), 124-129.
51. Auger, K. A.; Shah, S. S.; Richardson, T.; Hartley, D.; Hall, M.; Warniment, A.; Timmons, K.; Bosse, D.; Ferris, S. A.; Brady, P. W.; Schondelmeyer, A. C.; Thomson, J. E., Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.14348
52. Avanzato, V. A.; Matson, M. J.; Seifert, S. N.; Pryce, R.; Williamson, B. N.; Anzick, S. L.; Barbian, K.; Judson, S. D.; Fischer, E. R.; Martens, C.; Bowden, T. A.; de Wit, E.; Riedo, F. X.; Munster, V. J., Case Study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient. *Cell* **2020**. https://doi.org/10.1016/j.cell.2020.10.049
53. Aziz, M.; Fatima, R.; Assaly, R., Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis. *J Med Virol* **2020**.
54. Badr, H. S.; Du, H.; Marshall, M.; Dong, E.; Squire, M. M.; Gardner, L. M., Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study. *The Lancet Infectious Diseases* **2020**. https://doi.org/10.1016/S1473-3099(20)30553-3
55. Bae, S. H.; Shin, H.; Koo, H.-Y.; Lee, S. W.; Yang, J. M.; Yon, D. K., Asymptomatic Transmission of SARS-CoV-2 on Evacuation Flight. *Emerging Infectious Disease journal* **2020,** *26* (11). https://wwwnc.cdc.gov/eid/article/26/11/20-3353_article

56. Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D.-Y.; Chen, L.; Wang, M., Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*.
57. Baig, A. M., Chronic COVID Syndrome: Need for an appropriate medical terminology for Long-COVID and COVID Long-Haulers. *Journal of Medical Virology* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26624
58. Baldassarri, M.; Picchiotti, N.; Fava, F.; Fallerini, C.; Benetti, E.; Daga, S.; Valentino, F.; Doddato, G.; Furini, S.; Giliberti, A.; Tita, R.; Amitrano, S.; Bruttini, M.; Croci, S.; Meloni, I.; Pinto, A. M.; Gabbi, C.; Sciarra, F.; Venneri, M. A.; Gori, M.; Sanarico, M.; Crawley, F. P.; Pagotto, U.; Fanelli, F.; Mezzullo, M.; Dominguez-Garrido, E.; Planas-Serra, L.; Schluter, A.; Colobran, R.; Soler-Palacin, P.; Lapunzina, P.; Tenorio, J.; Pujol, A.; Castagna, M. G.; Marcelli, M.; Isidori, A. M.; Renieri, A.; Frullanti, E.; Mari, F., Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in males. *medRxiv* **2020**, 2020.11.04.20225680. http://medrxiv.org/content/early/2020/11/05/2020.11.04.20225680.abstract
59. Bao, L.; Deng, W.; Huang, B.; Gao, H.; Liu, J.; Ren, L.; Wei, Q.; Yu, P.; Xu, Y.; Qi, F.; Qu, Y.; Li, F.; Lv, Q.; Wang, W.; Xue, J.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Zhao, L.; Liu, P.; Zhao, L.; Ye, F.; Wang, H.; Zhou, W.; Zhu, N.; Zhen, W.; Yu, H.; Zhang, X.; Guo, L.; Chen, L.; Wang, C.; Wang, Y.; Wang, X.; Xiao, Y.; Sun, Q.; Liu, H.; Zhu, F.; Ma, C.; Yan, L.; Yang, M.; Han, J.; Xu, W.; Tan, W.; Peng, X.; Jin, Q.; Wu, G.; Qin, C., The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* **2020**.
60. Bao, L.; Gao, H.; Deng, W.; Lv, Q.; Yu, H.; Liu, M.; Yu, P.; Liu, J.; Qu, Y.; Gong, S.; Lin, K.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Xue, J.; Song, Z.; Xiang, Z.; Wang, G.; Wang, S.; Liu, X.; Zhao, W.; Han, Y.; Wei, Q.; Qin, C., Transmission of SARS-CoV-2 via close contact and respiratory droplets among hACE2 mice. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa281
61. Barakat, T.; Muylkens, B.; Su, B.-L., Is Particulate Matter of Air Pollution a Vector of Covid-19 Pandemic? *Matter* **2020,** *3* (4), 977-980. http://www.sciencedirect.com/science/article/pii/S2590238520305129
62. Barnkob, M. B.; Pottegård, A.; Støvring, H.; Haunstrup, T. M.; Homburg, K.; Larsen, R.; Hansen, M. B.; Titlestad, K.; Aagaard, B.; Møller, B. K.; Barington, T., Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. *Blood Advances* **2020,** *4* (20), 4990-4993. https://doi.org/10.1182/bloodadvances.2020002657
63. Barrington, L.; Cornwell, A., China's Sinopharm begins late stage trial of COVID-19 vaccine in UAE. https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-abu-dhabi-idUSKCN24H14T.
64. Bartlett, S. L.; Diel, D. G.; Wang, L.; Zec, S.; Laverack, M.; Martins, M.; Caserta, L. C.; Killian, M. L.; Terio, K.; Olmstead, C.; Delaney, M. A.; Stokol, T.; Ivančić, M.; Jenkins-Moore, M.; Ingerman, K.; Teegan, T.; McCann, C.; Thomas, P.; McAloose, D.; Sykes, J. M.; Calle, P. P., SARS-CoV-2 Infection And Longitudinal Fecal Screening In Malayan Tigers (Panthera tigris jacksoni), Amur Tigers (Panthera tigris altaica), And African Lions (Panthera leo krugeri) At The Bronx Zoo, New York, USA. *bioRxiv* **2020**, 2020.08.14.250928. https://www.biorxiv.org/content/biorxiv/early/2020/08/14/2020.08.14.250928.full.pdf
65. Bedford, T.; Neher, R., Genomic epidemiology of novel coronavirus (nCoV) using data from GISAID. https://nextstrain.org/ncov.
66. Behzadinasab, S.; Chin, A.; Hosseini, M.; Poon, L. L. M.; Ducker, W. A., A Surface Coating that Rapidly Inactivates SARS-CoV-2. *ACS Applied Materials & Interfaces* **2020**. https://doi.org/10.1021/acsami.0c11425
67. Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C.; Hohmann, E.; Chu, H. Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R. W.; Dierberg, K.; Tapson, V.; Hsieh, L.; Patterson, T. F.; Paredes, R.; Sweeney, D. A.; Short, W. R.; Touloumi, G.; Lye, D. C.; Ohmagari, N.; Oh, M.-d.; Ruiz-Palacios, G. M.; Benfield, T.; Fätkenheuer, G.; Kortepeter, M. G.; Atmar, R. L.; Creech, C. B.;

Lundgren, J.; Babiker, A. G.; Pett, S.; Neaton, J. D.; Burgess, T. H.; Bonnett, T.; Green, M.; Makowski, M.; Osinusi, A.; Nayak, S.; Lane, H. C., Remdesivir for the Treatment of Covid-19 — Final Report. *New England Journal of Medicine* **2020**. https://doi.org/10.1056/NEJMoa2007764
68. BGI, BGI Responds to Novel Coronavirus with Real-Time Detection Kits, Deploys Emergency Team to Wuhan. 2020. https://www.bgi.com/global/company/news/bgi-responds-to-novel-coronavirus-with-real-time-detection-kits-deploys-emergency-team-to-wuhan/
69. Bidra, A. S.; Pelletier, J. S.; Westover, J. B.; Frank, S.; Brown, S. M.; Tessema, B., Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse. *Journal of Prosthodontics* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/jopr.13209
70. Biggerstaff, M.; Cowling, B.; Cucunubá, Z.; Dinh, L.; Ferguson, N.; Gao, H.; Hill, V.; Imai, N.; Johansson, M.; Kada, S.; Morgan, O.; Pastore y Piontti, A.; Polonsky, J.; Prasad, P. V.; Quandelacy, T.; Rambaut, A.; Tappero, J.; Vandemaele, K.; Vespignani, A.; Warmbrod, K. L.; Wong, J., Early Insights from Statistical and Mathematical Modeling of Key Epidemiologic Parameters of COVID-19. *Emerging Infectious Disease journal* **2020,** *26* (11). https://wwwnc.cdc.gov/eid/article/26/11/20-1074_article
71. BioProcessing, K., KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers. https://clinicaltrials.gov/ct2/show/study/NCT04473690?term=vaccine&cond=covid-19&draw=3.
72. Biotech, M., Mesa Biotech Receives Emergency Use Authorization from FDA for a 30 Minute Point of Care Molecular COVID-19 Test. Mesa Biotech: 2020. https://www.mesabiotech.com/news/euacoronavirus
73. Biryukov, J.; Boydston, J. A.; Dunning, R. A.; Yeager, J. J.; Wood, S.; Reese, A. L.; Ferris, A.; Miller, D.; Weaver, W.; Zeitouni, N. E.; Phillips, A.; Freeburger, D.; Hooper, I.; Ratnesar-Shumate, S.; Yolitz, J.; Krause, M.; Williams, G.; Dawson, D. G.; Herzog, A.; Dabisch, P.; Wahl, V.; Hevey, M. C.; Altamura, L. A., Increasing Temperature and Relative Humidity Accelerates Inactivation of SARS-CoV-2 on Surfaces. *mSphere* **2020,** *5* (4), e00441-20. https://msphere.asm.org/content/msph/5/4/e00441-20.full.pdf
74. Bixler, D.; Miller, A. D.; Mattison, C. P.; al., e., SARS-CoV-2–Associated Deaths Among Persons Aged <21 Years — United States, February 12–July 31, 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1324-1329. https://www.cdc.gov/mmwr/volumes/69/wr/mm6937e4.htm
75. Blackburn, J.; Yiannoutsos, C. T.; Carroll, A. E.; Halverson, P. K.; Menachemi, N., Infection Fatality Ratios for COVID-19 Among Noninstitutionalized Persons 12 and Older: Results of a Random-Sample Prevalence Study. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-5352
76. Blair, R. V.; Vaccari, M.; Doyle-Meyers, L. A.; Roy, C. J.; Russell-Lodrigue, K.; Fahlberg, M.; Monjure, C. J.; Beddingfield, B.; Plante, K. S.; Plante, J. A.; Weaver, S. C.; Qin, X.; Midkiff, C. C.; Lehmicke, G.; Golden, N.; Threeton, B.; Penney, T.; Allers, C.; Barnes, M. B.; Pattison, M.; Datta, P. K.; Maness, N. J.; Birnbaum, A.; Bohm, R. P.; Rappaport, J., ARDS and Cytokine Storm in SARS-CoV-2 Infected Caribbean Vervets. *bioRxiv* **2020**, 2020.06.18.157933. http://biorxiv.org/content/early/2020/06/19/2020.06.18.157933.abstract
77. Böhmer, M. M.; Buchholz, U.; Corman, V. M.; Hoch, M.; Katz, K.; Marosevic, D. V.; Böhm, S.; Woudenberg, T.; Ackermann, N.; Konrad, R.; Eberle, U.; Treis, B.; Dangel, A.; Bengs, K.; Fingerle, V.; Berger, A.; Hörmansdorfer, S.; Ippisch, S.; Wicklein, B.; Grahl, A.; Pörtner, K.; Muller, N.; Zeitlmann, N.; Boender, T. S.; Cai, W.; Reich, A.; An der Heiden, M.; Rexroth, U.; Hamouda, O.; Schneider, J.; Veith, T.; Mühlemann, B.; Wölfel, R.; Antwerpen, M.; Walter, M.; Protzer, U.; Liebl, B.; Haas, W.; Sing, A.; Drosten, C.; Zapf, A., Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *The Lancet. Infectious diseases* **2020**, S1473-3099(20)30314-5. https://pubmed.ncbi.nlm.nih.gov/32422201
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228725/

78. Boni, M. F.; Lemey, P.; Jiang, X.; Lam, T. T.-Y.; Perry, B. W.; Castoe, T. A.; Rambaut, A.; Robertson, D. L., Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. *Nature Microbiology* **2020**. https://doi.org/10.1038/s41564-020-0771-4
79. Booth, W.; Johnson, C. Y., Britain to infect healthy volunteers with coronavirus in vaccine challenge trials. *Washington Post* 2020. https://www.washingtonpost.com/world/europe/covid-challenge-trials-uk/2020/10/20/00a31136-026c-11eb-b92e-029676f9ebec_story.html
80. Bosco-Lauth, A. M.; Hartwig, A. E.; Porter, S. M.; Gordy, P. W.; Nehring, M.; Byas, A. D.; VandeWoude, S.; Ragan, I. K.; Maison, R. M.; Bowen, R. A., Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats. *Proceedings of the National Academy of Sciences* **2020**, 202013102. http://www.pnas.org/content/early/2020/09/28/2013102117.abstract
81. Bosco-Lauth, A. M.; Hartwig, A. E.; Porter, S. M.; Gordy, P. W.; Nehring, M.; Byas, A. D.; VandeWoude, S.; Ragan, I. K.; Maison, R. M.; Bowen, R. A., Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats. *bioRxiv* **2020**, 2020.05.28.120998. http://biorxiv.org/content/early/2020/05/29/2020.05.28.120998.abstract
82. Boukli, N.; Le Mene, M.; Schnuriger, A.; Cuervo, N. S.; Laroche, C.; Morand-Joubert, L.; Gozlan, J., High incidence of false positive results in patients with other acute infections, using the LIAISON® SARS-CoV-2 commercial chemiluminescent micro-particle immunoassay for detection of IgG anti SARS-CoV-2 antibodies. *Journal of Clinical Microbiology* **2020**, JCM.01352-20. https://jcm.asm.org/content/jcm/early/2020/08/25/JCM.01352-20.full.pdf
83. Boulware, D. R.; Pullen, M. F.; Bangdiwala, A. S.; Pastick, K. A.; Lofgren, S. M.; Okafor, E. C.; Skipper, C. P.; Nascene, A. A.; Nicol, M. R.; Abassi, M.; Engen, N. W.; Cheng, M. P.; LaBar, D.; Lother, S. A.; MacKenzie, L. J.; Drobot, G.; Marten, N.; Zarychanski, R.; Kelly, L. E.; Schwartz, I. S.; McDonald, E. G.; Rajasingham, R.; Lee, T. C.; Hullsiek, K. H., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2016638
84. Bradburne, A. F.; Bynoe, M. L.; Tyrrell, D. A., Effects of a "new" human respiratory virus in volunteers. *British medical journal* **1967,** *3* (5568), 767-769. https://pubmed.ncbi.nlm.nih.gov/6043624 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1843247/
85. Brady, T., Irish company develops groundbreaking Covid spray that will provide near complete protection. https://www.independent.ie/irish-news/health/irish-company-develops-groundbreaking-covid-spray-that-will-provide-near-complete-protection-39717080.html (accessed 09 Nov 2020).
86. Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Kurth, F.; Hippenstiel, S.; Dingeldey, M.; Kruse, B.; Fauchere, F.; Baysal, E.; Mangold, M.; Henze, L.; Lauster, R.; Mall, M.; Beyer, K.; Roehmel, J.; Schmitz, J.; Miltenyi, S.; Mueller, M. A.; Witzenrath, M.; Suttorp, N.; Kern, F.; Reimer, U.; Wenschuh, H.; Drosten, C.; Corman, V. M.; Giesecke-Thiel, C.; Sander, L.-E.; Thiel, A., Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. *medRxiv* **2020**, 2020.04.17.20061440. https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.17.20061440.full.pdf
87. Brennan, Z., FDA issues 2nd EUA for decontamination system for N95 masks. *Regulatory Focus* 2020. https://www.raps.org/news-and-articles/news-articles/2020/4/fda-issues-2nd-eua-for-decontamination-system-for
88. Brocato, R.; Principe, L.; Kim, R.; Zeng, X.; Williams, J.; Liu, Y.; Li, R.; Smith, J.; Golden, J.; Gangemi, D.; Youssef, S.; Wang, Z.; Glanville, J.; Hooper, J., Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2 Infected Syrian Hamsters. *bioRxiv* **2020**, 2020.06.19.161612. http://biorxiv.org/content/early/2020/06/19/2020.06.19.161612.abstract
89. Brosseau, L. M., COMMENTARY: COVID-19 transmission messages should hinge on science. http://www.cidrap.umn.edu/news-perspective/2020/03/commentary-covid-19-transmission-messages-should-hinge-science.

90. Brosseau, L. M.; Jones, R., Commentary: Protecting health workers from airborne MERS-CoV - learning from SARS. http://www.cidrap.umn.edu/news-perspective/2014/05/commentary-protecting-health-workers-airborne-mers-cov-learning-sars.
91. Bryner, J., First US infant death linked to COVID-19 reported in Illinois. *LiveScience* 2020. https://www.livescience.com/us-infant-dies-coronavirus.html
92. Buitrago-Garcia, D.; Egli-Gany, D.; Counotte, M. J.; Hossmann, S.; Imeri, H.; Ipekci, A. M.; Salanti, G.; Low, N., Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLOS Medicine* **2020,** *17* (9), e1003346. https://doi.org/10.1371/journal.pmed.1003346
93. Burbelo, P. D.; Riedo, F. X.; Morishima, C.; Rawlings, S.; Smith, D.; Das, S.; Strich, J. R.; Chertow, D. S.; Davey, R. T.; Cohen, J. I., Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients. *J Infect Dis* **2020**.
94. Bussani, R.; Schneider, E.; Zentilin, L.; Collesi, C.; Ali, H.; Braga, L.; Volpe, M. C.; Colliva, A.; Zanconati, F.; Berlot, G.; Silvestri, F.; Zacchigna, S.; Giacca, M., Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. *EBioMedicine* **2020**. https://doi.org/10.1016/j.ebiom.2020.103104
95. Byambasuren, O.; Cardona, M.; Bell, K.; Clark, J.; McLaws, M.-L.; Glasziou, P., Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. *Available at SSRN 3586675* **2020**.
96. Callow, K.; Parry, H.; Sergeant, M.; Tyrrell, D., The time course of the immune response to experimental coronavirus infection of man. *Epidemiology & Infection* **1990,** *105* (2), 435-446.
97. Callow, K. A.; Parry, H. F.; Sergeant, M.; Tyrrell, D. A., The time course of the immune response to experimental coronavirus infection of man. *Epidemiology and infection* **1990,** *105* (2), 435-446. https://pubmed.ncbi.nlm.nih.gov/2170159 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2271881/
98. Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
99. Carfì, A.; Bernabei, R.; Landi, F.; Group, f. t. G. A. C.-P.-A. C. S., Persistent Symptoms in Patients After Acute COVID-19. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.12603
100. Caronna, E.; Ballvé, A.; Llauradó, A.; Gallardo, V. J.; María Ariton, D.; Lallana, S.; Maza, S. L.; Gadea, M. O.; Quibus, L.; Restrepo, J. L.; Rodrigo-Gisbert, M.; Vilaseca, A.; Gonzalez, M. H.; Gallo, M. M.; Alpuente, A.; Torres-Ferrus, M.; Borrell, R. P.; Alvarez-Sabin, J.; Pozo-Rosich, P., Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. *Cephalalgia* **2020,** *40* (13), 1410-1421. https://doi.org/10.1177/0333102420965157
101. Casey, M.; Griffin, J.; McAloon, C. G.; Byrne, A. W.; Madden, J. M.; McEvoy, D.; Collins, A. B.; Hunt, K.; Barber, A.; Butler, F.; Lane, E. A.; O Brien, K.; Wall, P.; Walsh, K. A.; More, S. J., Estimating pre-symptomatic transmission of COVID-19: a secondary analysis using published data. *medRxiv* **2020**, 2020.05.08.20094870. https://www.medrxiv.org/content/medrxiv/early/2020/05/11/2020.05.08.20094870.full.pdf
102. Cauchois, R.; Koubi, M.; Delarbre, D.; Manet, C.; Carvelli, J.; Blasco, V. B.; Jean, R.; Fouche, L.; Bornet, C.; Pauly, V.; Mazodier, K.; Pestre, V.; Jarrot, P.-A.; Dinarello, C. A.; Kaplanski, G., Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. *Proceedings of the*

National Academy of Sciences **2020**, 202009017. http://www.pnas.org/content/early/2020/07/21/2009017117.abstract
103. Cavalcanti, A. B.; Zampieri, F. G.; Rosa, R. G.; Azevedo, L. C. P.; Veiga, V. C.; Avezum, A.; Damiani, L. P.; Marcadenti, A.; Kawano-Dourado, L.; Lisboa, T.; Junqueira, D. L. M.; de Barros e Silva, P. G. M.; Tramujas, L.; Abreu-Silva, E. O.; Laranjeira, L. N.; Soares, A. T.; Echenique, L. S.; Pereira, A. J.; Freitas, F. G. R.; Gebara, O. C. E.; Dantas, V. C. S.; Furtado, R. H. M.; Milan, E. P.; Golin, N. A.; Cardoso, F. F.; Maia, I. S.; Hoffmann Filho, C. R.; Kormann, A. P. M.; Amazonas, R. B.; Bocchi de Oliveira, M. F.; Serpa-Neto, A.; Falavigna, M.; Lopes, R. D.; Machado, F. R.; Berwanger, O., Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2019014
104. CDC, 2019 Novel Coronavirus RT-PCR Identification Protocols. https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html.
105. CDC, About Masks. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/about-face-coverings.html.
106. CDC, Confirmation of COVID-19 in Two Pet Cats in New York. Centers for Disease Control and Prevention: 2020. https://www.cdc.gov/media/releases/2020/s0422-covid-19-cats-NYC.html
107. CDC, COVID-19 Forecasts. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/forecasting-us.html.
108. CDC, Interim healthcare infection prevention and control recommendations for patients under investigation for 2019 novel coronavirus. https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html.
109. CDC, Public Health Guidance for Community-Related Exposure. https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html.
110. CDC, Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. **2020**. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html
111. CDC, Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html.
112. CDC, Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission. https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-sars-cov-2.html.
113. CDC, Situation summary. https://www.cdc.gov/coronavirus/2019-nCoV/summary.html.
114. CDC, Symptoms of Coronavirus. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
115. CDC, Updated Isolation Guidance Does Not Imply Immunity to COVID-19. https://www.cdc.gov/media/releases/2020/s0814-updated-isolation-guidance.html.
116. CDC, C., China's CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html (accessed 01/27/2020).
117. CEID, Nowcasts for the US, states, and territories. http://2019-coronavirus-tracker.com/nowcast.html.
118. Celltrion, Celltrion presents efficacy and safety data for potential COVID-19 treatment candidate CT-P59 in patients with mild symptoms. 2020. https://www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=409&pagenumber=1&keyword=&keyword_type=
119. Centers for Disease Control and Prevention (CDC), Coronaivurs Disease 2019 (COVID-19) 2020 Interim Case Definition, Approved August 5 2020. https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/ (accessed 21 Sept 2020).
120. Centers for Disease Control and Prevention (CDC), Overview of Testing for SARS-CoV-2 (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html (accessed 22 September 2020).

121. Cevik, M.; Marcus, J.; Buckee, C.; Smith, T., SARS-CoV-2 transmission dynamics should inform policy. *Available at SSRN 3692807* **2020**.
122. Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.; Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; Yuen, K.-Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* **2020**. https://www.sciencedirect.com/science/article/pii/S0140673620301549
123. Chan, J. F.; Zhang, A. J.; Yuan, S.; Poon, V. K.; Chan, C. C.; Lee, A. C.; Chan, W. M.; Fan, Z.; Tsoi, H. W.; Wen, L.; Liang, R.; Cao, J.; Chen, Y.; Tang, K.; Luo, C.; Cai, J. P.; Kok, K. H.; Chu, H.; Chan, K. H.; Sridhar, S.; Chen, Z.; Chen, H.; To, K. K.; Yuen, K. Y., Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clin Infect Dis* **2020**. https://www.ncbi.nlm.nih.gov/pubmed/32215622
124. Chande, A. T.; Gussler, W.; Harris, M.; Lee, S.; Rishishwar, L.; Jordan, I. K.; Andris, C. M.; Weitz, J. S., Interactive COVID-19 Event Risk Assessment Planning Tool. http://covid19risk.biosci.gatech.edu/.
125. Chandrashekar, A.; Liu, J.; Martinot, A. J.; McMahan, K.; Mercado, N. B.; Peter, L.; Tostanoski, L. H.; Yu, J.; Maliga, Z.; Nekorchuk, M.; Busman-Sahay, K.; Terry, M.; Wrijil, L. M.; Ducat, S.; Martinez, D. R.; Atyeo, C.; Fischinger, S.; Burke, J. S.; Slein, M. D.; Pessaint, L.; Van Ry, A.; Greenhouse, J.; Taylor, T.; Blade, K.; Cook, A.; Finneyfrock, B.; Brown, R.; Teow, E.; Velasco, J.; Zahn, R.; Wegmann, F.; Abbink, P.; Bondzie, E. A.; Dagotto, G.; Gebre, M. S.; He, X.; Jacob-Dolan, C.; Kordana, N.; Li, Z.; Lifton, M. A.; Mahrokhian, S. H.; Maxfield, L. F.; Nityanandam, R.; Nkolola, J. P.; Schmidt, A. G.; Miller, A. D.; Baric, R. S.; Alter, G.; Sorger, P. K.; Estes, J. D.; Andersen, H.; Lewis, M. G.; Barouch, D. H., SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science* **2020**, eabc4776. https://science.sciencemag.org/content/sci/early/2020/05/19/science.abc4776.full.pdf
126. Chang, S.; Pierson, E.; Koh, P. W.; Gerardin, J.; Redbird, B.; Grusky, D.; Leskovec, J., Mobility network models of COVID-19 explain inequities and inform reopening. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2923-3
127. Changzheng, L. J. L., Experts in the medical treatment team: Wuhan's unexplained viral pneumonia patients can be controlled more. https://www.cn-healthcare.com/article/20200110/content-528579.html.
128. Chen, C.; Cao, M.; Peng, L.; Guo, X.; Yang, F.; Wu, W.; Chen, L.; Yang, Y.; Liu, Y.; Wang, F., Coronavirus Disease-19 Among Children Outside Wuhan, China. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546071
129. Chen, L.; Wang, G.; Long, X.; Hou, H.; Wei, J.; Cao, Y.; Tan, J.; Liu, W.; Huang, L.; Meng, F.; Huang, L.; Wang, N.; Zhao, J.; Huang, G.; Sun, Z.; Wang, W.; Zhou, J., Dynamics of Blood Viral Load is Strongly Associated with Clinical Outcomes in COVID-19 Patients: A Prospective Cohort Study. *The Journal of Molecular Diagnostics* **2020**. http://www.sciencedirect.com/science/article/pii/S1525157820305213
130. Cheng, H.-Y.; Jian, S.-W.; Liu, D.-P.; Ng, T.-C.; Huang, W.-T.; Lin, H.-H.; Team, f. t. T. C.-O. I., Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Internal Medicine* **2020**. https://doi.org/10.1001/jamainternmed.2020.2020
131. Chhatwal, J.; Ayer, T.; Linas, B. P. D., O. O.; Mueller, P.; Adee, M.; Ladd, M. A.; Xiao, J. Y. X., COVID-19. https://www.covid19sim.org/.
132. Chicago, Forecasting for Illinois SARS-CoV-2 model. https://github.com/cobeylab/covid_IL/tree/master/Forecasting.
133. Chin, A.; Chu, J.; Perera, M.; Hui, K.; Yen, H.-L.; Chan, M.; Peiris, M.; Poon, L., Stability of SARS-CoV-2 in different environmental conditions. *medRxiv* **2020**, 2020.03.15.20036673. https://www.medrxiv.org/content/medrxiv/early/2020/03/27/2020.03.15.20036673.full.pdf

134. Chin, A. W. H.; Chu, J. T. S.; Perera, M. R. A.; Hui, K. P. Y.; Yen, H.-L.; Chan, M. C. W.; Peiris, M.; Poon, L. L. M., Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe*. https://doi.org/10.1016/S2666-5247(20)30003-3
135. Chin, A. W. H.; Chu, J. T. S.; Perera, M. R. A.; Hui, K. P. Y.; Yen, H.-L.; Chan, M. C. W.; Peiris, M.; Poon, L. L. M., Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe* **2020,** *1* (1), e10. https://doi.org/10.1016/S2666-5247(20)30003-3
136. Choe, P. G.; Kang, C. K.; Suh, H. J.; Jung, J.; Kang, E.; Lee, S. Y.; Song, K.-H.; Kim, H. B.; Kim, N. J.; Park, W. B.; Kim, E. S.; Oh, M.-d., Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. *Emerging Infectious Disease journal* **2020,** *26* (10), 2484. https://wwwnc.cdc.gov/eid/article/26/10/20-2211_article
137. Choi, E.; Chu, D. K. W.; Cheng, P. K. C.; Tsang, D. N. C.; Peiris, M.; Bausch, D.; Poon, L. L. M.; Watson-Jones, D., In-Flight Transmission of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerging Infectious Disease journal* **2020,** *26* (11). https://wwwnc.cdc.gov/eid/article/26/11/20-3254_article
138. Christensen, B.; Favaloro, E. J.; Lippi, G.; Van Cott, E. M., Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19). *Semin Thromb Hemost* **2020,** (EFirst).
139. Chu, D. K.; Akl, E. A.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H. J.; Chu, D. K.; Akl, E. A.; El-harakeh, A.; Bognanni, A.; Lotfi, T.; Loeb, M.; Hajizadeh, A.; Bak, A.; Izcovich, A.; Cuello-Garcia, C. A.; Chen, C.; Harris, D. J.; Borowiack, E.; Chamseddine, F.; Schünemann, F.; Morgano, G. P.; Muti Schünemann, G. E. U.; Chen, G.; Zhao, H.; Neumann, I.; Chan, J.; Khabsa, J.; Hneiny, L.; Harrison, L.; Smith, M.; Rizk, N.; Giorgi Rossi, P.; AbiHanna, P.; El-khoury, R.; Stalteri, R.; Baldeh, T.; Piggott, T.; Zhang, Y.; Saad, Z.; Khamis, A.; Reinap, M.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H. J., Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)31142-9
140. Chulalongkorn, ChulaCov19 mRNA Vaccine in Healthy Adults. https://clinicaltrials.gov/ct2/show/NCT04566276.
141. Clark, K. E. N.; Collas, O.; Lachmann, H.; Singh, A.; Buckley, J.; Bhagani, S., Safety of intravenous Anakinra in COVID-19 with evidence of hyperinflammation, a case series. *Rheumatology Advances in Practice* **2020**. https://doi.org/10.1093/rap/rkaa040
142. Clean Flow, Clean Flow Healthcare Mini. https://cleanworkscorp.com/wp-content/uploads/2020/04/Clean_Works_Heathcare_Mini.pdf (accessed 09 Nov 2020).
143. CNBC, Russia approves second Covid-19 vaccine after preliminary trials. https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html.
144. Cockrell, A. S.; Yount, B. L.; Scobey, T.; Jensen, K.; Douglas, M.; Beall, A.; Tang, X.-C.; Marasco, W. A.; Heise, M. T.; Baric, R. S., A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nature microbiology* **2016,** *2* (2), 1-11.
145. Codagenix, Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19. https://clinicaltrials.gov/ct2/show/NCT04619628?term=NCT04619628&draw=2&rank=1.
146. Cohen, J., Mining coronavirus genomes for clues to the outbreak's origins. *Science* 2020. https://www.sciencemag.org/news/2020/01/mining-coronavirus-genomes-clues-outbreak-s-origins
147. Cohen, J., Wuhan seafood market may not be source of novel virus spreading globally. https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally (accessed 01/27/2020).
148. Control, E. C. f. D. P. a., Rapid Risk Assessment: Detection of new SARS-CoV-2 variants related to mink. *European Centre for Disease Prevention and Control* **2020**. https://www.ecdc.europa.eu/en/publications-data/detection-new-sars-cov-2-variants-mink?ftag=MSF0951a18

149. Courtemanche, C.; Garuccio, J.; Le, A.; Pinkston, J.; Yelowitz, A., Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate. *Health Affairs* **2020**, 10.1377/hlthaff.2020.00608. https://doi.org/10.1377/hlthaff.2020.00608
150. Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.; Decroly, E., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral research* **2020,** *176*, 104742.
151. Covaxx, A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine. https://clinicaltrials.gov/ct2/show/NCT04545749.
152. Cowling, B. J.; Ali, S. T.; Ng, T. W. Y.; Tsang, T. K.; Li, J. C. M.; Fong, M. W.; Liao, Q.; Kwan, M. Y.; Lee, S. L.; Chiu, S. S.; Wu, J. T.; Wu, P.; Leung, G. M., Impact assessment of non-pharmaceutical interventions against COVID-19 and influenza in Hong Kong: an observational study. *medRxiv* **2020**, 2020.03.12.20034660.
https://www.medrxiv.org/content/medrxiv/early/2020/03/16/2020.03.12.20034660.full.pdf
153. CureVax, A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults. https://clinicaltrials.gov/ct2/show/NCT04515147.
154. Daily, H., Wuhan Institute of Virology, Chinese Academy of Sciences and others have found that 3 drugs have a good inhibitory effect on new coronavirus. Chen, L., Ed. 2020.
http://news.cnhubei.com/content/2020-01/28/content_12656365.html
155. Damas, J.; Hughes, G. M.; Keough, K. C.; Painter, C. A.; Persky, N. S.; Corbo, M.; Hiller, M.; Koepfli, K.-P.; Pfenning, A. R.; Zhao, H.; Genereux, D. P.; Swofford, R.; Pollard, K. S.; Ryder, O. A.; Nweeia, M. T.; Lindblad-Toh, K.; Teeling, E. C.; Karlsson, E. K.; Lewin, H. A., Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. *Proceedings of the National Academy of Sciences* **2020**, 202010146. https://www.pnas.org/content/pnas/early/2020/08/20/2010146117.full.pdf
156. Dasgupta, S.; Bowen, V. B. L., A.; al., e., Association Between Social Vulnerability and a County's Risk for Becoming a COVID-19 Hotspot — United States, June 1–July 25, 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1535-1541.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6942a3.htm
157. Davies, A.; Thompson, K. A.; Giri, K.; Kafatos, G.; Walker, J.; Bennett, A., Testing the efficacy of homemade masks: would they protect in an influenza pandemic? *Disaster Med Public Health Prep* **2013,** *7* (4), 413-8. https://www.ncbi.nlm.nih.gov/pubmed/24229526
158. Davoudi-Monfared, E.; Rahmani, H.; Khalili, H.; Hajiabdolbaghi, M.; Salehi, M.; Abbasian, L.; Kazemzadeh, H.; Yekaninejad, M. S., Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial. *medRxiv* **2020**, 2020.05.28.20116467.
https://www.medrxiv.org/content/medrxiv/early/2020/05/30/2020.05.28.20116467.full.pdf
159. De Albuquerque, N.; Baig, E.; Ma, X.; Zhang, J.; He, W.; Rowe, A.; Habal, M.; Liu, M.; Shalev, I.; Downey, G. P.; Gorczynski, R.; Butany, J.; Leibowitz, J.; Weiss, S. R.; McGilvray, I. D.; Phillips, M. J.; Fish, E. N.; Levy, G. A., Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. *J Virol* **2006,** *80* (21), 10382-94.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1641767/pdf/0747-06.pdf
160. de Haan, C. A. M.; Haijema, B. J.; Schellen, P.; Schreur, P. W.; te Lintelo, E.; Vennema, H.; Rottier, P. J. M., Cleavage of Group 1 Coronavirus Spike Proteins: How Furin Cleavage Is Traded Off against Heparan Sulfate Binding upon Cell Culture Adaptation. *Journal of Virology* **2008,** *82* (12), 6078-6083.
https://jvi.asm.org/content/jvi/82/12/6078.full.pdf
161. de Vries, R. D.; Schmitz, K. S.; Bovier, F. T.; Noack, D.; Haagmans, B. L.; Biswas, S.; Rockx, B.; Gellman, S. H.; Alabi, C. A.; de Swart, R. L.; Moscona, A.; Porotto, M., Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets. *bioRxiv* **2020**, 2020.11.04.361154.
https://www.biorxiv.org/content/biorxiv/early/2020/11/05/2020.11.04.361154.full.pdf

162. Dediego, M. L.; Pewe, L.; Alvarez, E.; Rejas, M. T.; Perlman, S.; Enjuanes, L., Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology* **2008,** *376* (2), 379-389. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810402/
163. Degesys, N. F.; Wang, R. C.; Kwan, E.; Fahimi, J.; Noble, J. A.; Raven, M. C., Correlation Between N95 Extended Use and Reuse and Fit Failure in an Emergency Department. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.9843
164. Delahoy, M. J.; Whitaker, M.; O'Halloran, A.; al., e., Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 — COVID-NET, 13 States, March 1–August 22, 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 16 September 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6938e1.htm?s_cid=mm6938e1_w
165. Demichev, V.; Tober-Lau, P.; Nazarenko, T.; Thibeault, C.; Whitwell, H.; Lemke, O.; Röhl, A.; Freiwald, A.; Szyrwiel, L.; Ludwig, D.; Correia-Melo, C.; Helbig, E. T.; Stubbemann, P.; Grüning, N.-M.; Blyuss, O.; Vernardis, S.; White, M.; Messner, C. B.; Joannidis, M.; Sonnweber, T.; Klein, S. J.; Pizzini, A.; Wohlfarter, Y.; Sahanic, S.; Hilbe, R.; Schaefer, B.; Wagner, S.; Mittermaier, M.; Machleidt, F.; Garcia, C.; Ruwwe-Glösenkamp, C.; Lingscheid, T.; de Jarcy, L. B.; Stegemann, M. S.; Pfeiffer, M.; Jürgens, L.; Denker, S.; Zickler, D.; Enghard, P.; Zelezniak, A.; Campbell, A.; Hayward, C.; Porteous, D. J.; Marioni, R. E.; Uhrig, A.; Müller-Redetzky, H.; Zoller, H.; Löffler-Ragg, J.; Keller, M. A.; Tancevski, I.; Timms, J. F.; Zaikin, A.; Hippenstiel, S.; Ramharter, M.; Witzenrath, M.; Suttorp, N.; Lilley, K.; Mülleder, M.; Sander, L. E.; Ralser, M.; Kurth, F., A time-resolved proteomic and diagnostic map characterizes COVID-19 disease progression and predicts outcome. *medRxiv* **2020**, 2020.11.09.20228015. https://www.medrxiv.org/content/medrxiv/early/2020/11/12/2020.11.09.20228015.full.pdf
166. Deng, C., China to Fast-Track Coronavirus Vaccine Trial Based on Advanced Genetics Technology https://www.wsj.com/articles/china-to-fast-track-coronavirus-vaccine-trial-based-on-advanced-genetics-technology-11593180841.
167. Deng, C.; Jones, R., In Global Covid-19 Vaccine Race, Chinese Shot Receives First Foreign Approval. *Wall Street Journal* 2020. https://www.wsj.com/articles/in-global-covid-19-vaccine-race-chinese-shot-receives-first-foreign-approval-11600171149
168. Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Chen, T.; Liu, X.; Zhao, W.; Han, Y.; Qin, C., Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. *Nature Communications* **2020,** *11* (1), 4400. https://doi.org/10.1038/s41467-020-18149-6
169. Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Liu, X.; Zhao, W.; Han, Y.; Qin, C., Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques. *bioRxiv* **2020**.
170. Deng, W.; Bao, L.; Liu, J.; Xiao, C.; Liu, J.; Xue, J.; Lv, Q.; Qi, F.; Gao, H.; Yu, P.; Xu, Y.; Qu, Y.; Li, F.; Xiang, Z.; Yu, H.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Liu, Y.; Zhao, W.; Han, Y.; Zhao, L.; Liu, X.; Wei, Q.; Qin, C., Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science* **2020**, eabc5343. https://science.sciencemag.org/content/sci/early/2020/07/01/science.abc5343.full.pdf
171. Deng, X.; Gu, W.; Federman, S.; du Plessis, L.; Pybus, O. G.; Faria, N.; Wang, C.; Yu, G.; Bushnell, B.; Pan, C.-Y.; Guevara, H.; Sotomayor-Gonzalez, A.; Zorn, K.; Gopez, A.; Servellita, V.; Hsu, E.; Miller, S.; Bedford, T.; Greninger, A. L.; Roychoudhury, P.; Starita, L. M.; Famulare, M.; Chu, H. Y.; Shendure, J.; Jerome, K. R.; Anderson, C.; Gangavarapu, K.; Zeller, M.; Spencer, E.; Andersen, K. G.; MacCannell, D.; Paden, C. R.; Li, Y.; Zhang, J.; Tong, S.; Armstrong, G.; Morrow, S.; Willis, M.; Matyas, B. T.; Mase, S.; Kasirye, O.; Park, M.; Masinde, G.; Chan, C.; Yu, A. T.; Chai, S. J.; Villarino, E.; Bonin, B.; Wadford, D. A.; Chiu, C. Y., Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California.

Science **2020**, eabb9263.
https://science.sciencemag.org/content/sci/early/2020/06/05/science.abb9263.full.pdf
172. Dentali, F.; Sironi, A. P.; Ageno, W.; Turato, S.; Bonfanti, C.; Frattini, F.; Crestani, S.; Franchini, M., In *Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature*, Seminars in thrombosis and hemostasis, Thieme Medical Publishers: 2012; pp 535-548.
173. Dequin, P. F.; Heming, N.; Meziani, F.; Plantefève, G.; Voiriot, G.; Badié, J.; François, B.; Aubron, C.; Ricard, J. D.; Ehrmann, S.; Jouan, Y.; Guillon, A.; Leclerc, M.; Coffre, C.; Bourgoin, H.; Lengellé, C.; Caille-Fénérol, C.; Tavernier, E.; Zohar, S.; Giraudeau, B.; Annane, D.; Le Gouge, A., Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *Jama* **2020**. https://jamanetwork.com/journals/jama/fullarticle/2770276
174. Deslandes, A.; Berti, V.; Tandjaoui-Lambotte, Y.; Alloui, C.; Carbonnelle, E.; Zahar, J. R.; Brichler, S.; Cohen, Y., SARS-CoV-2 was already spreading in France in late December 2019. *International Journal of Antimicrobial Agents* **2020**, 106006.
http://www.sciencedirect.com/science/article/pii/S0924857920301643
175. DHS, Estimated Airborne Decay of SARS-CoV-2. https://www.dhs.gov/science-and-technology/sars-airborne-calculator.
176. DHS, Estimated Natural Decay of SARS-CoV-2 (virus that causes COVID-19) on surfaces under a range of temperatures and relative humidity. https://www.dhs.gov/science-and-technology/sars-calculator.
177. DHS, *Low-Cost Decontamination of N95 Respirators*; Department of Homeland Security Science &Technology Directorate: 2020.
https://www.dhs.gov/sites/default/files/publications/multicooker_n95_decontamination_factsheet_v9_2020_06_15.pdf
178. Ding, X.; Yin, K.; Li, Z.; Lalla, R. V.; Ballesteros, E.; Sfeir, M. M.; Liu, C., Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay. *Nature Communications* **2020,** *11* (1), 4711. https://doi.org/10.1038/s41467-020-18575-6
179. Doi, Y.; Hibino, M.; Hase, R.; Yamamoto, M.; Kasamatsu, Y.; Hirose, M.; Mutoh, Y.; Homma, Y.; Terada, M.; Ogawa, T.; Kashizaki, F.; Yokoyama, T.; Koba, H.; Kasahara, H.; Yokota, K.; Kato, H.; Yoshida, J.; Kita, T.; Kato, Y.; Kamio, T.; Kodama, N.; Uchida, Y.; Ikeda, N.; Shinoda, M.; Nakagawa, A.; Nakatsumi, H.; Horiguchi, T.; Iwata, M.; Matsuyama, A.; Banno, S.; Koseki, T.; Teramachi, M.; Miyata, M.; Tajima, S.; Maeki, T.; Nakayama, E.; Taniguchi, S.; Lim, C. K.; Saijo, M.; Imai, T.; Yoshida, H.; Kabata, D.; Shintani, A.; Yuzawa, Y.; Kondo, M., A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. *Antimicrob Agents Chemother* **2020**.
180. Dollard, P.; Griffin, I.; Berro, A.; al., e., Risk Assessment and Management of COVID-19 Among Travelers Arriving at Designated U.S. Airports, January 17–September 13, 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1681-1685.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6945a4.htm
181. Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S., Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. *Pediatrics* **2020**, e20200702.
https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.pdf
182. Doung-Ngern, P.; Suphanchaimat, R.; Panjangampatthana, A.; Janekrongtham, C.; Ruampoom, D.; Daochaeng, N.; Eungkanit, N.; Pisitpayat, N.; Srisong, N.; Yasopa, O.; Plernprom, P.; Promduangsi, P.; Kumphon, P.; Suangtho, P.; Watakulsin, P.; Chaiya, S.; Kripattanapong, S.; Chantian, T.; Bloss, E.; Namwat, C.; Limmathurotsakul, D., Case-Control Study of Use of Personal Protective Measures and Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Thailand. *Emerg Infect Dis* **2020,** *26* (11).
183. Du, Z.; Xu, X.; Wang, L.; Fox, S. J.; Cowling, B. J.; Galvani, A. P.; Meyers, L. A., Effects of Proactive Social Distancing on COVID-19 Outbreaks in 58 Cities, China. *Emerg Infect Dis* **2020,** *26* (9).

184. Du, Z.; Xu, x.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., COVID-19 serial interval estimates based on confirmed cases in public reports from 86 Chinese cities. *medRxiv* **2020**, 2020.04.23.20075796. https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20075796.full.pdf
185. Du, Z.; Xu, X.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., The serial interval of COVID-19 from publicly reported confirmed cases. *medRxiv* **2020**, 2020.02.19.20025452. https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.02.19.20025452.full.pdf
186. Duan, S.; Zhao, X.; Wen, R.; Huang, J.-j.; Pi, G.; Zhang, S.; Han, J.; Bi, S.; Ruan, L.; Dong, X.-p., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomedical and environmental sciences: BES* **2003,** *16* (3), 246-255.
187. Dunker, S.; Hornick, T.; Szczepankiewicz, G.; Maier, M.; Bastl, M.; Bumberger, J.; Treudler, R.; Liebert, U. G.; Simon, J.-C., No SARS-CoV-2 detected in air samples (pollen and particulate matter) in Leipzig during the first spread. *Science of The Total Environment* **2020**, 142881. http://www.sciencedirect.com/science/article/pii/S0048969720364111
188. Dzien, C.; Halder, W.; Winner, H.; Lechleitner, M., Covid-19 screening: are forehead temperature measurements during cold outdoor temperatures really helpful? *Wiener Klinische Wochenschrift* **2020**, 1-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582437/
189. E, B., Biological E's novel Covid-19 vaccine of SARS-CoV-2 for protection against Covid-19 disease. . http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329&EncHid=&userName=covid-19%20vaccine.
190. Edridge, A. W. D.; Kaczorowska, J.; Hoste, A. C. R.; Bakker, M.; Klein, M.; Jebbink, M. F.; Matser, A.; Kinsella, C. M.; Rueda, P.; Prins, M.; Sastre, P.; Deijs, M.; Hoek, L. v. d., Coronavirus protective immunity is short-lasting *Pre-print* **2020**. https://www.medrxiv.org/content/10.1101/2020.05.11.20086439v2.full.pdf
191. Eikenberry, S. E.; Mancuso, M.; Iboi, E.; Phan, T.; Eikenberry, K.; Kuang, Y.; Kostelich, E.; Gumel, A. B., To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. *Infectious Disease Modelling* **2020**.
192. Endeman, H.; van der Zee, P.; van Genderen, M. E.; van den Akker, J. P. C.; Gommers, D., Progressive respiratory failure in COVID-19: a hypothesis. *The Lancet Infectious Diseases* **2020**. https://doi.org/10.1016/S1473-3099(20)30366-2
193. Endo, A.; Abbott, S.; Kucharski, A.; Funk, S., Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China [version 1; peer review: 1 approved, 1 approved with reservations]. *Wellcome Open Research* **2020,** *5* (67). https://wellcomeopenresearch.org/articles/5-67/v1
194. Entos, A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults. https://clinicaltrials.gov/ct2/show/NCT04591184.
195. Environmental Protection Agency (EPA), List N: Disinfectants for Use Against SARS-CoV-2 (COVID-19). https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2-covid-19 (accessed 21 Sept 2020).
196. Environmental Protection Agency (EPA), Section 18 Emergency Exemption Requests and Coronavirus (COVID-19). https://www.epa.gov/pesticide-registration/section-18-emergency-exemption-requests-and-coronavirus-covid-19 (accessed 31 August 2020).
197. ExpressPharma, Bharat Biotech starts human trials for Covaxin, India's first COVID-19 vaccine. https://www.expresspharma.in/latest-updates/bharat-biotech-starts-human-trials-for-covaxin-indias-first-covid-19-vaccine/.
198. Facchetti, F.; Bugatti, M.; Drera, E.; Tripodo, C.; Sartori, E.; Cancila, V.; Papaccio, M.; Castellani, R.; Casola, S.; Boniotti, M. B.; Cavadini, P.; Lavazza, A., SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. *EBioMedicine* **2020,** *59*. https://doi.org/10.1016/j.ebiom.2020.102951
199. Fagre, A.; Lewis, J.; Eckley, M.; Zhan, S.; Rocha, S. M.; Sexton, N. R.; Burke, B.; Geiss, B. J.; Peersen, O.; Kading, R.; Rovnak, J.; Ebel, G. D.; Tjalkens, R. B.; Aboellail, T.; Schountz, T., SARS-CoV-2 infection,

neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents. *bioRxiv* **2020**, 2020.08.07.241810.
http://biorxiv.org/content/early/2020/08/07/2020.08.07.241810.abstract
200. FDA, Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection. Food and Drug Administration: 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-test-detects-neutralizing-antibodies-recent-or
201. FDA, Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. U.S. Food and Drug Administration: 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and
202. FDA, COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19. Food and Drug Administration: 2020. https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized
203. FDA, Development and Licensure of Vaccines to Prevent COVID-19 Guidance for Industry. https://www.fda.gov/media/139638/download.
204. FDA, *Emergency Use Authorization*; Food and Drug Administration: 2020. https://www.fda.gov/media/136529/download
205. FDA, FAQs on Shortages of Surgical Masks and Gowns. https://www.fda.gov/medical-devices/personal-protective-equipment-infection-control/faqs-shortages-surgical-masks-and-gowns#kn95.
206. FDA, FAQs on Testing for SARS-CoV-2. https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-testing-sars-cov-2#nolonger.
207. FDA, FDA In Brief: FDA Issues Guidance on Emergency Use Authorization for COVID-19 Vaccines. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-issues-guidance-emergency-use-authorization-covid-19-vaccines.
208. FDA, *ID NOW COVID-19*; Food and Drug Administration: 2020. https://www.fda.gov/media/136525/download
209. FDA, Protective Barrier Enclosures Without Negative Pressure Used During the COVID-19 Pandemic May Increase Risk to Patients and Health Care Providers - Letter to Health Care Providers. Food and Drug Administration: 2020. https://www.fda.gov/medical-devices/letters-health-care-providers/protective-barrier-enclosures-without-negative-pressure-used-during-covid-19-pandemic-may-increase
210. FDA, Respirator Models Removed from Appendix A. https://www.fda.gov/media/137928/download (accessed 05/15/2020).
211. FDA, U. S., FDA Approves First Treatment for COVID-19. 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
212. FDA, U. S., FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration's Fight Against Pandemic. 2020. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment
213. Fears, A.; Klimstra, W.; Duprex, P.; Hartman, A.; Weaver, S.; Plante, K.; Mirchandani, D.; Plante, J. A.; Aguilar, P.; Fernández, D.; Nalca, A.; Totura, A.; Dyer, D.; Kearney, B.; Lackemeyer, M.; Bohannon, J. K.; Johnson, R.; Garry, R.; Reed, D.; Roy, C., Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions. *Emerging Infectious Disease journal* **2020,** *26* (9). https://wwwnc.cdc.gov/eid/article/26/9/20-1806_article

214. Feldman, O.; Meir, M.; Shavit, D.; Idelman, R.; Shavit, I., Exposure to a Surrogate Measure of Contamination From Simulated Patients by Emergency Department Personnel Wearing Personal Protective Equipment. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.6633
215. Ferguson, N.; Laydon, D.; Nedjati-Gilani, G.; Imai, N.; Ainslie, K.; Baguelin, M.; Bhatia, S.; Boonyasiri, A.; Cucunuba, Z.; Cuomo-Dannenburg, G.; Dighe, A.; Dorigatti, I.; Fu, H.; Gaythorpe, K.; Green, W.; Hamlet, A.; Hinsley, W.; Okell, L.; van Elsland, S.; Thompson, H.; Verity, R.; Volz, E.; Wang, H.; Wang, Y.; Walker, P.; Walters, C.; Winskill, P.; Whittaker, C.; Donnelly, C.; Riley, S.; Ghani, A., *Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand*; 2020. https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf
216. Figueiredo-Campos, P.; Blankenhaus, B.; Mota, C.; Gomes, A.; Serrano, M.; Ariotti, S.; Costa, C.; Nunes-Cabaço, H.; Mendes, A. M.; Gaspar, P.; Pereira-Santos, M. C.; Rodrigues, F.; Condeço, J.; Escoval, M. A.; Santos, M.; Ramirez, M.; Melo-Cristino, J.; Simas, J. P.; Vasconcelos, E.; Afonso, Â.; Veldhoen, M., Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to six months post disease onset. *European Journal of Immunology n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/eji.202048970
217. Finlay, Estudio Fase I, abierto, secuencial y adaptativo, para evaluar la seguridad, reactogenicidad y explorar la inmunogenicidad, del Candidato Vacunal profiláctico FINLAY- FR-2 anti SARS-CoV-2 (COVID-19). https://rpcec.sld.cu/ensayos/RPCEC00000340-Sp.
218. Fiolet, T.; Guihur, A.; Rebeaud, M.; Mulot, M.; Peiffer-Smadja, N.; Mahamat-Saleh, Y., Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis. *Clinical Microbiology and Infection* **2020**. http://www.sciencedirect.com/science/article/pii/S1198743X2030505X
219. Firth, J. A.; Hellewell, J.; Klepac, P.; Kissler, S. M.; Group, C. C.-W.; Kucharski, A. J.; Spurgin, L. G., Combining fine-scale social contact data with epidemic modelling reveals interactions between contact tracing, quarantine, testing and physical distancing for controlling COVID-19. *Preprint* **2020**. https://cmmid.github.io/topics/covid19/reports/2020_05_25_firth_et_al_manuscript.pdf
220. Fischer, E. P.; Fischer, M. C.; Grass, D.; Henrion, I.; Warren, W. S.; Westman, E., Low-cost measurement of facemask efficacy for filtering expelled droplets during speech. *Science Advances* **2020,** *07 August 2020*.
221. Fischer, K. A.; Olson, S. M.; Tenforde, M. W.; al., e., Telework Before Illness Onset Among Symptomatic Adults Aged ≥18 Years With and Without COVID-19 in 11 Outpatient Health Care Facilities — United States, July 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1648-1653. https://www.cdc.gov/mmwr/volumes/69/wr/mm6944a4.htm?s_cid=mm6944a4_w
222. Fischer, R.; Morris, D.; van Doremalen, N.; Sarchette, S.; Matson, M. J.; Bushmaker, T.; Yinda, C. K.; Seifert, S.; Gamble, A.; Williamson, B.; Judson, S.; de Wit, E.; Lloyd-Smith, J.; Munster, V., Effectiveness of N95 Respirator Decontamination and Reuse against SARS-CoV-2 Virus. *Emerging Infectious Disease journal* **2020,** *26* (9), 2253. https://wwwnc.cdc.gov/eid/article/26/9/20-1524_article
223. Fischer, R.; Morris, D. H.; van Doremalen, N.; Sarchette, S.; Matson, J.; Bushmaker, T.; Yinda, C. K.; Seifert, S.; Gamble, A.; Williamson, B.; Judson, S.; de Wit, E.; Lloyd-Smith, J.; Munster, V., Assessment of N95 respirator decontamination and re-use for SARS-CoV-2. *medRxiv* **2020**, 2020.04.11.20062018. https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.11.20062018.full.pdf
224. Fisher, D.; Reilly, A.; Zheng, A. K. E.; Cook, A. R.; Anderson, D. E., Seeding of outbreaks of COVID-19 by contaminated fresh and frozen food. *bioRxiv* **2020**, 2020.08.17.255166. https://www.biorxiv.org/content/biorxiv/early/2020/08/18/2020.08.17.255166.full.pdf
225. Fisher, K. A., Factors associated with cloth face covering use among adults during the COVID-19 pandemic—United States, April and May 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020,** *69*.

226. Fisher, K. A.; Tenforde, M. W.; Feldstein, L. R.; al., e., Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1258-1264. https://www.cdc.gov/mmwr/volumes/69/wr/mm6936a5.htm
227. Fisman, D. N.; Greer, A. L.; Tuite, A. R., Bidirectional impact of imperfect mask use on reproduction number of COVID-19: A next generation matrix approach. *Infectious Disease Modelling* **2020,** *5*, 405-408. http://www.sciencedirect.com/science/article/pii/S2468042720300191
228. Fitzpatrick, J.; DeSalvo, K., Helping public health officials combat COVID-19. Google: 2020. https://www.blog.google/technology/health/covid-19-community-mobility-reports?hl=en
229. Flahault, A.; Manetti, E.; Simonson, T.; Lee, G.; Choirat, C., COVID-19 Forecasting. https://renkulab.shinyapps.io/COVID-19-Epidemic-Forecasting/_w_e0463e1e/#shiny-tab-about.
230. Flannery, D. D.; Gouma, S.; Dhudasia, M. B.; Mukhopadhyay, S.; Pfeifer, M. R.; Woodford, E. C.; Gerber, J. S.; Arevalo, C. P.; Bolton, M. J.; Weirick, M. E.; Goodwin, E. C.; Anderson, E. M.; Greenplate, A. R.; Kim, J.; Han, N.; Pattekar, A.; Dougherty, J.; Kuthuru, O.; Mathew, D.; Baxter, A. E.; Vella, L. A.; Weaver, J.; Verma, A.; Leite, R.; Morris, J. S.; Rader, D. J.; Elovitz, M. A.; Wherry, E. J.; Puopolo, K. M.; Hensley, S. E., SARS-CoV-2 seroprevalence among parturient women in Philadelphia. *Science Immunology* **2020,** *5* (49), eabd5709. https://immunology.sciencemag.org/content/immunology/5/49/eabd5709.full.pdf
231. Flores-Alanis, A.; Sandner-Miranda, L.; Delgado, G.; Cravioto, A.; Morales-Espinosa, R., The receptor binding domain of SARS-CoV-2 spike protein is the result of an ancestral recombination between the bat-CoV RaTG13 and the pangolin-CoV MP789. *BMC Research Notes* **2020,** *13* (1), 398. https://doi.org/10.1186/s13104-020-05242-8
232. Florez, H.; Singh, S., Online dashboard and data analysis approach for assessing COVID-19 case and death data [version 1; peer review: 2 approved, 1 approved with reservations]. *F1000Research* **2020,** *9* (570). http://openr.es/kke
233. Food and Drug Administration (FDA), Coronavirus (COVID-19) Update: Daily Roundup October 15, 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-15-2020 (accessed 16 Oct 2020).
234. Food and Drug Administration (FDA), SARS-CoV-2 Reference Panel Comparative Data. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data (accessed 28 Sept 2020).
235. Forbes, H.; Morton, C. E.; Bacon, S.; McDonald, H. I.; Minassian, C.; Brown, J. P.; Rentsch, C. T.; Mathur, R.; Schultze, A.; DeVito, N. J.; MacKenna, B.; Hulme, W. J.; Croker, R.; Walker, A. J.; Williamson, E. J.; Bates, C.; Mehrkar, A.; Curtis, H. J.; Evans, D.; Wing, K.; Inglesby, P.; Drysdale, H.; Wong, A. Y.; Cockburn, J.; McManus, R.; Parry, J.; Hester, F.; Harper, S.; Douglas, I. J.; Smeeth, L.; Evans, S. J.; Bhaskaran, K.; Eggo, R. M.; Goldacre, B.; Tomlinson, L. A., Association between living with children and outcomes from COVID-19: an OpenSAFELY cohort study of 12 million adults in England. *medRxiv* **2020**, 2020.11.01.20222315. https://www.medrxiv.org/content/medrxiv/early/2020/11/02/2020.11.01.20222315.full.pdf
236. Frank, S.; Brown, S. M.; Capriotti, J. A.; Westover, J. B.; Pelletier, J. S.; Tessema, B., In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2. *JAMA Otolaryngology–Head & Neck Surgery* **2020**. https://doi.org/10.1001/jamaoto.2020.3053
237. Fraser, D. D.; Slessarev, M.; Martin, C. M.; Daley, M.; Patel, M. A.; Miller, M. R.; Patterson, E. K.; O'Gorman, D. B.; Gill, S. E.; Wishart, D. S.; Mandal, R.; Cepinskas, G.; Team, O. b. o. t. L. C. S., Metabolomics Profiling of Critically Ill Coronavirus Disease 2019 Patients: Identification of Diagnostic and Prognostic Biomarkers. *Critical Care Explorations* **2020,** *2* (10), e0272. https://journals.lww.com/ccejournal/Fulltext/2020/10000/Metabolomics_Profiling_of_Critically_Ill.44.aspx

238. Freuling, C. M.; Breithaupt, A.; Müller, T.; Sehl, J.; Balkema-Buschmann, A.; Rissmann, M.; Klein, A.; Wylezich, C.; Höper, D.; Wernike, K.; Aebischer, A.; Hoffmann, D.; Friedrichs, V.; Dorhoi, A.; Groschup, M. H.; Beer, M.; Mettenleiter, T. C., Susceptibility of raccoon dogs for experimental SARS-CoV-2 infection. *bioRxiv* **2020**, 2020.08.19.256800.
http://biorxiv.org/content/early/2020/08/20/2020.08.19.256800.abstract
239. Fu, W.; Liu, Y.; Liu, L.; Hu, H.; Cheng, X.; Liu, P.; Song, Z.; Zha, L.; Bai, S.; Xu, T.; Yuan, S.; Lu, F.; Shang, Z.; Zhao, Y.; Wang, J.; Zhao, J.; Ding, L.; Chen, J.; Zhang, L.; Zhu, T.; Zhang, X.; Lu, H.; Xu, J., An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19. *EClinicalMedicine* **2020**, 100547.
240. FUJIFILM Toyama Chemical Co., L., Anti-influenza drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients. Fujifilm, 2020.
https://www.fujifilm.com/news/n200923.html
241. Gaebler, C.; Wang, Z.; Lorenzi, J. C. C.; Muecksch, F.; Finkin, S.; Tokuyama, M.; Ladinsky, M.; Cho, A.; Jankovic, M.; Schaefer-Babajew, D.; Oliveira, T. Y.; Cipolla, M.; Viant, C.; Barnes, C. O.; Hurley, A.; Turroja, M.; Gordon, K.; Millard, K. G.; Ramos, V.; Schmidt, F.; Weisblum, Y.; Jha, D.; Tankelevich, M.; Yee, J.; Shimeliovich, I.; Robbiani, D. F.; Zhao, Z.; Gazumyan, A.; Hatziioannou, T.; Bjorkman, P. J.; Mehandru, S.; Bieniasz, P. D.; Caskey, M.; Nussenzweig, M. C., Evolution of Antibody Immunity to SARS-CoV-2. *bioRxiv* **2020**, 2020.11.03.367391.
https://www.biorxiv.org/content/biorxiv/early/2020/11/05/2020.11.03.367391.full.pdf
242. Gallaway, M. S.; Rigler, J.; Robinson, S.; al., e., Trends in COVID-19 Incidence After Implementation of Mitigation Measures — Arizona, January 22–August 7, 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1460-1463.
243. Gamaleya, Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 (RESIST).
https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2.
244. Gao, G.; Wang, A.; Wang, S.; Qian, F.; Chen, M.; Yu, F.; Zhang, J.; Wang, X.; Ma, X.; Zhao, T.; Zhang, F.; Chen, Z., A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients. *J Acquir Immune Defic Syndr* **2020**.
245. Garg, M.; Sharma, A. L.; Singh, S., Advancement in biosensors for inflammatory biomarkers of SARS-CoV-2 during 2019–2020. *Biosensors and Bioelectronics* **2021,** *171*, 112703.
http://www.sciencedirect.com/science/article/pii/S0956566320306928
246. Garg, S., Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020,** *69*.
247. Garvin, M. R.; Alvarez, C.; Miller, J. I.; Prates, E. T.; Walker, A. M.; Amos, B. K.; Mast, A. E.; Justice, A.; Aronow, B.; Jacobson, D., A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. *eLife* **2020,** *9*, e59177. https://doi.org/10.7554/eLife.59177
248. Gasser, R.; Cloutier, M.; Prévost, J.; Fink, C.; Ducas, É.; Ding, S.; Dussault, N.; Landry, P.; Tremblay, T.; Laforce-Lavoie, A.; Lewin, A.; Beaudoin-Bussières, G.; Laumaea, A.; Medjahed, H.; Larochelle, C.; Richard, J.; Dekaban, G. A.; Dikeakos, J. D.; Bazin, R.; Finzi, A., Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. *bioRxiv* **2020**, 2020.10.09.333278.
https://www.biorxiv.org/content/biorxiv/early/2020/10/09/2020.10.09.333278.full.pdf
249. Gatto, M.; Bertuzzo, E.; Mari, L.; Miccoli, S.; Carraro, L.; Casagrandi, R.; Rinaldo, A., Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures. *Proceedings of the National Academy of Sciences* **2020**, 202004978.
https://www.pnas.org/content/pnas/early/2020/04/22/2004978117.full.pdf

250. Gendelman, O.; Amital, H.; Bragazzi, N. L.; Watad, A.; Chodick, G., Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. *Autoimmunity Reviews* **2020**, 102566. http://www.sciencedirect.com/science/article/pii/S1568997220301282
251. Genexine, Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults. https://clinicaltrials.gov/ct2/show/NCT04445389?term=vaccine&cond=covid-19&draw=3.
252. Gilliam, W. S.; Malik, A. A.; Shafiq, M.; Klotz, M.; Reyes, C.; Humphries, J. E.; Murray, T.; Elharake, J. A.; Wilkinson, D.; Omer, S. B., COVID-19 Transmission in US Child Care Programs. *Pediatrics* **2020**, e2020031971. https://pediatrics.aappublications.org/content/pediatrics/early/2020/10/12/peds.2020-031971.full.pdf
253. Godfred-Cato, S.; Bryant, B.; Leung, J.; Oster, M. E.; Conklin, L.; Abrams, J.; Roguski, K.; Wallace, B.; Prezzato, E.; Koumans, E. H.; Lee, E. H.; Geevarughese, A.; Lash, M. K.; Reilly, K. H.; Pulver, W. P.; Thomas, D.; Feder, K. A.; Hsu, K. K.; Plipat, N.; Richardson, G.; Reid, H.; Lim, S.; Schmitz, A.; Pierce, T.; Hrapcak, S.; Datta, D.; Morris, S. B.; Clarke, K.; Belay, E.; Team, C. M.-C. R., COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020. https://www.cdc.gov/mmwr/volumes/69/wr/mm6932e2.htm?s_cid=mm6932e2_w.
254. Godoy, M., Mystery Inflammatory Syndrome In Kids And Teens Likely Linked To COVID-19. *NPR* 2020. https://www.npr.org/sections/health-shots/2020/05/07/851725443/mystery-inflammatory-syndrome-in-kids-and-teens-likely-linked-to-covid-19
255. Gold, J. A.; Rossen, L. M.; Ahmad, F. B.; al., e., Race, Ethnicity, and Age Trends in Persons Who Died from COVID-19 — United States, May–August 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 16 October 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6942e1.htm
256. Goldbaum, C., Is the Subway Risky? It May Be Safer Than You Think. *The New York Times* 2020. https://www.nytimes.com/2020/08/02/nyregion/nyc-subway-coronavirus-safety.html
257. Golinelli, D.; Boetto, E.; Maietti, E.; Fantini, M. P., The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. *PLOS ONE* **2020,** *15* (9), e0239508. https://doi.org/10.1371/journal.pone.0239508
258. Gonzalez-Reiche, A. S.; Hernandez, M. M.; Sullivan, M. J.; Ciferri, B.; Alshammary, H.; Obla, A.; Fabre, S.; Kleiner, G.; Polanco, J.; Khan, Z.; Alburquerque, B.; van de Guchte, A.; Dutta, J.; Francoeur, N.; Melo, B. S.; Oussenko, I.; Deikus, G.; Soto, J.; Sridhar, S. H.; Wang, Y.-C.; Twyman, K.; Kasarskis, A.; Altman, D. R.; Smith, M.; Sebra, R.; Aberg, J.; Krammer, F.; García-Sastre, A.; Luksza, M.; Patel, G.; Paniz-Mondolfi, A.; Gitman, M.; Sordillo, E. M.; Simon, V.; van Bakel, H., Introductions and early spread of SARS-CoV-2 in the New York City area. *Science* **2020**, eabc1917. https://science.sciencemag.org/content/sci/early/2020/05/28/science.abc1917.full.pdf
259. Google, U.S. COVID-19 Public Forecasts. https://datastudio.google.com/reporting/52f6e744-66c6-47aa-83db-f74201a7c4df/page/EfwUB?s=ou-b6M0HXag.
260. Goren, A.; Vaño-Galván, S.; Wambier, C. G.; McCoy, J.; Gomez-Zubiaur, A.; Moreno-Arrones, O. M.; Shapiro, J.; Sinclair, R. D.; Gold, M. H.; Kovacevic, M.; Mesinkovska, N. A.; Goldust, M.; Washenik, K., A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain – A potential clue to the role of androgens in COVID-19 severity. *Journal of Cosmetic Dermatology n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.13443
261. Goren, A.; Wambier, C. G.; Herrera, S.; McCoy, J.; Vaño-Galván, S.; Gioia, F.; Comeche, B.; Ron, R.; Serrano-Villar, S.; Ramos, P. M.; Cadegiani, F. A.; Kovacevic, M.; Tosti, A.; Shapiro, J.; Sinclair, R., Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. *J Eur Acad Dermatol Venereol* **2020**.

262. Götzinger, F.; Santiago-García, B.; Noguera-Julián, A.; al., e., COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *The Lancet Child & Adolescent Health* **2020**. https://doi.org/10.1016/S2352-4642(20)30177-2
263. Goyal, M. K.; Simpson, J. N.; Boyle, M. D.; Badolato, G. M.; Delaney, M.; McCarter, R.; Cora-Bramble, D., Racial/Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children. *Pediatrics* **2020**, e2020009951. https://pediatrics.aappublications.org/content/pediatrics/early/2020/08/03/peds.2020-009951.full.pdf
264. Griffin, B. D.; Chan, M.; Tailor, N.; Mendoza, E. J.; Leung, A.; Warner, B. M.; Duggan, A. T.; Moffat, E.; He, S.; Garnett, L.; Tran, K. N.; Banadyga, L.; Albietz, A.; Tierney, K.; Audet, J.; Bello, A.; Vendramelli, R.; Boese, A. S.; Fernando, L.; Lindsay, L. R.; Jardine, C. M.; Wood, H.; Poliquin, G.; Strong, J. E.; Drebot, M.; Safronetz, D.; Embury-Hyatt, C.; Kobasa, D., North American deer mice are susceptible to SARS-CoV-2. *bioRxiv* **2020**, 2020.07.25.221291. http://biorxiv.org/content/early/2020/07/26/2020.07.25.221291.abstract
265. Griffin, S., Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds. *BMJ* **2020,** *370*, m2650. http://www.bmj.com/content/370/bmj.m2650.abstract
266. Grifoni, A.; Weiskopf, D.; Ramirez, S. I.; Mateus, J.; Dan, J. M.; Moderbacher, C. R.; Rawlings, S. A.; Sutherland, A.; Premkumar, L.; Jadi, R. S., Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell* **2020**.
267. Grijalva, C. G.; Rolfes, M. A.; Zhu, Y.; al., e., Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub* (30 October 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e1.htm?s_cid=mm6944e1_w
268. GSK, Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate. https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/.
269. Gu, Y., COVID-19 Projections Using Machine Learning. https://covid19-projections.com/#view-projections.
270. Guan, L.; Zhou, L.; Zhang, J.; Peng, W.; Chen, R., More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. *European Respiratory Journal* **2020,** *55* (3), 2000352. https://erj.ersjournals.com/content/erj/55/3/2000352.full.pdf
271. Guan, W.-j.; Ni, Z.-y.; Hu, Y.; Liang, W.-h.; Ou, C.-q.; He, J.-x.; Liu, L.; Shan, H.; Lei, C.-l.; Hui, D. S. C.; Du, B.; Li, L.-j.; Zeng, G.; Yuen, K.-Y.; Chen, R.-c.; Tang, C.-l.; Wang, T.; Chen, P.-y.; Xiang, J.; Li, S.-y.; Wang, J.-l.; Liang, Z.-j.; Peng, Y.-x.; Wei, L.; Liu, Y.; Hu, Y.-h.; Peng, P.; Wang, J.-m.; Liu, J.-y.; Chen, Z.; Li, G.; Zheng, Z.-j.; Qiu, S.-q.; Luo, J.; Ye, C.-j.; Zhu, S.-y.; Zhong, N.-s., Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine* **2020,** *382*, 1708-1720. https://www.nejm.org/doi/full/10.1056/NEJMoa2002032?query=recirc_artType_railA_article
272. Guardian, Covid patients have lung damage 'weeks after leaving hospital'. *The Guardian* 2020. https://www.theguardian.com/world/2020/sep/06/covid-patients-have-lung-damage-weeks-after-leaving-hospital
273. Gudbjartsson, D. F.; Norddahl, G. L.; Melsted, P.; Gunnarsdottir, K.; Holm, H.; Eythorsson, E.; Arnthorsson, A. O.; Helgason, D.; Bjarnadottir, K.; Ingvarsson, R. F.; Thorsteinsdottir, B.; Kristjansdottir, S.; Birgisdottir, K.; Kristinsdottir, A. M.; Sigurdsson, M. I.; Arnadottir, G. A.; Ivarsdottir, E. V.; Andresdottir, M.; Jonsson, F.; Agustsdottir, A. B.; Berglund, J.; Eiriksdottir, B.; Fridriksdottir, R.; Gardarsdottir, E. E.; Gottfredsson, M.; Gretarsdottir, O. S.; Gudmundsdottir, S.; Gudmundsson, K. R.; Gunnarsdottir, T. R.; Gylfason, A.; Helgason, A.; Jensson, B. O.; Jonasdottir, A.; Jonsson, H.; Kristjansson, T.; Kristinsson, K. G.; Magnusdottir, D. N.; Magnusson, O. T.; Olafsdottir, L. B.; Rognvaldsson, S.; le Roux, L.; Sigmundsdottir, G.; Sigurdsson, A.; Sveinbjornsson, G.; Sveinsdottir, K. E.; Sveinsdottir, M.; Thorarensen, E. A.; Thorbjornsson, B.; Thordardottir, M.; Saemundsdottir, J.; Kristjansson, S. H.;

Josefsdottir, K. S.; Masson, G.; Georgsson, G.; Kristjansson, M.; Moller, A.; Palsson, R.; Gudnason, T.; Thorsteinsdottir, U.; Jonsdottir, I.; Sulem, P.; Stefansson, K., Humoral Immune Response to SARS-CoV-2 in Iceland. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2026116
274. Gudmundsdottir, Á.; Scheving, R.; Lindberg, F.; Stefansson, B., Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against common cold. *Journal of Medical Virology n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26554
275. Guilamo-Ramos, V.; Benzekri, A.; Thimm-Kaiser, M.; Hidalgo, A.; Perlman, D. C., Reconsidering assumptions of adolescent and young adult SARS-CoV-2 transmission dynamics. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1348
276. Gussow, A. B.; Auslander, N.; Faure, G.; Wolf, Y. I.; Zhang, F.; Koonin, E. V., Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. *Proceedings of the National Academy of Sciences* **2020**, 202008176. https://www.pnas.org/content/pnas/early/2020/06/09/2008176117.full.pdf
277. Halfmann, P. J.; Hatta, M.; Chiba, S.; Maemura, T.; Fan, S.; Takeda, M.; Kinoshita, N.; Hattori, S. I.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Imai, M.; Kawaoka, Y., Transmission of SARS-CoV-2 in Domestic Cats. *N Engl J Med* **2020**.
278. Hamburg-Eppendorf, U., Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19. https://clinicaltrials.gov/ct2/show/NCT04569383.
279. Han, J.; Zhang, X.; He, S.; Jia, P., Can the coronavirus disease be transmitted from food? A review of evidence, risks, policies and knowledge gaps. *Environmental Chemistry Letters* **2020**. https://doi.org/10.1007/s10311-020-01101-x
280. Hao, X.; Cheng, S.; Wu, D.; Wu, T.; Lin, X.; Wang, C., Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2554-8
281. Harbourt, D.; Haddow, A.; Piper, A.; Bloomfield, H.; Kearney, B.; Gibson, K.; Minogue, T., Modeling the Stability of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on Skin, Currency, and Clothing. *medRxiv* **2020**, 2020.07.01.20144253. https://www.medrxiv.org/content/medrxiv/early/2020/07/03/2020.07.01.20144253.full.pdf
282. Harris, J. E., Data from the COVID-19 epidemic in Florida suggest that younger cohorts have been transmitting their infections to less socially mobile older adults. *Review of Economics of the Household* **2020**. https://doi.org/10.1007/s11150-020-09496-w
283. Hart, B.; Tu, Y. P.; Jennings, R.; Verma, P.; Padgett, L. R.; Rains, D.; Vojta, D.; Berke, E. M., A comparison of health care worker-collected foam and polyester nasal swabs in convalescent COVID-19 patients. *PLoS One* **2020,** *15* (10), e0241100.
284. Hartman, A. L.; Nambulli, S.; McMillen, C. M.; White, A. G.; Tilston-Lunel, N.; Albe, J. R.; Cottle, E. L.; Dunn, M. D.; Frye, L. J.; Gilliland, T. H.; Olsen, E. L.; Malley, K. J.; Schwarz, M. M.; Tomko, J. A.; Walker, R. C.; Xia, M.; Hartman, M. S.; Klein, E.; Scanga, C.; Flynn, J. L.; Klimstra, W. B.; McElroy, A. K.; Reed, D. S.; Duprex, W. P., SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts. *bioRxiv* **2020**, 2020.06.20.137687. http://biorxiv.org/content/early/2020/06/21/2020.06.20.137687.abstract
285. Harvey, A. P.; Fuhrmeister, E. R.; Cantrell, M.; Pitol, A. K.; Swarthout, J. M.; Powers, J. E.; Nadimpalli, M. L.; Julian, T. R.; Pickering, A. J., Longitudinal monitoring of SARS-CoV-2 RNA on high-touch surfaces in a community setting. *medRxiv* **2020**, 2020.10.27.20220905. https://www.medrxiv.org/content/medrxiv/early/2020/11/01/2020.10.27.20220905.full.pdf
286. He, D.; Zhao, S.; Xu, X.; Lin, Q.; Zhuang, Z.; Cao, P.; Wang, M. H.; Lou, Y.; Xiao, L.; Wu, Y.; Yang, L., Low dispersion in the infectiousness of COVID-19 cases implies difficulty in control. *BMC Public Health* **2020,** *20* (1), 1558. https://doi.org/10.1186/s12889-020-09624-2

287. He, R.; Lu, Z.; Zhang, L.; Fan, T.; Xiong, R.; Shen, X.; Feng, H.; Meng, H.; Lin, W.; Jiang, W.; Geng, Q., The clinical course and its correlated immune status in COVID-19 pneumonia. *Journal of Clinical Virology* **2020,** *127*, 104361. http://www.sciencedirect.com/science/article/pii/S1386653220301037
288. He, X.; Lau, E. H. Y.; Wu, P.; Deng, X.; Wang, J.; Hao, X.; Lau, Y. C.; Wong, J. Y.; Guan, Y.; Tan, X.; Mo, X.; Chen, Y.; Liao, B.; Chen, W.; Hu, F.; Zhang, Q.; Zhong, M.; Wu, Y.; Zhao, L.; Zhang, F.; Cowling, B. J.; Li, F.; Leung, G. M., Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0869-5
289. Hermine, O.; Mariette, X.; Tharaux, P.-L.; Resche-Rigon, M.; Porcher, R.; Ravaud, P.; Group, C.-C., Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. *JAMA Internal Medicine* **2020**. https://doi.org/10.1001/jamainternmed.2020.6820
290. Hernández-Mora, M. G.; Cabello Úbeda, A.; Pérez, L. P.; Álvarez, F. V.; Álvarez, B.; Rodríguez Nieto, M. J.; Acosta, I. C.; Ormaechea, I. F.; Al-Hayani, A. W. M.; Carballosa, P.; Martínez, S. C.; Ezzine, F.; González, M. C.; Naya, A.; de Las Heras, M. L.; Rodríguez Guzmán, M. J.; Guijarro, A. C.; Lavado, A. B.; Valcayo, A. M.; García, M. M.; Martínez, J. B.; Roblas, R. F.; Piris Pinilla, M.; Alen, J. F.; Pernaute, O. S.; Bueno, F. R.; Frades, S. H.; Romero, G. P. B., Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. *Int J Infect Dis* **2020**.
291. Hoehl, S.; Karaca, O.; Kohmer, N.; Westhaus, S.; Graf, J.; Goetsch, U.; Ciesek, S., Assessment of SARS-CoV-2 Transmission on an International Flight and Among a Tourist Group. *JAMA Network Open* **2020,** *3* (8), e2018044-e2018044. https://doi.org/10.1001/jamanetworkopen.2020.18044
292. Hoiland, R. L.; Fergusson, N. A.; Mitra, A. R.; Griesdale, D. E. G.; Devine, D. V.; Stukas, S.; Cooper, J.; Thiara, S.; Foster, D.; Chen, L. Y. C.; Lee, A. Y. Y.; Conway, E. M.; Wellington, C. L.; Sekhon, M. S., The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. *Blood Advances* **2020,** *4* (20), 4981-4989. https://doi.org/10.1182/bloodadvances.2020002623
293. Holmes, L.; Enwere, M.; Williams, J.; Ogundele, B.; Chavan, P.; Piccoli, T.; Chinacherem, C.; Comeaux, C.; Pelaez, L.; Okundaye, O.; Stalnaker, L.; Kalle, F.; Deepika, K.; Philipcien, G.; Poleon, M.; Ogungbade, G.; Elmi, H.; John, V.; Dabney, K. W., Black–White Risk Differentials in COVID-19 (SARS-COV2) Transmission, Mortality and Case Fatality in the United States: Translational Epidemiologic Perspective and Challenges. *International Journal of Environmental Research and Public Health* **2020,** *17* (12), 4322. https://www.mdpi.com/1660-4601/17/12/4322
294. HongyingLi; YewLeong, F.; GeorgeXu; ZhengweiGe; WeiKang, C.; HuiLim, K., Dispersion of evaporating cough droplets in tropical outdoor environment. *Physics of Fluids* **2020,** *32* (11), 113301. https://aip.scitation.org/doi/abs/10.1063/5.0026360
295. Horby, P.; Lim, W. S.; Emberson, J.; Mafham, M.; Bell, J.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Chappell, L. C.; Faust, S. N.; Jaki, T.; Jeffery, K.; Montgomery, A.; Rowan, K.; Juszczak, E.; Baillie, J. K.; Haynes, R.; Landray, M. J., Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. *medRxiv* **2020**, 2020.06.22.20137273. https://www.medrxiv.org/content/medrxiv/early/2020/06/22/2020.06.22.20137273.full.pdf
296. Hou, Y. J.; Chiba, S.; Halfmann, P.; Ehre, C.; Kuroda, M.; Dinnon, K. H.; Leist, S. R.; Schäfer, A.; Nakajima, N.; Takahashi, K.; Lee, R. E.; Mascenik, T. M.; Graham, R.; Edwards, C. E.; Tse, L. V.; Okuda, K.; Markmann, A. J.; Bartelt, L.; de Silva, A.; Margolis, D. M.; Boucher, R. C.; Randell, S. H.; Suzuki, T.; Gralinski, L. E.; Kawaoka, Y.; Baric, R. S., SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science* **2020**, eabe8499. https://science.sciencemag.org/content/sci/early/2020/11/11/science.abe8499.full.pdf
297. Hu, M.; Lin, H.; Wang, J.; Xu, C.; Tatem, A. J.; Meng, B.; Zhang, X.; Liu, Y.; Wang, P.; Wu, G.; Xie, H.; Lai, S., The risk of COVID-19 transmission in train passengers: an epidemiological and modelling study. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1057

298. Hu, Z.; Song, C.; Xu, C.; Jin, G.; Chen, Y.; Xu, X.; Ma, H.; Chen, W.; Lin, Y.; Zheng, Y.; Wang, J.; Hu, Z.; Yi, Y.; Shen, H., Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences* **2020**. https://doi.org/10.1007/s11427-020-1661-4
299. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* **2020**. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext
300. Huang, L.; Xu, S.; Wang, Z.; Xue, K.; Su, J.; Song, Y.; Chen, S.; Zhu, C.; Tang, B. Z.; Ye, R., Self-Reporting and Photothermally Enhanced Rapid Bacterial Killing on a Laser-Induced Graphene Mask. *ACS Nano* **2020,** *14* (9), 12045-12053. https://doi.org/10.1021/acsnano.0c05330
301. Huang, R.; Xia, J.; Chen, Y.; Shan, C.; Wu, C., A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. *The Lancet Infectious Diseases* **2020,** *20* (5), 534-535. https://doi.org/10.1016/S1473-3099(20)30147-X
302. Huang, Y.; Lyu, X.; Li, D.; Wang, Y.; Wang, L.; Zou, W.; Wei, Y.; Wu, X., A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19. *medRxiv* **2020**, 2020.04.18.20070656. https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.18.20070656.full.pdf
303. Huang, Z.; Tian, D.; Liu, Y.; Lin, Z.; Lyon, C. J.; Lai, W.; Fusco, D.; Drouin, A.; Yin, X.; Hu, T.; Ning, B., Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis. *Biosensors and Bioelectronics* **2020,** *164*, 112316. http://www.sciencedirect.com/science/article/pii/S0956566320303110
304. Hung, I. F.-N.; Lung, K.-C.; Tso, E. Y.-K.; Liu, R.; Chung, T. W.-H.; Chu, M.-Y.; Ng, Y.-Y.; Lo, J.; Chan, J.; Tam, A. R.; Shum, H.-P.; Chan, V.; Wu, A. K.-L.; Sin, K.-M.; Leung, W.-S.; Law, W.-L.; Lung, D. C.; Sin, S.; Yeung, P.; Yip, C. C.-Y.; Zhang, R. R.; Fung, A. Y.-F.; Yan, E. Y.-W.; Leung, K.-H.; Ip, J. D.; Chu, A. W.-H.; Chan, W.-M.; Ng, A. C.-K.; Lee, R.; Fung, K.; Yeung, A.; Wu, T.-C.; Chan, J. W.-M.; Yan, W.-W.; Chan, W.-M.; Chan, J. F.-W.; Lie, A. K.-W.; Tsang, O. T.-Y.; Cheng, V. C.-C.; Que, T.-L.; Lau, C.-S.; Chan, K.-H.; To, K. K.-W.; Yuen, K.-Y., Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)31042-4
305. Hutchins, H. J.; Wolff, B.; Leeb, R.; al., e., COVID-19 Mitigation Behaviors by Age Group — United States, April–June 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1584-1590. https://www.cdc.gov/mmwr/volumes/69/wr/mm6943e4.htm?s_cid=mm6943e4_w
306. Hyman, J. B.; Leibner, E. S.; Tandon, P.; Egorova, N. N.; Bassily-Marcus, A.; Kohli-Seth, R.; Arvind, V.; Chang, H. L.; Lin, H. M.; Levin, M. A., Timing of Intubation and In-Hospital Mortality in Patients With Coronavirus Disease 2019. *Crit Care Explor* **2020,** *2* (10), e0254.
307. Ibrahim, D.; Dulipsingh, L.; Zapatka, L.; Eadie, R.; Crowell, R.; Williams, K.; Wakefield, D. B.; Cook, L.; Puff, J.; Hussain, S. A., Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial. *Infect Dis Ther* **2020**, 1-14.
308. IHME, COVID-19 Projections. https://covid19.healthdata.org/united-states-of-america.
309. IHME, First COVID-19 Global Forecast: IHME Projects Three-Quarters of a Million Lives Could be Saved by January 1. Institute for Health Metrics and Evaluation: 2020. https://www.prnewswire.com/il/news-releases/first-covid-19-global-forecast-ihme-projects-three-quarters-of-a-million-lives-could-be-saved-by-january-1-807013447.html
310. ImmunityBio, Study of the Safety of Prophylactic Vaccination With 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy Volunteers. https://clinicaltrials.gov/ct2/show/NCT04591717?term=immunitybio&draw=2&rank=1.

311. Inovio, Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19. https://clinicaltrials.gov/ct2/show/NCT04447781?term=NCT04447781&draw=2&rank=1.
312. Institute of Museum and Library Services; OCLC; Battelle, REopening Archives, Libraries, and Museums (REALM) Test 5: Natural attenuation as a decontamination approach for SARS-CoV-2 on textile materials. https://www.webjunction.org/content/dam/WebJunction/Documents/webJunction/realm/test5-report.pdf (accessed 26 Oct 2020).
313. Institute, S. S., Public Health Authority, State Serum Institute, Report of Findings. 2020. https://coronasmitte.dk/-/media/mediefiler/corona/mink/risikovurdering-af-human-sundhed-ved-fortsat-minkavl_03112020.pdf?la=da&hash=721871D898F1D9F1F9D99E3A002C35F9537F5CEA
314. International Commission on Microbiological Specifications for Foods (ICMSF), ICMSF opinion on SARS-CoV-2 and its relationship to food safety. https://www.icmsf.org/wp-content/uploads/2020/09/ICMSF2020-Letterhead-COVID-19-opinion-final-03-Sept-2020.BF_.pdf (accessed 08 Sept 2020).
315. Ionescu, F.; Jaiyesimi, I.; Petrescu, I.; Lawler, P. R.; Castillo, E.; Munoz-Maldonado, Y.; Imam, Z.; Narasimhan, M.; Abbas, A. E.; Konde, A.; Nair, G. B., Association of Anticoagulation Dose and Survival in Hospitalized COVID-19 Patients: A Retrospective Propensity Score Weighted Analysis. *Eur J Haematol* **2020**.
316. IQ, H., COVID-19 Forecast for United States. https://app.hospiq.com/covid19?region=.
317. Iwata, K.; Doi, A.; Miyakoshi, C., Was School Closure Effective in Mitigating Coronavirus Disease 2019 (COVID-19)? Time Series Analysis Using Bayesian Inference. **2020**.
318. JAFFE-HOFFMAN, M., Israeli COVID-19 vaccine to begin human trials next week. https://www.jpost.com/health-science/israel-to-kick-off-human-trials-of-covid-19-vaccine-candidate-on-nov-1-646904.
319. Jafferali, M. H.; Khatami, K.; Atasoy, M.; Birgersson, M.; Williams, C.; Cetecioglu, Z., Benchmarking virus concentration methods for quantification of SARS-CoV-2 in raw wastewater. *Science of The Total Environment* **2020**, 142939. http://www.sciencedirect.com/science/article/pii/S004896972036469X
320. Janssen, A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE). https://clinicaltrials.gov/ct2/show/NCT04505722.
321. Jarvis, C. I.; Van Zandvoort, K.; Gimma, A.; Prem, K.; Klepac, P.; Rubin, G. J.; Edmunds, W. J., Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. *BMC Med* **2020,** *18* (1), 124.
322. Jenco, M., CDC details COVID-19-related inflammatory syndrome in children. *AAP News* 2020. https://www.aappublications.org/news/2020/05/14/covid19inflammatory051420
323. JHU, Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.
324. Jiangsu, Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell). https://clinicaltrials.gov/ct2/show/NCT04530656.
325. John, A. R.; Raju, S.; Cadnum, J. L.; Lee, K.; McClellan, P.; Akkus, O.; Miller, S. K.; Jennings, W. D.; Buehler, J. A.; Li, D. F.; Redmond, S. N.; Braskie, M.; Hoyen, C. K.; Donskey, C. J., Scalable In-hospital Decontamination of N95 Filtering Facepiece Respirator with a Peracetic Acid Room Disinfection System. *Infection Control & Hospital Epidemiology* **2020**, 1-26. https://www.cambridge.org/core/article/scalable-inhospital-decontamination-of-n95-filtering-facepiece-respirator-with-a-peracetic-acid-room-disinfection-system/4B56043CF6D905CA6E8EF07B19FCF054
326. Johndrow, J. E.; Lum, K.; Ball, P., Estimating SARS-CoV-2-positive Americans using deaths-only data. *arXiv preprint arXiv:2004.02605* **2020**.

327. Johnston, S. C.; Jay, A.; Raymond, J. L.; Rossi, F.; Zeng, X.; Scruggs, J.; Dyer, D.; Frick, O.; Moore, J.; Berrier, K.; Esham, H.; Shamblin, J.; Sifford, W.; Fiallos, J.; Klosterman, L.; Stevens, S.; White, L.; Bowling, P.; Garcia, T.; Jensen, C.; Ghering, J.; Nyakiti, D.; Bellanca, S.; Kearney, B.; Giles, W.; Alli, N.; Paz, F.; Akers, K.; Danner, D.; Barth, J.; Johnson, J. A.; Durant, M.; Kim, R.; Pitt, M. L. M.; Nalca, A., Development of a Coronavirus Disease 2019 Nonhuman Primate Model Using Airborne Exposure. *bioRxiv* **2020**, 2020.06.26.174128. http://biorxiv.org/content/early/2020/06/26/2020.06.26.174128.abstract
328. Jones, R. M., Relative contributions of transmission routes for COVID-19 among healthcare personnel providing patient care. *Journal of Occupational and Environmental Hygiene* **2020**, 1-8. https://doi.org/10.1080/15459624.2020.1784427
329. Joyner, M. J.; Bruno, K. A.; Klassen, S. A.; Kunze, K. L.; Johnson, P. W.; Lesser, E. R.; Wiggins, C. C.; Senefeld, J. W.; Klompas, A. M.; Hodge, D. O.; Shepherd, J. R. A.; Rea, R. F.; Whelan, E. R.; Clayburn, A. J.; Spiegel, M. R.; Baker, S. E.; Larson, K. F.; Ripoll, J. G.; Andersen, K. J.; Buras, M. R.; Vogt, M. N. P.; Herasevich, V.; Dennis, J. J.; Regimbal, R. J.; Bauer, P. R.; Blair, J. E.; Van Buskirk, C. M.; Winters, J. L.; Stubbs, J. R.; van Helmond, N.; Butterfield, B. P.; Sexton, M. A.; Diaz Soto, J. C.; Paneth, N. S.; Verdun, N. C.; Marks, P.; Casadevall, A.; Fairweather, D.; Carter, R. E.; Wright, R. S., Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. *Mayo Clinic Proceedings* **2020**. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368917/
330. Joyner, M. J.; Senefeld, J. W.; Klassen, S. A.; Mills, J. R.; Johnson, P. W.; Theel, E. S.; Wiggins, C. C.; Bruno, K. A.; Klompas, A. M.; Lesser, E. R.; Kunze, K. L.; Sexton, M. A.; Diaz Soto, J. C.; Baker, S. E.; Shepherd, J. R. A.; van Helmond, N.; van Buskirk, C. M.; Winters, J. L.; Stubbs, J. R.; Rea, R. F.; Hodge, D. O.; Herasevich, V.; Whelan, E. R.; Clayburn, A. J.; Larson, K. F.; Ripoll, J. G.; Andersen, K. J.; Buras, M. R.; Vogt, M. N. P.; Dennis, J. J.; Regimbal, R. J.; Bauer, P. R.; Blair, J. E.; Paneth, N. S.; Fairweather, D.; Wright, R. S.; Carter, R. E.; Casadevall, A., Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. *medRxiv* **2020**, 2020.08.12.20169359. http://medrxiv.org/content/early/2020/08/12/2020.08.12.20169359.abstract
331. Jüni, P.; Rothenbühler, M.; Bobos, P.; Thorpe, K. E.; da Costa, B. R.; Fisman, D. N.; Slutsky, A. S.; Gesink, D., Impact of climate and public health interventions on the COVID-19 pandemic: A prospective cohort study. *Canadian Medical Association Journal* **2020**, cmaj.200920. https://www.cmaj.ca/content/cmaj/early/2020/05/08/cmaj.200920.full.pdf
332. Kangtai, A phase I clinical trial for inactivated SARS-CoV-2 Vaccine(Vero Cells). http://www.chictr.org.cn/showprojen.aspx?proj=62350.
333. Karnakov, P.; Arampatzis, G.; Kičić, I.; Wermelinger, F.; Wälchli, D.; Papadimitriou, C.; Koumoutsakos, P., Data driven inference of the reproduction number (R0) for COVID-19 before and after interventions for 51 European countries. **2020**.
334. Kawamura, Y.; Higashimoto, Y.; Miura, H.; Ihira, M.; Inaba, M.; Ito, R.; Kozawa, K.; Yoshikawa, T., Immune response against SARS-CoV-2 in pediatric patients including young infants. *Journal of Medical Virology* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26493
335. Keller, M. J.; Kitsis, E. A.; Arora, S.; Chen, J. T.; Agarwal, S.; Ross, M. J.; Tomer, Y.; Southern, W., Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19. *Journal of Hospital Medicine* **2020,** *Online First, July 22nd, 2020*.
336. Kelly, M.; O'Connor, R.; Townsend, L.; Coghlan, M.; Relihan, E.; Moriarty, M.; Carr, B.; Melanophy, G.; Doyle, C.; Bannan, C.; O'Riordan, R.; Merry, C.; Clarke, S.; Bergin, C., Clinical outcomes and adverse events in patients hospitalised with COVID -19, treated with off- label hydroxychloroquine and azithromycin. *Br J Clin Pharmacol* **2020**.
337. Kennedy, M.; Lee, S. J.; Epstein, M., Modeling aerosol transmission of SARS-CoV-2 in multi-room facility. *Journal of Loss Prevention in the Process Industries* **2020**, 104336. http://www.sciencedirect.com/science/article/pii/S0950423020306239

338. Kerr, C. C.; Stuart, R. M.; Mistry, D.; Abeysuriya, R. G.; Hart, G.; Rosenfeld, K.; Selvaraj, P.; Nunez, R. C.; Hagedorn, B.; George, L.; Izzo, A.; Palmer, A.; Delport, D.; Bennette, C.; Wagner, B.; Chang, S.; Cohen, J. A.; Panovska-Griffiths, J.; Jastrzebski, M.; Oron, A. P.; Wenger, E.; Famulare, M.; Klein, D. J., Covasim: an agent-based model of COVID-19 dynamics and interventions. *medRxiv* **2020**, 2020.05.10.20097469. https://www.medrxiv.org/content/medrxiv/early/2020/05/15/2020.05.10.20097469.full.pdf
339. Khanh, N. C.; Thai, P. Q.; Quach, H.-L.; Thi, N.-A. H.; Dinh, P. C.; Duong, T. N.; Mai, L. T. Q.; Nghia, N. D.; Tu, T. A.; Quang, L. N.; Quang, T. D.; Nguyen, T.-T.; Vogt, F.; Anh, D. D., Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 During Long Flight. *Emerging Infectious Disease journal* **2020,** *26* (11). https://wwwnc.cdc.gov/eid/article/26/11/20-3299_article
340. Kim, L.; Whitaker, M.; O'Halloran, A.; al., e., Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 7 August 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6932e3.htm?s
341. Kim, S. E.; Jeong, H. S.; Yu, Y.; Shin, S. U.; Kim, S.; Oh, T. H.; Kim, U. J.; Kang, S. J.; Jang, H. C.; Jung, S. I.; Park, K. H., Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients. *Int J Infect Dis* **2020**.
342. Kim, U. J.; Lee, S. Y.; Lee, J. Y.; Lee, A.; Kim, S. E.; Choi, O.-J.; Lee, J. S.; Kee, S.-J.; Jang, H.-C., Air and Environmental Contamination Caused by COVID-19 Patients: a Multi-Center Study. *J Korean Med Sci* **2020,** *35* (37). https://doi.org/10.3346/jkms.2020.35.e332
343. Kim, Y.-I.; Kim, S.-G.; Kim, S.-M.; Kim, E.-H.; Park, S.-J.; Yu, K.-M.; Chang, J.-H.; Kim, E. J.; Lee, S.; Casel, M. A. B.; Um, J.; Song, M.-S.; Jeong, H. W.; Lai, V. D.; Kim, Y.; Chin, B. S.; Park, J.-S.; Chung, K.-H.; Foo, S.-S.; Poo, H.; Mo, I.-P.; Lee, O.-J.; Webby, R. J.; Jung, J. U.; Choi, Y. K., Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host & Microbe* **2020**. http://www.sciencedirect.com/science/article/pii/S1931312820301876
344. Kissler, S. M.; Tedijanto, C.; Goldstein, E.; Grad, Y. H.; Lipsitch, M., Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science* **2020**, eabb5793. https://science.sciencemag.org/content/sci/early/2020/04/14/science.abb5793.full.pdf
345. Knight, S. R.; Ho, A.; Pius, R.; Buchan, I.; Carson, G.; Drake, T. M.; Dunning, J.; Fairfield, C. J.; Gamble, C.; Green, C. A.; Gupta, R.; Halpin, S.; Hardwick, H. E.; Holden, K. A.; Horby, P. W.; Jackson, C.; Mclean, K. A.; Merson, L.; Nguyen-Van-Tam, J. S.; Norman, L.; Noursadeghi, M.; Olliaro, P. L.; Pritchard, M. G.; Russell, C. D.; Shaw, C. A.; Sheikh, A.; Solomon, T.; Sudlow, C.; Swann, O. V.; Turtle, L. C.; Openshaw, P. J.; Baillie, J. K.; Semple, M. G.; Docherty, A. B.; Harrison, E. M., Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. *BMJ* **2020,** *370*, m3339. https://www.bmj.com/content/bmj/370/bmj.m3339.full.pdf
346. Kociolek, L. K.; Muller, W. J.; Yee, R.; Dien Bard, J.; Brown, C. A.; Revell, P.; Wardell, H.; Savage, T. J.; Jung, S.; Dominguez, S.; Parikh, B. A.; Jerris, R. C.; Kehl, S. C.; Campigotto, A.; Bender, J. M.; Zheng, X.; Muscat, E.; Linam, M.; Abuogi, L.; Smith, C.; Graff, K.; Hernandez-Leyva, A.; Williams, D.; Pollock, N. R., Comparison of upper respiratory viral load distributions in asymptomatic and symptomatic children diagnosed with SARS-CoV-2 infection in pediatric hospital testing programs. *Journal of Clinical Microbiology* **2020**, JCM.02593-20. https://jcm.asm.org/content/jcm/early/2020/10/22/JCM.02593-20.full.pdf
347. Koh, W. C.; Naing, L.; Chaw, L.; Rosledzana, M. A.; Alikhan, M. F.; Jamaludin, S. A.; Amin, F.; Omar, A.; Shazli, A.; Griffith, M.; Pastore, R.; Wong, J., What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. *PLOS ONE* **2020,** *15* (10), e0240205. https://doi.org/10.1371/journal.pone.0240205

348. Konda, A.; Prakash, A.; Moss, G. A.; Schmoldt, M.; Grant, G. D.; Guha, S., Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. *ACS Nano* **2020**. https://www.ncbi.nlm.nih.gov/pubmed/32329337
349. Kong, D.; Zheng, Y.; Wu, H.; Pan, H.; Wagner, A. L.; Zheng, Y.; Gong, X.; Zhu, Y.; Jin, B.; Xiao, W.; Mao, S.; Lin, S.; Han, R.; Yu, X.; Cui, P.; Jiang, C.; Fang, Q.; Lu, Y.; Fu, C., Pre-symptomatic transmission of novel coronavirus in community settings. *Influenza and Other Respiratory Viruses* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12773
350. Kong, T.-k., Longer incubation period of coronavirus disease 2019 (COVID-19) in older adults. *AGING MEDICINE* **2020,** *3* (2), 102-109. https://onlinelibrary.wiley.com/doi/abs/10.1002/agm2.12114
351. Koo, J. R.; Cook, A. R.; Park, M.; Sun, Y.; Sun, H.; Lim, J. T.; Tam, C.; Dickens, B. L., Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. *The Lancet Infectious Diseases* **2020,** *20* (6), 678-688. https://doi.org/10.1016/S1473-3099(20)30162-6
352. Korber, B.; Fischer, W. M.; Gnanakaran, S.; Yoon, H.; Theiler, J.; Abfalterer, W.; Hengartner, N.; Giorgi, E. E.; Bhattacharya, T.; Foley, B.; Hastie, K. M.; Parker, M. D.; Partridge, D. G.; Evans, C. M.; Freeman, T. M.; de Silva, T. I.; McDanal, C.; Perez, L. G.; Tang, H.; Moon-Walker, A.; Whelan, S. P.; LaBranche, C. C.; Saphire, E. O.; Montefiori, D. C.; Angyal, A.; Brown, R. L.; Carrilero, L.; Green, L. R.; Groves, D. C.; Johnson, K. J.; Keeley, A. J.; Lindsey, B. B.; Parsons, P. J.; Raza, M.; Rowland-Jones, S.; Smith, N.; Tucker, R. M.; Wang, D.; Wyles, M. D., Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* **2020**. https://doi.org/10.1016/j.cell.2020.06.043
353. Korevaar, H. M.; Becker, A. D.; Miller, I. F.; Grenfell, B. T.; Metcalf, C. J. E.; Mina, M. J., Quantifying the impact of US state non-pharmaceutical interventions on COVID-19 transmission. *medRxiv* **2020**, 2020.06.30.20142877.
https://www.medrxiv.org/content/medrxiv/early/2020/07/01/2020.06.30.20142877.full.pdf
354. Kori, N.; Periyasamy, P.; Ng, B. H.; Satariah Ali, U. K.; Zainol Rashid, N. Z., Aerosolised COVID-19 Transmission Risk: Surgical or N95 Masks? *Infection Control & Hospital Epidemiology* **2020**, 1-8.
https://www.cambridge.org/core/article/aerosolised-covid19-transmission-risk-surgical-or-n95-masks/C9589405A1F76BF0FC469FB04776279C
355. Korte, W.; Buljan, M.; Rösslein, M.; Wick, P.; Golubov, V.; Jentsch, J.; Reut, M.; Peier, K.; Nohynek, B.; Fischer, A.; Stolz, R.; Cettuzzi, M.; Nolte, O., SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on. *Journal of Infection* **2020**.
https://doi.org/10.1016/j.jinf.2020.08.032
356. Kraemer, M. U. G.; Yang, C.-H.; Gutierrez, B.; Wu, C.-H.; Klein, B.; Pigott, D. M.; du Plessis, L.; Faria, N. R.; Li, R.; Hanage, W. P.; Brownstein, J. S.; Layan, M.; Vespignani, A.; Tian, H.; Dye, C.; Pybus, O. G.; Scarpino, S. V., The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science* **2020**, eabb4218.
https://science.sciencemag.org/content/sci/early/2020/03/25/science.abb4218.full.pdf
357. Kratzel, A.; Todt, D.; V'kovski, P.; Steiner, S.; Gultom, M. L.; Thao, T. T. N.; Ebert, N.; Holwerda, M.; Steinmann, J.; Niemeyer, D.; Dijkman, R.; Kampf, G.; Drosten, C.; Steinmann, E.; Thiel, V.; Pfaender, S., Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols. *bioRxiv* **2020**, 2020.03.10.986711.
https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.10.986711.full.pdf
358. Kucharski, A. J.; Klepac, P.; Conlan, A. J. K.; Kissler, S. M.; Tang, M. L.; Fry, H.; Gog, J. R.; Edmunds, W. J., Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. *Lancet Infect Dis* **2020**.
359. Kucharski, A. J.; Russell, T. W.; Diamond, C.; Liu, Y.; Edmunds, J.; Funk, S.; Eggo, R. M.; Sun, F.; Jit, M.; Munday, J. D., Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *The lancet infectious diseases* **2020**.

360. Kucirka, L. M.; Lauer, S. A.; Laeyendecker, O.; Boon, D., Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-1495
361. Kucuksahin, E., Turkish university tests COVID-19 vaccine candidate. https://www.aa.com.tr/en/health/turkish-university-tests-covid-19-vaccine-candidate/2033228.
362. Kupferschmidt, K., Remdesivir and interferon fall flat in WHO's megastudy of COVID-19 treatments. *Science Magazine* **2020**, 1. https://www.sciencemag.org/news/2020/10/remdesivir-and-interferon-fall-flat-who-s-megastudy-covid-19-treatments
363. Laguarta, J.; Hueto, F.; Subirana, B., COVID-19 Artificial Intelligence Diagnosis using only Cough Recordings. *IEEE Open Journal of Engineering in Medicine and Biology* **2020**, 1-1.
364. Lai, S.; Ruktanonchai, N. W.; Zhou, L.; Prosper, O.; Luo, W.; Floyd, J. R.; Wesolowski, A.; Santillana, M.; Zhang, C.; Du, X.; Yu, H.; Tatem, A. J., Effect of non-pharmaceutical interventions to contain COVID-19 in China. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2293-x
365. Lam, T. T.-Y.; Shum, M. H.-H.; Zhu, H.-C.; Tong, Y.-G.; Ni, X.-B.; Liao, Y.-S.; Wei, W.; Cheung, W. Y.-M.; Li, W.-J.; Li, L.-F.; Leung, G. M.; Holmes, E. C.; Hu, Y.-L.; Guan, Y., Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2169-0
366. Lan, F.-Y.; Suharlim, C.; Kales, S. N.; Yang, J., Association between SARS-CoV-2 infection, exposure risk and mental health among a cohort of essential retail workers in the USA. *Occupational and Environmental Medicine* **2020**, oemed-2020-106774. https://oem.bmj.com/content/oemed/early/2020/10/11/oemed-2020-106774.full.pdf
367. LANL, COVID-19 Confirmed and Forecasted Case Data. https://covid-19.bsvgateway.org/.
368. Lapin, T., About a dozen US mink farms in quarantine as officials probe COVID-19 outbreaks. *New York Post* 2020. https://nypost.com/2020/11/10/us-mink-farms-in-quarantine-as-officials-probe-covid-19-outbreaks/
369. Larsen, J. R.; Martin, M. R.; Martin, J. D.; Kuhn, P.; Hicks, J. B., Modeling the Onset of Symptoms of COVID-19. *Frontiers in Public Health* **2020,** *8* (473). https://www.frontiersin.org/article/10.3389/fpubh.2020.00473
370. Lasry, A.; Kidder, D.; Hast, M.; Poovey, J.; Sunshine, G.; Zviedrite, N.; Ahmed, F.; Ethier, K. A., Timing of community mitigation and changes in reported COVID-19 and community mobility—four US metropolitan areas, February 26–April 1, 2020. *morbidity and Mortality Weekly Report* **2020,** *69*, 451-457. https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e2.htm
371. Lassaunière, R.; Frische, A.; Harboe, Z. B.; Nielsen, A. C.; Fomsgaard, A.; Krogfelt, K. A.; Jørgensen, C. S., Evaluation of nine commercial SARS-CoV-2 immunoassays. *medRxiv* **2020**, 2020.04.09.20056325. https://www.medrxiv.org/content/medrxiv/early/2020/04/10/2020.04.09.20056325.full.pdf
372. Latinne, A.; Hu, B.; Olival, K. J.; Zhu, G.; Zhang, L.; Li, H.; Chmura, A. A.; Field, H. E.; Zambrana-Torrelio, C.; Epstein, J. H.; Li, B.; Zhang, W.; Wang, L.-F.; Shi, Z.-L.; Daszak, P., Origin and cross-species transmission of bat coronaviruses in China. *Nature Communications* **2020,** *11* (1), 4235. https://doi.org/10.1038/s41467-020-17687-3
373. Latz, C. A.; DeCarlo, C.; Boitano, L.; Png, C. Y. M.; Patell, R.; Conrad, M. F.; Eagleton, M.; Dua, A., Blood type and outcomes in patients with COVID-19. *Annals of Hematology* **2020**. https://doi.org/10.1007/s00277-020-04169-1
374. Lau, M. S. Y.; Grenfell, B.; Thomas, M.; Bryan, M.; Nelson, K.; Lopman, B., Characterizing superspreading events and age-specific infectiousness of SARS-CoV-2 transmission in Georgia, USA. *Proceedings of the National Academy of Sciences* **2020**, 202011802. https://www.pnas.org/content/pnas/early/2020/08/19/2011802117.full.pdf
375. Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A. S.; Reich, N. G.; Lessler, J., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported

Confirmed Cases: Estimation and Application. *Annals of Internal Medicine* **2020**. https://doi.org/10.7326/M20-0504
376. Lavery, A. M.; Preston, L. E.; Ko, J. Y.; al., e., Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission — United States, March–August 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 9 November 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6945e2.htm
377. Lavezzo, E.; Franchin, E.; Ciavarella, C.; Cuomo-Dannenburg, G.; Barzon, L.; Del Vecchio, C.; Rossi, L.; Manganelli, R.; Loregian, A.; Navarin, N.; Abate, D.; Sciro, M.; Merigliano, S.; De Canale, E.; Vanuzzo, M. C.; Besutti, V.; Saluzzo, F.; Onelia, F.; Pacenti, M.; Parisi, S.; Carretta, G.; Donato, D.; Flor, L.; Cocchio, S.; Masi, G.; Sperduti, A.; Cattarino, L.; Salvador, R.; Nicoletti, M.; Caldart, F.; Castelli, G.; Nieddu, E.; Labella, B.; Fava, L.; Drigo, M.; Gaythorpe, K. A. M.; Ainslie, K. E. C.; Baguelin, M.; Bhatt, S.; Boonyasiri, A.; Boyd, O.; Cattarino, L.; Ciavarella, C.; Coupland, H. L.; Cucunubá, Z.; Cuomo-Dannenburg, G.; Djafaara, B. A.; Donnelly, C. A.; Dorigatti, I.; van Elsland, S. L.; FitzJohn, R.; Flaxman, S.; Gaythorpe, K. A. M.; Green, W. D.; Hallett, T.; Hamlet, A.; Haw, D.; Imai, N.; Jeffrey, B.; Knock, E.; Laydon, D. J.; Mellan, T.; Mishra, S.; Nedjati-Gilani, G.; Nouvellet, P.; Okell, L. C.; Parag, K. V.; Riley, S.; Thompson, H. A.; Unwin, H. J. T.; Verity, R.; Vollmer, M. A. C.; Walker, P. G. T.; Walters, C. E.; Wang, H.; Wang, Y.; Watson, O. J.; Whittaker, C.; Whittles, L. K.; Xi, X.; Ferguson, N. M.; Brazzale, A. R.; Toppo, S.; Trevisan, M.; Baldo, V.; Donnelly, C. A.; Ferguson, N. M.; Dorigatti, I.; Crisanti, A.; Imperial College, C.-R. T., Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2488-1
378. Laxminarayan, R.; Wahl, B.; Dudala, S. R.; Gopal, K.; Mohan, C.; Neelima, S.; Jawahar Reddy, K. S.; Radhakrishnan, J.; Lewnard, J. A., Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science* **2020**, eabd7672. https://science.sciencemag.org/content/sci/early/2020/09/29/science.abd7672.full.pdf
379. Le Bert, N.; Tan, A. T.; Kunasegaran, K.; Tham, C. Y. L.; Hafezi, M.; Chia, A.; Chng, M. H. Y.; Lin, M.; Tan, N.; Linster, M.; Chia, W. N.; Chen, M. I. C.; Wang, L.-F.; Ooi, E. E.; Kalimuddin, S.; Tambyah, P. A.; Low, J. G.-H.; Tan, Y.-J.; Bertoletti, A., SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2550-z
380. Leclerc, Q.; Fuller, N.; Knight, L.; null, n.; Funk, S.; Knight, G., What settings have been linked to SARS-CoV-2 transmission clusters? [version 2; peer review: 2 approved]. *Wellcome Open Research* **2020,** *5* (83). https://wellcomeopenresearch.org/articles/5-83/v2
381. Lednicky, J. A.; Lauzardo, M.; Fan, Z. H.; Jutla, A. S.; Tilly, T. B.; Gangwar, M.; Usmani, M.; Shankar, S. N.; Mohamed, K.; Eiguren-Fernandez, A.; Stephenson, C. J.; Alam, M. M.; Elbadry, M. A.; Loeb, J. C.; Subramaniam, K.; Waltzek, T. B.; Cherabuddi, K.; Morris, J. G.; Wu, C.-Y., Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. *medRxiv* **2020**, 2020.08.03.20167395. https://www.medrxiv.org/content/medrxiv/early/2020/08/04/2020.08.03.20167395.full.pdf
382. Lee, C. Y.-P.; Amrun, S. N.; Chee, R. S.-L.; Goh, Y. S.; Mak, T.-M.; Octavia, S.; Yeo, N. K.-W.; Chang, Z. W.; Tay, M. Z.; Torres-Ruesta, A.; Carissimo, G.; Poh, C. M.; Fong, S.-W.; Bei, W.; Lee, S.; Young, B. E.; Tan, S.-Y.; Leo, Y.-S.; Lye, D. C.; Lin, R. T. P.; Maurer-Stroh, S.; Lee, B.; Cheng-I, W.; Renia, L.; Ng, L. F. P., Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant. *bioRxiv* **2020**, 2020.10.08.332544. https://www.biorxiv.org/content/biorxiv/early/2020/10/09/2020.10.08.332544.full.pdf
383. Lee, J.; Hughes, T.; Lee, M.-H.; Field, H.; Rovie-Ryan, J. J.; Sitam, F. T.; Sipangkui, S.; Nathan, S. K. S. S.; Ramirez, D.; Kumar, S. V.; Lasimbang, H.; Epstein, J. H.; Daszak, P., No evidence of coronaviruses or other potentially zoonotic viruses in Sunda pangolins (Manis javanica) entering the wildlife trade via Malaysia. *bioRxiv* **2020**, 2020.06.19.158717. https://www.biorxiv.org/content/biorxiv/early/2020/06/19/2020.06.19.158717.full.pdf

384. Lee, Y.-H.; Hong, C. M.; Kim, D. H.; Lee, T. H.; Lee, J., Clinical Course of Asymptomatic and Mildly Symptomatic Patients with Coronavirus Disease Admitted to Community Treatment Centers, South Korea. *Emerging Infectious Disease journal* **2020,** *26* (10). https://wwwnc.cdc.gov/eid/article/26/10/20-1620_article
385. Lemos, A. C. B.; do Espírito Santo, D. A.; Salvetti, M. C.; Gilio, R. N.; Agra, L. B.; Pazin-Filho, A.; Miranda, C. H., Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). *Thrombosis Research* **2020,** *196*, 359-366. http://www.sciencedirect.com/science/article/pii/S0049384820305302
386. Lenze, E. J.; Mattar, C.; Zorumski, C. F.; Stevens, A.; Schweiger, J.; Nicol, G. E.; Miller, J. P.; Yang, L.; Yingling, M.; Avidan, M. S.; Reiersen, A. M., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.22760
387. Letizia, A. G.; Ramos, I.; Obla, A.; Goforth, C.; Weir, D. L.; Ge, Y.; Bamman, M. M.; Dutta, J.; Ellis, E.; Estrella, L.; George, M.-C.; Gonzalez-Reiche, A. S.; Graham, W. D.; van de Guchte, A.; Gutierrez, R.; Jones, F.; Kalomoiri, A.; Lizewski, R.; Lizewski, S.; Marayag, J.; Marjanovic, N.; Millar, E. V.; Nair, V. D.; Nudelman, G.; Nunez, E.; Pike, B. L.; Porter, C.; Regeimbal, J.; Rirak, S.; Santa Ana, E.; Sealfon, R. S. G.; Sebra, R.; Simons, M. P.; Soares-Schanoski, A.; Sugiharto, V.; Termini, M.; Vangeti, S.; Williams, C.; Troyanskaya, O. G.; van Bakel, H.; Sealfon, S. C., SARS-CoV-2 Transmission among Marine Recruits during Quarantine. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2029717
388. Leung, N. H. L.; Chu, D. K. W.; Shiu, E. Y. C.; Chan, K.-H.; McDevitt, J. J.; Hau, B. J. P.; Yen, H.-L.; Li, Y.; Ip, D. K. M.; Peiris, J. S. M.; Seto, W.-H.; Leung, G. M.; Milton, D. K.; Cowling, B. J., Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0843-2
389. Lewis, D., Is the coronavirus airborne? Experts can't agree. *Nature* **2020**. 10.1038/d41586-020-00974-w
390. Li, D.; Jin, M.; Bao, P.; Zhao, W.; Zhang, S., Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. *JAMA Network Open* **2020,** *3* (5), e208292-e208292. https://doi.org/10.1001/jamanetworkopen.2020.8292
391. Li, K.; Wohlford-Lenane, C.; Perlman, S.; Zhao, J.; Jewell, A. K.; Reznikov, L. R.; Gibson-Corley, K. N.; Meyerholz, D. K.; McCray, P. B., Jr., Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. *J Infect Dis* **2016,** *213* (5), 712-22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747621/pdf/jiv499.pdf
392. Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K. S. M.; Lau, E. H. Y.; Wong, J. Y.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Liu, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T. T. Y.; Wu, J. T.; Gao, G. F.; Cowling, B. J.; Yang, B.; Leung, G. M.; Feng, Z., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2001316 https://www.nejm.org/doi/10.1056/NEJMoa2001316
393. Li, Q.; Li, W.; Jin, Y.; Xu, W.; Huang, C.; Li, L.; Huang, Y.; Fu, Q.; Chen, L., Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study. *Infect Dis Ther* **2020**.
394. Li, R.; Pei, S.; Chen, B.; Song, Y.; Zhang, T.; Yang, W.; Shaman, J., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* **2020**, eabb3221. https://science.sciencemag.org/content/sci/early/2020/03/13/science.abb3221.full.pdf
395. Li, X.; Giorgi, E. E.; Marichannegowda, M. H.; Foley, B.; Xiao, C.; Kong, X.-P.; Chen, Y.; Gnanakaran, S.; Korber, B.; Gao, F., Emergence of SARS-CoV-2 through recombination and strong purifying selection.

Science Advances **2020**, eabb9153.
https://advances.sciencemag.org/content/advances/early/2020/05/28/sciadv.abb9153.full.pdf
396. Li, X.; Xiao, K.; Chen, X.; Liang, X.; Zhang, X.; Zhang, Z.; Zhai, J.; Wang, R.; Zhou, N.; Chen, Z.-J.; Su, R.; Zhou, F.; Holmes, E. C.; Irwin, D. M.; Chen, R.-A.; He, Q.; Wu, Y.-J.; Wang, C.; Du, X.-Q.; Peng, S.-M.; Xie, W.-J.; Shan, F.; Li, W.-P.; Dai, J.-W.; Shen, X.; Feng, Y.; Xiao, L.; Chen, W.; Shen, Y., Pathogenicity, tissue tropism and potential vertical transmission of SARSr-CoV-2 in Malayan pangolins. *bioRxiv* **2020**, 2020.06.22.164442. http://biorxiv.org/content/early/2020/06/22/2020.06.22.164442.abstract
397. Li, X.; Zai, J.; Zhao, Q.; Nie, Q.; Li, Y.; Foley, B. T.; Chaillon, A., Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. *Journal of Medical Virology* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25731
398. Li, Y.; Campbell, H.; Kulkarni, D.; Harpur, A.; Nundy, M.; Wang, X.; Nair, H., The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries. *The Lancet Infectious Diseases* **2020**. https://doi.org/10.1016/S1473-3099(20)30785-4
399. Li, Y.; Qian, H.; Hang, J.; Chen, X.; Hong, L.; Liang, P.; Li, J.; Xiao, S.; Wei, J.; Liu, L.; Kang, M., Evidence for probable aerosol transmission of SARS-CoV-2 in a poorly ventilated restaurant. *medRxiv* **2020**, 2020.04.16.20067728.
https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.16.20067728.full.pdf
400. Li, Y.; Shi, J.; Xia, J.; Duan, J.; Chen, L.; Yu, X.; Lan, W.; Ma, Q.; Wu, X.; Yuan, Y.; Gong, L.; Yang, X.; Gao, H.; Wu, C., Asymptomatic and Symptomatic Patients With Non-severe Coronavirus Disease (COVID-19) Have Similar Clinical Features and Virological Courses: A Retrospective Single Center Study. *Frontiers in Microbiology* **2020,** *11* (1570). https://www.frontiersin.org/article/10.3389/fmicb.2020.01570
401. Li, Y.; Xie, Z.; Lin, W.; Cai, W.; Wen, C.; Guan, Y.; Mo, X.; Wang, J.; Wang, Y.; Peng, P.; Chen, X.; Hong, W.; Xiao, G.; Liu, J.; Zhang, L.; Hu, F.; Li, F.; Zhang, F.; Deng, X.; Li, L., Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. *Med*. https://doi.org/10.1016/j.medj.2020.04.001
402. Liao, J.; Fan, S.; Chen, J.; Wu, J.; Xu, S.; Guo, Y.; Li, C.; Zhang, X.; Wu, C.; Mou, H., Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. *The Innovation* **2020,** *1* (1), 100001.
403. Lieu, A.; Mah, J.; Zanichelli, V.; Exantus, R. C.; Longtin, Y., Impact of Extended Use and Decontamination with Vaporized Hydrogen Peroxide on N95 Respirator Fit. *American Journal of Infection Control* **2020**. https://doi.org/10.1016/j.ajic.2020.08.010
404. Lilly, E., Bamlanivimab for COVID-19. Eli Lilly: 2020. https://www.lilly.com/news/media/media-kits/bamlanivimab-covid19
405. Lilly, E., Lilly Statement Regarding NIH's ACTIV-3 Clinical Trial. Eli Lilly and Company: 2020. https://www.lilly.com/news/stories/statement-activ3-clinical-trial-nih-covid19
406. Liotta, E. M.; Batra, A.; Clark, J. R.; Shlobin, N. A.; Hoffman, S. C.; Orban, Z. S.; Koralnik, I. J., Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. *Annals of Clinical and Translational Neurology* **2020,** *n/a* (n/a).
https://onlinelibrary.wiley.com/doi/abs/10.1002/acn3.51210
407. Liotti, F. M.; Menchinelli, G.; Marchetti, S.; Posteraro, B.; Landi, F.; Sanguinetti, M.; Cattani, P., Assessment of SARS-CoV-2 RNA Test Results Among Patients Who Recovered From COVID-19 With Prior Negative Results. *JAMA Internal Medicine* **2020**. https://doi.org/10.1001/jamainternmed.2020.7570
408. Lisboa Bastos, M.; Tavaziva, G.; Abidi, S. K.; Campbell, J. R.; Haraoui, L.-P.; Johnston, J. C.; Lan, Z.; Law, S.; MacLean, E.; Trajman, A.; Menzies, D.; Benedetti, A.; Ahmad Khan, F., Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ* **2020,** *370*, m2516.
https://www.bmj.com/content/bmj/370/bmj.m2516.full.pdf

409. Liu, J.; Zhang, S.; Dong, X.; Li, Z.; Xu, Q.; Feng, H.; Cai, J.; Huang, S.; Guo, J.; Zhang, L.; Chen, Y.; Zhu, W.; Du, H.; Liu, Y.; Wang, T.; Chen, L.; Wen, Z.; Annane, D.; Qu, J.; Chen, D., Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. *J Clin Invest* **2020**.
410. Liu, M.; Li, Q.; Zhou, J.; Ai, W.; Zheng, X.; Zeng, J.; Liu, Y.; Xiang, X.; Guo, R.; Li, X.; Wu, X.; Xu, H.; Jiang, L.; Zhang, H.; Chen, J.; Tian, L.; Luo, J.; Luo, C., Value of swab types and collection time on SARS-COV-2 detection using RT-PCR assay. *Journal of Virological Methods* **2020,** *286*, 113974. http://www.sciencedirect.com/science/article/pii/S0166093420302263
411. Liu, P.; Chen, W.; Chen, J.-P., Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica). *Viruses* **2019,** *11* (11), 979. https://www.mdpi.com/1999-4915/11/11/979
412. Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Li, L.; Zhou, J.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? *PLOS Pathogens* **2020,** *16* (5), e1008421. https://doi.org/10.1371/journal.ppat.1008421
413. Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (2019-nCoV) ? *bioRxiv* **2020**, 2020.02.18.954628. http://biorxiv.org/content/early/2020/02/20/2020.02.18.954628.abstract
414. Liu, S., U of Guelph team tests produce decontamination technology on hospital gowns. https://www.cbc.ca/news/canada/kitchener-waterloo/decontaminate-hospital-gowns-1.5788587 (accessed 09 Nov 2020).
415. Liu, W.; Zhang, Q.; Chen, J.; Xiang, R.; Song, H.; Shu, S.; Chen, L.; Liang, L.; Zhou, J.; You, L.; Wu, P.; Zhang, B.; Lu, Y.; Xia, L.; Huang, L.; Yang, Y.; Liu, F.; Semple, M. G.; Cowling, B. J.; Lan, K.; Sun, Z.; Yu, H.; Liu, Y., Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2003717
416. Liu, Y.; Funk, S.; Flasche, S., *The Contribution of Pre-symptomatic Transmission to the COVID-19 Outbreak*; London School of Hygiene and Tropical Medicine: 2020. https://cmmid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html
417. Liu, Y.; Li, T.; Deng, Y.; Liu, S.; Zhang, D.; Li, H.; Wang, X.; Jia, L.; Han, J.; Bei, Z.; Zhou, Y.; Li, L.; Li, J., Stability of SARS-CoV-2 on environmental surfaces and in human excreta. *medRxiv* **2020**, 2020.05.07.20094805. https://www.medrxiv.org/content/medrxiv/early/2020/05/12/2020.05.07.20094805.full.pdf
418. Long, Q.-X.; Liu, B.-Z.; Deng, H.-J.; Wu, G.-C.; Deng, K.; Chen, Y.-K.; Liao, P.; Qiu, J.-F.; Lin, Y.; Cai, X.-F.; Wang, D.-Q.; Hu, Y.; Ren, J.-H.; Tang, N.; Xu, Y.-Y.; Yu, L.-H.; Mo, Z.; Gong, F.; Zhang, X.-L.; Tian, W.-G.; Hu, L.; Zhang, X.-X.; Xiang, J.-L.; Du, H.-X.; Liu, H.-W.; Lang, C.-H.; Luo, X.-H.; Wu, S.-B.; Cui, X.-P.; Zhou, Z.; Zhu, M.-M.; Wang, J.; Xue, C.-J.; Li, X.-F.; Wang, L.; Li, Z.-J.; Wang, K.; Niu, C.-C.; Yang, Q.-J.; Tang, X.-J.; Zhang, Y.; Liu, X.-M.; Li, J.-J.; Zhang, D.-C.; Zhang, F.; Liu, P.; Yuan, J.; Li, Q.; Hu, J.-L.; Chen, J.; Huang, A.-L., Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0897-1
419. Long, Q.-X.; Tang, X.-J.; Shi, Q.-L.; Li, Q.; Deng, H.-J.; Yuan, J.; Hu, J.-L.; Xu, W.; Zhang, Y.; Lv, F.-J.; Su, K.; Zhang, F.; Gong, J.; Wu, B.; Liu, X.-M.; Li, J.-J.; Qiu, J.-F.; Chen, J.; Huang, A.-L., Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0965-6
420. Long, S. W.; Olsen, R. J.; Christensen, P. A.; Bernard, D. W.; Davis, J. J.; Shukla, M.; Nguyen, M.; Saavedra, M. O.; Yerramilli, P.; Pruitt, L.; Subedi, S.; Kuo, H.-C.; Hendrickson, H.; Eskandari, G.; Nguyen, H. A. T.; Long, J. H.; Kumaraswami, M.; Goike, J.; Boutz, D.; Gollihar, J.; McLellan, J. S.; Chou, C.-W.; Javanmardi, K.; Finkelstein, I. J.; Musser, J., Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. *medRxiv* **2020**, 2020.09.22.20199125. http://medrxiv.org/content/early/2020/09/25/2020.09.22.20199125.abstract

421. Longcom, A. Z., Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine. https://clinicaltrials.gov/ct2/show/NCT04445194?term=NCT04445194&draw=2&rank=1.
422. Lu, J.; Plessis, L. d.; Liu, Z.; Hill, V.; Kang, M.; Lin, H.; Sun, J.; Francois, S.; Kraemer, M. U. G.; Faria, N. R.; McCrone, J. T.; Peng, J.; Xiong, Q.; Yuan, R.; Zeng, L.; Zhou, P.; Liang, C.; Yi, L.; Liu, J.; Xiao, J.; Hu, J.; Liu, T.; Ma, W.; Li, W.; Su, J.; Zheng, H.; Peng, B.; Fang, S.; Su, W.; Li, K.; Sun, R.; Bai, R.; Tang, X.; Liang, M.; Quick, J.; Song, T.; Rambaut, A.; Loman, N.; Raghwani, J.; Pybus, O.; Ke, C., Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China. *medRxiv* **2020**, 2020.04.01.20047076. https://www.medrxiv.org/content/medrxiv/early/2020/04/04/2020.04.01.20047076.full.pdf
423. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W. J.; Wang, D.; Xu, W.; Holmes, E. C.; Gao, G. F.; Wu, G.; Chen, W.; Shi, W.; Tan, W., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)30251-8
424. Lu, S.; Zhao, Y.; Yu, W.; Yang, Y.; Gao, J.; Wang, J.; Kuang, D.; Yang, M.; Yang, J.; Ma, C.; Xu, J.; Qian, X.; Li, H.; Zhao, S.; Li, J.; Wang, H.; Long, H.; Zhou, J.; Luo, F.; Ding, K.; Wu, D.; Zhang, Y.; Dong, Y.; Liu, Y.; Zheng, Y.; Lin, X.; Jiao, L.; Zheng, H.; Dai, Q.; Sun, Q.; Hu, Y.; Ke, C.; Liu, H.; Peng, X., Comparison of nonhuman primates identified the suitable model for COVID-19. *Signal Transduction and Targeted Therapy* **2020,** *5* (1), 157. https://doi.org/10.1038/s41392-020-00269-6
425. Lu, S.; Zhao, Y.; Yu, W.; Yang, Y.; Gao, J.; Wang, J.; Kuang, D.; Yang, M.; Yang, J.; Ma, C.; Xu, J.; Qian, X.; Li, H.; Zhao, S.; Li, J.; Wang, H.; Long, H.; Zhou, J.; Luo, F.; Ding, K.; Wu, D.; Zhang, Y.; Dong, Y.; Liu, Y.; Zheng, Y.; Lin, X.; Jiao, L.; Zheng, H.; Dai, Q.; Sun, Q.; Hu, Y.; Ke, C.; Liu, H.; Peng, X., Comparison of SARS-CoV-2 infections among 3 species of non-human primates. *bioRxiv* **2020**, 2020.04.08.031807. https://www.biorxiv.org/content/biorxiv/early/2020/04/12/2020.04.08.031807.full.pdf
426. Lu, X.; Zhang, L.; Du, H.; Zhang, J.; Li, Y. Y.; Qu, J.; Zhang, W.; Wang, Y.; Bao, S.; Li, Y.; Wu, C.; Liu, H.; Liu, D.; Shao, J.; Peng, X.; Yang, Y.; Liu, Z.; Xiang, Y.; Zhang, F.; Silva, R. M.; Pinkerton, K. E.; Shen, K.; Xiao, H.; Xu, S.; Wong, G. W. K., SARS-CoV-2 Infection in Children. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2005073
427. Lu, Y.-f.; Pan, L.-y.; Zhang, W.-W.; Cheng, F.; Hu, S.-S.; Zhang, X.; Jiang, H.-y., A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. *International Journal of Infectious Diseases* **2020**. https://doi.org/10.1016/j.ijid.2020.08.023
428. Lu, Y.; Li, Y.; Deng, W.; Liu, M.; He, Y.; Huang, L.; Lv, M.; Li, J.; Du, H., Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan. *Pediatr Infect Dis J* **2020**.
429. Luo, K.; Lei, Z.; Hai, Z.; Xiao, S.; Rui, J.; Yang, H.; Jing, X.; Wang, H.; Xie, Z.; Luo, P.; Li, W.; Li, Q.; Tan, H.; Xu, Z.; Yang, Y.; Hu, S.; Chen, T., Transmission of SARS-CoV-2 in Public Transportation Vehicles: A Case Study in Hunan Province, China. *Open Forum Infectious Diseases* **2020,** *7* (10). https://doi.org/10.1093/ofid/ofaa430
430. Luo, Y.; Trevathan, E.; Qian, Z.; Li, Y.; Li, J.; Xiao, W.; Tu, N.; Zeng, Z.; Mo, P.; Xiong, Y.; Ye, G., Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China. *Emerging Infectious Disease journal* **2020,** *26* (8). https://wwwnc.cdc.gov/eid/article/26/8/20-1016_article
431. Ma, J.; Qi, X.; Chen, H.; Li, X.; Zhang, Z.; Wang, H.; Sun, L.; Zhang, L.; Guo, J.; Morawska, L.; Grinshpun, S. A.; Biswas, P.; Flagan, R. C.; Yao, M., COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per hour. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1283
432. Magleby, R.; Westblade, L. F.; Trzebucki, A.; Simon, M. S.; Rajan, M.; Park, J.; Goyal, P.; Safford, M. M.; Satlin, M. J., Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa851

433. Maier, B. F.; Brockmann, D., Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China. *Science* **2020,** *368* (6492), 742-746. https://science.sciencemag.org/content/sci/368/6492/742.full.pdf
434. Majumder, M.; Mandl, K., Early transmissibility assessment of a novel coronavirus in Wuhan, China. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3524675
435. Malgie, J.; Schoones, J. W.; Pijls, B. G., Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies. *Clin Infect Dis* **2020**.
436. Mallapaty, S., Coronavirus can infect cats — dogs, not so much. *Nature* **2020**. https://www.nature.com/articles/d41586-020-00984-8
437. Mallett, S.; Allen, A. J.; Graziadio, S.; Taylor, S. A.; Sakai, N. S.; Green, K.; Suklan, J.; Hyde, C.; Shinkins, B.; Zhelev, Z.; Peters, J.; Turner, P. J.; Roberts, N. W.; di Ruffano, L. F.; Wolff, R.; Whiting, P.; Winter, A.; Bhatnagar, G.; Nicholson, B. D.; Halligan, S., At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. *BMC Med* **2020,** *18* (1), 346.
438. Maor, Y.; Cohen, D.; Paran, N.; Israely, T.; Ezra, V.; Axelrod, O.; Shinar, E.; Izak, M.; Rahav, G.; Rahimi-Levene, N.; Bazofin, B. M.; Gelman, R.; Dicker, D.; Brosh-Nissimov, T.; Megged, O.; Dahan, D.; Benov, A.; Paz, A.; Edward, K.; Moran, A.; Rogowski, O.; Sorkine, P.; Mayo, A.; Zimhony, O.; Chen, J., Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. *EClinicalMedicine* **2020**, 100525.
439. Masana, L.; Correig, E.; Rodríguez-Borjabad, C.; Anoro, E.; Arroyo, J. A.; Jericó, C.; Pedragosa, A.; Miret, M.; Näf, S.; Pardo, A.; Perea, V.; Pérez-Bernalte, R.; Plana, N.; Ramírez-Montesinos, R.; Royuela, M.; Soler, C.; Urquizu-Padilla, M.; Zamora, A.; Pedro-Botet, J.; Group, O., EFFECT oF STATIN THERAPY oN SARS-CoV-2 INFECTION-RELATED. *Eur Heart J Cardiovasc Pharmacother* **2020**.
440. Mateus, J.; Grifoni, A.; Tarke, A.; Sidney, J.; Ramirez, S. I.; Dan, J. M.; Burger, Z. C.; Rawlings, S. A.; Smith, D. M.; Phillips, E.; Mallal, S.; Lammers, M.; Rubiro, P.; Quiambao, L.; Sutherland, A.; Yu, E. D.; da Silva Antunes, R.; Greenbaum, J.; Frazier, A.; Markmann, A. J.; Premkumar, L.; de Silva, A.; Peters, B.; Crotty, S.; Sette, A.; Weiskopf, D., Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* **2020**, eabd3871. https://science.sciencemag.org/content/sci/early/2020/08/04/science.abd3871.full.pdf
441. Matta, A.; Chaudhary, S.; Bryan Lo, K.; DeJoy, R., 3rd; Gul, F.; Torres, R.; Chaisson, N.; Patarroyo-Aponte, G., Timing of Intubation and Its Implications on Outcomes in Critically Ill Patients With Coronavirus Disease 2019 Infection. *Crit Care Explor* **2020,** *2* (10), e0262.
442. McCoy, J.; Cadegiani, F. A.; Wambier, C. G.; Herrera, S.; Vaño-Galván, S.; Mesinkovska, N. A.; Ramos, P. M.; Shapiro, J.; Sinclair, R.; Tosti, A.; Goren, A., 5-Alpha-Reductase Inhibitors are Associated with Reduced Frequency of COVID-19 Symptoms in Males with Androgenetic Alopecia. *J Eur Acad Dermatol Venereol* **2020**.
443. McCulloch, D. J.; Kim, A. E.; Wilcox, N. C.; Logue, J. K.; Greninger, A. L.; Englund, J. A.; Chu, H. Y., Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection. *JAMA Network Open* **2020,** *3* (7), e2016382-e2016382. https://doi.org/10.1001/jamanetworkopen.2020.16382
444. McElvaney, O. J.; Hobbs, B. D.; Qiao, D.; McElvaney, O. F.; Moll, M.; McEvoy, N. L.; Clarke, J.; O'Connor, E.; Walsh, S.; Cho, M. H.; Curley, G. F.; McElvaney, N. G., A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. *EBioMedicine* **2020,** *61*, 103026. http://www.sciencedirect.com/science/article/pii/S2352396420304023
445. Medicine, U. S. N. L. o., Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. https://clinicaltrials.gov/ct2/show/NCT04334980.
446. Medicine, U. S. N. L. o., Immunity and Safety of Covid-19 Synthetic Minigene Vaccine. ClinicalTrials.gov: 2020. https://clinicaltrials.gov/ct2/show/NCT04276896

447. Medicine, U. S. N. L. o., Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Frontline Healthcare Workers and First Responders. https://clinicaltrials.gov/ct2/show/NCT04386252?term=Aivita+Biomedical&draw=2&rank=1.
448. Medicine, U. S. N. L. o., SCB-2019 as COVID-19 Vaccine. https://clinicaltrials.gov/ct2/show/NCT04405908?term=SCB-2019&draw=2&rank=1.
449. Medicine, U. S. N. L. o., Tableted COVID-19 Therapeutic Vaccine (COVID-19). https://clinicaltrials.gov/ct2/show/NCT04380532?term=immunitor&draw=2&rank=11.
450. Medigen, A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901. https://clinicaltrials.gov/ct2/show/study/NCT04487210?term=vaccine&cond=covid-19&draw=7.
451. Menachery, V. D.; Dinnon, K. H.; Yount, B. L.; McAnarney, E. T.; Gralinski, L. E.; Hale, A.; Graham, R. L.; Scobey, T.; Anthony, S. J.; Wang, L.; Graham, B.; Randell, S. H.; Lipkin, W. I.; Baric, R. S., Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. *Journal of Virology* **2020,** *94* (5), e01774-19. https://jvi.asm.org/content/jvi/94/5/e01774-19.full.pdf
452. Merck, A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001). https://clinicaltrials.gov/ct2/show/NCT04498247.
453. Merkler, A. E.; Parikh, N. S.; Mir, S.; Gupta, A.; Kamel, H.; Lin, E.; Lantos, J.; Schenck, E. J.; Goyal, P.; Bruce, S. S.; Kahan, J.; Lansdale, K. N.; LeMoss, N. M.; Murthy, S. B.; Stieg, P. E.; Fink, M. E.; Iadecola, C.; Segal, A. Z.; Cusick, M.; Campion, T. R., Jr; Diaz, I.; Zhang, C.; Navi, B. B., Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. *JAMA Neurology* **2020**. https://doi.org/10.1001/jamaneurol.2020.2730
454. Millett, G. A.; Jones, A. T.; Benkeser, D.; Baral, S.; Mercer, L.; Beyrer, C.; Honermann, B.; Lankiewicz, E.; Mena, L.; Crowley, J. S.; Sherwood, J.; Sullivan, P., Assessing Differential Impacts of COVID-19 on Black Communities. *Annals of Epidemiology* **2020**. http://www.sciencedirect.com/science/article/pii/S1047279720301769
455. Mina, M. J.; Parker, R.; Larremore, D. B., Rethinking Covid-19 Test Sensitivity — A Strategy for Containment. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMp2025631
456. MIT, DELPHI Epidemiological Case Predictions. https://www.covidanalytics.io/projections.
457. Mitchell, S. L.; Ventura, S. E., Evaluation and Comparison of the Hologic Aptima SARS-CoV-2 and the CDC 2019 nCoV real-time RT-PCR Diagnostic Panel using a Four-Sample Pooling Approach. *Journal of Clinical Microbiology* **2020**, JCM.02241-20. https://jcm.asm.org/content/jcm/early/2020/09/17/JCM.02241-20.full.pdf
458. Mitja, O.; Ubals, M.; Corbacho, M.; Alemany, A.; Suner, C.; Tebe, C.; Tobias, A.; Penafiel, J.; Ballana, E.; Perez, C. A.; Admella, P.; Riera-Marti, N.; Laporte, P.; Mitja, J.; Clua, M.; Bertran, L.; Gavilan, S.; Ara, J.; Sarquella, M.; Argimon, J. M.; Cuatrecasas, G.; Canadas, P.; Elizalde-Torrent, A.; Fabregat, R.; Farre, M.; Forcada, A.; Flores-Mateo, G.; Lopez, C.; Muntada, E.; Nadal, N.; Narejos, S.; Gil-Ortega, A. N.; Prat, N.; Puig, J.; Quinones, C.; Ramirez-Viaplana, F.; Reyes-Uruena, J.; Riveira-Munoz, E.; Ruiz, L.; Sanz, S.; Sentis, A.; Sierra, A.; Velasco, C.; Vivanco-Hidalgo, R. M.; Zamora, J.; Casabona, J.; Vall-Mayans, M.; G-Beiras, C.; Clotet, B., A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease. *medRxiv* **2020**, 2020.07.20.20157651. http://medrxiv.org/content/early/2020/07/26/2020.07.20.20157651.abstract
459. MITRE, COVID-19 Dashboard and Tools. https://dashboards.c19hcc.org/.
460. Mizumoto, K.; Kagaya, K.; Zarebski, A.; Chowell, G., Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* **2020,** *25* (10), 2000180. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000180

461. Moderna, Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study. https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy.
462. Moghadam, S. A.; Dini, P.; Nassiri, S.; Motavaselian, M.; Hajibaba, M.; Sohrabi, M., Clinical features of pregnant women in Iran who died due to COVID-19. *International Journal of Gynecology & Obstetrics* **2020,** *n/a* (n/a). https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13461
463. Moiseev, S.; Avdeev, S.; Tao, E.; Brovko, M.; Bulanov, N.; Zykova, A.; Akulkina, L.; Smirnova, I.; Fomin, V., Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study. *Annals of the Rheumatic Diseases* **2020**, annrheumdis-2020-219265. http://ard.bmj.com/content/early/2020/10/30/annrheumdis-2020-219265.abstract
464. Monchatre-Leroy, E.; Lesellier, S.; Wasniewski, M.; Picard-Meyer, E.; Richomme, C.; Boué, F.; Lacôte, S.; Murri, S.; Pulido, C.; Vulin, J.; Salguero, F. J.; Gouilh, M. A.; Servat, A.; Marianneau, P., Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2. *bioRxiv* **2020**, 2020.09.24.311977.
http://biorxiv.org/content/early/2020/09/24/2020.09.24.311977.abstract
465. Monk, P. D.; Marsden, R. J.; Tear, V. J.; Brookes, J.; Batten, T. N.; Mankowski, M.; Gabbay, F. J.; Davies, D. E.; Holgate, S. T.; Ho, L. P.; Clark, T.; Djukanovic, R.; Wilkinson, T. M. A., Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir Med* **2020**.
466. Monreal, E.; Sainz de la Maza, S.; Natera-Villalba, E.; Beltrán-Corbellini, Á.; Rodríguez-Jorge, F.; Fernández-Velasco, J. I.; Walo-Delgado, P.; Muriel, A.; Zamora, J.; Alonso-Canovas, A.; Fortún, J.; Manzano, L.; Montero-Errasquín, B.; Costa-Frossard, L.; Masjuan, J.; Villar, L. M., High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. *Eur J Clin Microbiol Infect Dis* **2020**, 1-9.
467. Montopoli, M.; Zumerle, S.; Vettor, R.; Rugge, M.; Zorzi, M.; Catapano, C. V.; Carbone, G.; Cavalli, A.; Pagano, F.; Ragazzi, E., Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n= 4532). *Annals of Oncology* **2020**.
468. Moore, J. T.; Ricaldi, J. N.; Rose, C. E.; al., e., Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots During June 5–18, 2020 — 22 States, February–June 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 14 August 2020*.
469. Morawska, L.; Milton, D. K., It is Time to Address Airborne Transmission of COVID-19. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa939
470. Moriarty, L. F.; Plucinski, M. M.; Marston, B. J. e. a., Public Health Responses fo COVID-19 Outbreaks on Cruise Ships - Worldwide, February - March 2020. *MMWR* **2020,** (ePub: 23 March 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e3.htm
471. Morley, C. P.; Anderson, K. B.; Shaw, J.; Stewart, T.; Thomas, S. J.; Wang, D., Social Distancing Metrics and Estimates of SARS-CoV-2 Transmission Rates: Associations Between Mobile Telephone Data Tracking and R. *Journal of Public Health Management and Practice* **9000,** *Publish Ahead of Print*. https://journals.lww.com/jphmp/Fulltext/9000/Social_Distancing_Metrics_and_Estimates_of.99258.aspx
472. Morris, S. B.; Schwartz, N. G.; Patel, P.; al., e., Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection — United Kingdom and United States, March–August 2020. *Morbidity and Mortality Weekly Report* **2020,** *2 October 2020*.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6940e1.htm
473. Mudd, P. A.; Crawford, J. C.; Turner, J. S.; Souquette, A.; Reynolds, D.; Bender, D.; Bosanquet, J. P.; Anand, N. J.; Striker, D. A.; Martin, R. S.; Boon, A. C. M.; House, S. L.; Remy, K. E.; Hotchkiss, R. S.; Presti, R. M.; O'Halloran, J. A.; Powderly, W. G.; Thomas, P. G.; Ellebedy, A. H., Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. *Science Advances*

2020, eabe3024.
https://advances.sciencemag.org/content/advances/early/2020/11/13/sciadv.abe3024.full.pdf
474. Munster, V. J.; Feldmann, F.; Williamson, B. N.; van Doremalen, N.; Pérez-Pérez, L.; Schulz, J.; Meade-White, K.; Okumura, A.; Callison, J.; Brumbaugh, B.; Avanzato, V. A.; Rosenke, R.; Hanley, P. W.; Saturday, G.; Scott, D.; Fischer, E. R.; de Wit, E., Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. *bioRxiv* **2020**, 2020.03.21.001628.
https://www.biorxiv.org/content/biorxiv/early/2020/03/21/2020.03.21.001628.full.pdf
475. Murat, S.; Dogruoz Karatekin, B.; Icagasioglu, A.; Ulasoglu, C.; İçten, S.; Incealtin, O., Clinical presentations of pain in patients with COVID-19 infection. *Ir J Med Sci* **2020**.
476. Murphy, N.; Boland, M.; Bambury, N.; Fitzgerald, M.; Comerford, L.; Dever, N.; O'Sullivan, M. B.; Petty-Saphon, N.; Kiernan, R.; Jensen, M.; O'Connor, L., A large national outbreak of COVID-19 linked to air travel, Ireland, summer 2020. *Eurosurveillance* **2020,** *25* (42), 2001624.
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.42.2001624
477. Mykytyn, A. Z.; Lamers, M. M.; Okba, N. M. A.; Breugem, T. I.; Schipper, D.; van den Doel, P. B.; van Run, P.; van Amerongen, G.; de Waal, L.; Koopmans, M.; Stittelaar, K. J.; van den Brand, J.; Haagmans, B. L., Susceptibility of rabbits to SARS-CoV-2. *bioRxiv* **2020**, 2020.08.27.263988.
http://biorxiv.org/content/early/2020/08/27/2020.08.27.263988.abstract
478. Naderi-Azad, S.; Vender, R., Lessons From the First Wave of the Pandemic: Skin Features of COVID-19 can be Divided Into Inflammatory and Vascular Patterns. *Journal of Cutaneous Medicine and Surgery* **2020**, 1203475420972343. https://doi.org/10.1177/1203475420972343
479. Nadkarni, G. N.; Lala, A.; Bagiella, E.; Chang, H. L.; Moreno, P.; Pujadas, E.; Arvind, V.; Bose, S.; Charney, A. W.; Chen, M. D.; Cordon-Cardo, C.; Dunn, A. S.; Farkouh, M. E.; Glicksberg, B.; Kia, A.; Kohli-Seth, R.; Levin, M. A.; Timsina, P.; Zhao, S.; Fayad, Z. A.; Fuster, V., Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study. *Journal of the American College of Cardiology* **2020**, 27631.
https://www.onlinejacc.org/content/accj/early/2020/08/24/j.jacc.2020.08.041.full.pdf
480. Nasa, P.; Singh, A.; Upadhyay, S.; Bagadia, S.; Polumuru, S.; Shrivastava, P. K.; Sankar, R.; Vijayan, L.; Soliman, M. A.; Ali, A.; Patidar, S., Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers. *Indian J Crit Care Med* **2020,** *24* (9), 771-776.
481. NASEM, *Airborne transmission of SARS-CoV-2; Proceedings of a Workshop - in Brief*; National Academies of Sciences, Engineering, and Medicine: 2020. https://www.nap.edu/read/25958/chapter/1
482. Ng, K. W.; Faulkner, N.; Cornish, G. H.; Rosa, A.; Harvey, R.; Hussain, S.; Ulferts, R.; Earl, C.; Wrobel, A. G.; Benton, D. J.; Roustan, C.; Bolland, W.; Thompson, R.; Agua-Doce, A.; Hobson, P.; Heaney, J.; Rickman, H.; Paraskevopoulou, S.; Houlihan, C. F.; Thomson, K.; Sanchez, E.; Shin, G. Y.; Spyer, M. J.; Joshi, D.; O'Reilly, N.; Walker, P. A.; Kjaer, S.; Riddell, A.; Moore, C.; Jebson, B. R.; Wilkinson, M.; Marshall, L. R.; Rosser, E. C.; Radziszewska, A.; Peckham, H.; Ciurtin, C.; Wedderburn, L. R.; Beale, R.; Swanton, C.; Gandhi, S.; Stockinger, B.; McCauley, J.; Gamblin, S. J.; McCoy, L. E.; Cherepanov, P.; Nastouli, E.; Kassiotis, G., Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science* **2020**, eabe1107.
https://science.sciencemag.org/content/sci/early/2020/11/05/science.abe1107.full.pdf
483. Ng, O. T.; Marimuthu, K.; Koh, V.; Pang, J.; Linn, K. Z.; Sun, J.; De Wang, L.; Chia, W. N.; Tiu, C.; Chan, M.; Ling, L. M.; Vasoo, S.; Abdad, M. Y.; Chia, P. Y.; Lee, T. H.; Lin, R. J.; Sadarangani, S. P.; Chen, M. I. C.; Said, Z.; Kurupatham, L.; Pung, R.; Wang, L.-F.; Cook, A. R.; Leo, Y.-S.; Lee, V. J. M., SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. *The Lancet Infectious Diseases*. https://doi.org/10.1016/S1473-3099(20)30833-1
484. Ngonghala, C. N.; Iboi, E.; Eikenberry, S.; Scotch, M.; MacIntyre, C. R.; Bonds, M. H.; Gumel, A. B., Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019

novel Coronavirus. *Mathematical Biosciences* **2020,** *325*, 108364. http://www.sciencedirect.com/science/article/pii/S0025556420300560
485. Nguyen-Contant, P.; Embong, A. K.; Kanagaiah, P.; Chaves, F. A.; Yang, H.; Branche, A. R.; Topham, D. J.; Sangster, M. Y., S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. *mBio* **2020,** *11* (5), e01991-20. https://mbio.asm.org/content/mbio/11/5/e01991-20.full.pdf
486. Nguyen, L. H.; Drew, D. A.; Graham, M. S.; Joshi, A. D.; Guo, C.-G.; Ma, W.; Mehta, R. S.; Warner, E. T.; Sikavi, D. R.; Lo, C.-H.; Kwon, S.; Song, M.; Mucci, L. A.; Stampfer, M. J.; Willett, W. C.; Eliassen, A. H.; Hart, J. E.; Chavarro, J. E.; Rich-Edwards, J. W.; Davies, R.; Capdevila, J.; Lee, K. A.; Lochlainn, M. N.; Varsavsky, T.; Sudre, C. H.; Cardoso, M. J.; Wolf, J.; Spector, T. D.; Ourselin, S.; Steves, C. J.; Chan, A. T., Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health* **2020**. http://www.thelancet-press.com/embargo/hcwcovid.pdf
487. NIH, *Fact Sheet for Patients And Parent/Caregivers - Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)*; National Institutes of Health: 2020. https://www.fda.gov/media/137565/download
488. NIH, NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 Begins. National Institutes of Health: 2020. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-testing-hyperimmune-intravenous-immunoglobulin-plus-remdesivir-treat-covid-19-begins
489. Nishiura, H.; Kobayashi, T.; Miyama, T.; Suzuki, A.; Jung, S.-m.; Hayashi, K.; Kinoshita, R.; Yang, Y.; Yuan, B.; Akhmetzhanov, A. R.; Linton, N. M., Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *International Journal of Infectious Diseases* **2020,** *94*, 154-155. http://www.sciencedirect.com/science/article/pii/S1201971220301399
490. Northeastern, Modeling of COVID-19 epidemic in the United States. https://covid19.gleamproject.org/#icubedproj.
491. Novavax, Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom. https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united.
492. Now, C. A., America's COVID warning system. https://covidactnow.org/?s=38532.
493. O'Hare, R.; Wighton, K., Imperial to begin first human trials of new COVID-19 vaccine. https://www.imperial.ac.uk/news/198314/imperial-begin-first-human-trials-covid-19/.
494. O'Hearn, K.; Gertsman, S.; Webster, R.; Tsampalieros, A.; Ng, R.; Gibson, J.; Sampson, M.; Sikora, L.; McNally, J. D., Efficacy and Safety of Disinfectants for Decontamination of N95 and SN95 Filtering Facepiece Respirators: A Systematic Review. *Journal of Hospital Infection*. https://doi.org/10.1016/j.jhin.2020.08.005
495. Oetjens, M. T.; Luo, J. Z.; Chang, A.; Leader, J. B.; Hartzel, D. N.; Moore, B. S.; Strande, N. T.; Kirchner, H. L.; Ledbetter, D. H.; Justice, A. E.; Carey, D. J.; Mirshahi, T., Electronic health record analysis identifies kidney disease as the leading risk factor for hospitalization in confirmed COVID-19 patients. *PLoS One* **2020,** *15* (11), e0242182.
496. Offeddu, V.; Yung, C. F.; Low, M. S. F.; Tam, C. C., Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis. *Clin Infect Dis* **2017,** *65* (11), 1934-1942. https://www.ncbi.nlm.nih.gov/pubmed/29140516
497. Ogega, C. O.; Skinner, N. E.; Blair, P. W.; Park, H.-S.; Littlefield, K.; Ganesan, A.; Ladiwala, P.; Antar, A. A.; Ray, S. C.; Betenbaugh, M. J.; Pekosz, A.; Klein, S.; Manabe, Y. C.; Cox, A. L.; Bailey, J. R., Durable SARS-CoV-2 B cell immunity after mild or severe disease. *medRxiv* **2020**, 2020.10.28.20220996. https://www.medrxiv.org/content/medrxiv/early/2020/10/30/2020.10.28.20220996.full.pdf

498. Oh, C.; Araud, E.; Puthussery, J. V.; Bai, H.; Clark, G. G.; Wang, L.; Verma, V.; Nguyen, T. H., Dry Heat as a Decontamination Method for N95 Respirator Reuse. *Environmental Science & Technology Letters* **2020**. https://doi.org/10.1021/acs.estlett.0c00534
499. Olson, D. R.; Huynh, M.; Fine, A.; Baumgartner, J.; Castro, A.; Chan, H. T.; Daskalakis, D.; Devinney, K.; Guerra, K.; Harper, S.; Kennedy, J.; Konty, K.; Li, W.; McGibbon, E.; Shaff, J.; Thompson, C.; Vora, N. M.; Van Wye, G., Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak — New York City, March 11–May 2, 2020. *Morbidity and Mortality Weekly Report* **2020,** (ePub: 11 May 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e5.htm?s_cid=mm6919e5_w
500. Omori, R.; Matsuyama, R.; Nakata, Y., The age distribution of mortality from novel coronavirus disease (COVID-19) suggests no large difference of susceptibility by age. *Scientific Reports* **2020,** *10* (1), 16642. https://doi.org/10.1038/s41598-020-73777-8
501. OncoSec, CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) (CORVax12). https://clinicaltrials.gov/ct2/show/NCT04627675.
502. OnCubaNews, Cuba to start clinical trials of its own vaccine against new coronavirus. https://oncubanews.com/en/cuba/cuba-to-start-clinical-trials-of-its-own-vaccine-against-new-coronavirus/.
503. Onder, G.; Rezza, G.; Brusaferro, S., Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.4683
504. Ong, S. W. X.; Tan, Y. K.; Chia, P. Y.; Lee, T. H.; Ng, O. T.; Wong, M. S. Y.; Marimuthu, K., Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *Jama* **2020**. https://jamanetwork.com/journals/jama/articlepdf/2762692/jama_ong_2020_ld_200016.pdf
505. Oran, D. P.; Topol, E. J., Prevalence of Asymptomatic SARS-CoV-2 Infection. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-3012
506. Ortolan, A.; Lorenzin, M.; Felicetti, M.; Doria, A.; Ramonda, R., Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis. *International Journal of Infectious Diseases* **2020**. https://doi.org/10.1016/j.ijid.2020.07.076
507. Oster, A. M.; Caruso, E.; DeVies, J.; Hartnett, K. P.; Boehmer, T. K., Transmission Dynamics by Age Group in COVID-19 Hotspot Counties — United States, April–September 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub* (9 October 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6941e1.htm
508. Osterrieder, N.; Bertzbach, L. D.; Dietert, K.; Abdelgawad, A.; Vladimirova, D.; Kunec, D.; Hoffmann, D.; Beer, M.; Gruber, A. D.; Trimpert, J., Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters. *Viruses* **2020,** *12* (7).
509. Oude Munnink, B. B.; Sikkema, R. S.; Nieuwenhuijse, D. F.; Molenaar, R. J.; Munger, E.; Molenkamp, R.; van der Spek, A.; Tolsma, P.; Rietveld, A.; Brouwer, M.; Bouwmeester-Vincken, N.; Harders, F.; der Honing, R. H.-v.; Wegdam-Blans, M. C. A.; Bouwstra, R. J.; GeurtsvanKessel, C.; van der Eijk, A. A.; Velkers, F. C.; Smit, L. A. M.; Stegeman, A.; van der Poel, W. H. M.; Koopmans, M. P. G., Jumping back and forth: anthropozoonotic and zoonotic transmission of SARS-CoV-2 on mink farms. *bioRxiv* **2020**, 2020.09.01.277152. https://www.biorxiv.org/content/biorxiv/early/2020/09/01/2020.09.01.277152.full.pdf
510. Oxford, Oxford COVID-19 vaccine to begin phase II/III human trials. University of Oxford: 2020. http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials
511. Pairo-Castineira, E.; Clohisey, S.; Klaric, L.; Bretherick, A.; Rawlik, K.; Parkinson, N.; Pasko, D.; Walker, S.; Richmond, A.; Head Fourman, M.; Law, A.; Furniss, J.; Gountouna, E.; Wrobel, N.; Russell, C. D.; Moutsianas, L.; Wang, B.; Meynert, A.; Yang, Z.; Zhai, R.; Zheng, C.; Griffith, F.; Oosthuyzen, W.; Shih, B.; Keating, S.; Zechner, M.; Haley, C.; Porteous, D. J.; Hayward, C.; Knight, J.; Summers, C.; Shankar-Hari, M.; Turtle, L.; Ho, A.; Hinds, C.; Horby, P.; Nichol, A.; Maslove, D.; Ling, L.; Klenerman, P.; McAuley, D.;

Montgomery, H.; Walsh, T.; Shen, X.; Rowan, K.; Fawkes, A.; Murphy, L.; Ponting, C. P.; Tenesa, A.; Caulfield, M.; Scott, R.; Openshaw, P. J. M.; Semple, M. G.; Vitart, V.; Wilson, J. F.; Baillie, J. K., Genetic mechanisms of critical illness in Covid-19. *medRxiv* **2020**, 2020.09.24.20200048. http://medrxiv.org/content/early/2020/09/25/2020.09.24.20200048.1.abstract

512. Pan, D.; Sze, S.; Minhas, J. S.; Bangash, M. N.; Pareek, N.; Divall, P.; Williams, C. M. L.; Oggioni, M. R.; Squire, I. B.; Nellums, L. B.; Hanif, W.; Khunti, K.; Pareek, M., The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. *EClinicalMedicine*. https://doi.org/10.1016/j.eclinm.2020.100404

513. Pan, F.; Ye, T.; Sun, P.; Gui, S.; Liang, B.; Li, L.; Zheng, D.; Wang, J.; Hesketh, R. L.; Yang, L.; Zheng, C., Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology 0* (0), 200370. https://pubs.rsna.org/doi/abs/10.1148/radiol.2020200370

514. Pan, H.; Peto, R.; Abdool Karim, Q.; Alejandria, M.; Henao Restrepo, A. M.; Hernandez Garcia, C.; Kieny, M. P.; Malekzadeh, R.; Murthy, S.; Preziosi, M.-P.; Reddy, S.; Roses, M.; Sathiyamoorthy, V.; Rottingen, J.-A.; Swaminathan, S., Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. *medRxiv* **2020**, 2020.10.15.20209817. https://www.medrxiv.org/content/medrxiv/early/2020/10/15/2020.10.15.20209817.full.pdf

515. Paranjpe, I.; Fuster, V.; Lala, A.; Russak, A.; Glicksberg, B. S.; Levin, M. A.; Charney, A. W.; Narula, J.; Fayad, Z. A.; Bagiella, E.; Zhao, S.; Nadkarni, G. N., Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. *Journal of the American College of Cardiology* **2020**, 27327. http://www.onlinejacc.org/content/accj/early/2020/05/05/j.jacc.2020.05.001.full.pdf

516. Park, S. W.; Champredon, D.; Earn, D. J. D.; Li, M.; Weitz, J. S.; Grenfell, B. T.; Dushoff, J., Reconciling early-outbreak preliminary estimates of the basic reproductive number and its uncertainty: a new framework and applications to the novel coronavirus (2019-nCoV) outbreak. **2020**, 1-13.

517. Park, S. Y.; Kim, Y.-M.; Yi, S.; Lee, S.; Na, B.-J.; Kim, C. B.; Kim, J.-i.; Kim, H. S.; Kim, Y. B.; Park, Y.; Huh, I. S.; Kim, H. K.; Yoon, H. J.; Jang, H.; Kim, K.; Chang, Y.; Kim, I.; Lee, H.; Gwack, J.; Kim, S. S.; Kim, M.; Kweon, S.; Choe, Y. J.; Park, O.; Park, Y. J.; Jeong, E. K., Coronavirus Disease Outbreak in Call Center, South Korea. *Emerging Infectious Disease journal* **2020,** *26* (8), 1666. https://wwwnc.cdc.gov/eid/article/26/8/20-1274_article

518. Parker, C. W.; Singh, N.; Tighe, S.; Blachowicz, A.; Wood, J. M.; Seuylemezian, A.; Vaishampayan, P.; Urbaniak, C.; Hendrickson, R.; Laaguiby, P.; Clark, K.; Clement, B. G.; O'Hara, N. B.; Couto-Rodriguez, M.; Bezdan, D.; Mason, C. E.; Venkateswaran, K., End-to-End Protocol for the Detection of SARS-CoV-2 from Built Environments. *mSystems* **2020,** *5* (5), e00771-20. https://msystems.asm.org/content/msys/5/5/e00771-20.full.pdf

519. Parri, N.; Lenge, M.; Buonsenso, D., Children with Covid-19 in Pediatric Emergency Departments in Italy. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2007617

520. Pasteur, I., Clinical Trial to Evaluate the Safety and Immunogenicitiy of the COVID-19 Vaccine (COVID-19-101). https://clinicaltrials.gov/ct2/show/NCT04497298.

521. Patanavanich, R.; Glantz, S. A., Smoking Is Associated With COVID-19 Progression: A Meta-analysis. *Nicotine Tob Res* **2020,** *22* (9), 1653-1656.

522. Patolia, H.; Pan, J.; Harb, C.; Marr, L. C.; Baffoe-Bonnie, A., Filtration evaluation and clinical use of expired elastomeric P-100 filter cartridges during the COVID-19 pandemic. *Infection Control & Hospital Epidemiology* **2020**, 1-6. https://www.cambridge.org/core/article/filtration-evaluation-and-clinical-use-of-expired-elastomeric-p100-filter-cartridges-during-the-covid19-pandemic/D5EFCC5EEF65FEA210E1070149CB9DEF

523. Pau, A. K.; Aberg, J.; Baker, J.; Belperio, P. S.; Coopersmith, C. M.; Crew, P.; Glidden, D. V.; Grund, B.; Gulick, R. M.; Harrison, C.; Kim, A.; Lane, H. C.; Masur, H.; Sheikh, V.; Singh, K.; Yazdany, J.; Tebas, P., Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health

COVID-19 Treatment Guidelines Panel. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-6448
524. Payne, D. C., SARS-CoV-2 Infections and Serologic Responses from a Sample of US Navy Service Members—USS Theodore Roosevelt, April 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020,** *69*.
525. Peccia, J.; Zulli, A.; Brackney, D. E.; Grubaugh, N. D.; Kaplan, E. H.; Casanovas-Massana, A.; Ko, A. I.; Malik, A. A.; Wang, D.; Wang, M.; Warren, J. L.; Weinberger, D. M.; Arnold, W.; Omer, S. B., Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics. *Nature Biotechnology* **2020**. https://doi.org/10.1038/s41587-020-0684-z
526. Peltier, R. E.; Wang, J.; Hollenbeck, B. L.; Lanza, J.; Furtado, R. M.; Cyr, J.; Ellison, R.; Kobayashi, K. J., Addressing Decontaminated Respirators: Some Methods Appear to Damage Mask Integrity and Protective Function. *Infection Control & Hospital Epidemiology* **2020**, 1-9.
527. Perchetti, G. A.; Huang, M.-L.; Peddu, V.; Jerome, K. R.; Greninger, A. L., Stability of SARS-CoV-2 in PBS for Molecular Detection. *Journal of Clinical Microbiology* **2020**.
528. Pereda, R.; González, D.; Rivero, H. B.; Rivero, J. C.; Pérez, A.; López, L. D. R.; Mezquia, N.; Venegas, R.; Betancourt, J. R.; Domínguez, R. E., Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience. *J Interferon Cytokine Res* **2020,** *40* (9), 438-442.
529. Perkins, A.; Espana, G., NotreDame-FRED COVID-19 forecasts. https://github.com/confunguido/covid19_ND_forecasting/blob/master/README.md.
530. Perry, R. J.; Smith, C. J.; Roffe, C.; Simister, R. J.; Narayanamoorthi, S.; Marigold, R.; Willmot, M.; Dixit, A.; Hassan, A.; Quinn, T.; Ankolekar, S.; Zhang, L.; Banerjee, S.; Ahmed, U.; Padmanabhan, N.; Ferdinand, P.; McGrane, F.; Banaras, A.; Marks, I. H.; Werring, D. J., Characteristics and outcomes of COVID-19-associated stroke: a UK multicentre case-control study. *Journal of Neurology, Neurosurgery & Psychiatry* **2020**, jnnp-2020-324927. https://jnnp.bmj.com/content/jnnp/early/2020/11/03/jnnp-2020-324927.full.pdf
531. Peto, L.; Rodger, G.; Carter, D. P.; Osman, K. L.; Yavuz, M.; Johnson, K.; Raza, M.; Parker, M. D.; Wyles, M. D.; Andersson, M.; Justice, A.; Vaughan, A.; Hoosdally, S.; Stoesser, N.; Matthews, P. C.; Eyre, D. W.; Peto, T. E.; Carroll, M. W.; de Silva, T. I.; Crook, D. W.; Evans, C. M.; Pullan, S. T., Diagnosis of SARS-CoV-2 infection with LamPORE, a high-throughput platform combining loop-mediated isothermal amplification and nanopore sequencing. *medRxiv* **2020**, 2020.09.18.20195370. https://www.medrxiv.org/content/medrxiv/early/2020/09/25/2020.09.18.20195370.full.pdf
532. Petrakis, D.; Margină, D.; Tsarouhas, K.; Tekos, F.; Stan, M.; Nikitovic, D.; Kouretas, D.; Spandidos, D. A.; Tsatsakis, A., Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality (Review). *Mol Med Rep* **2020,** *22* (1), 9-19. https://doi.org/10.3892/mmr.2020.11127
533. Pfizer, PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against.
534. Pickering, B.; Smith, G.; Pinette, M.; Embury-Hyatt, C.; Moffat, E.; Marszal, P.; Lewis, C. E., Susceptibility of domestic swine to experimental infection with SARS-CoV-2. *bioRxiv* **2020**, 2020.09.10.288548. http://biorxiv.org/content/early/2020/09/10/2020.09.10.288548.abstract
535. Pierce, C. A.; Preston-Hurlburt, P.; Dai, Y.; Aschner, C. B.; Cheshenko, N.; Galen, B.; Garforth, S. J.; Herrera, N. G.; Jangra, R. K.; Morano, N. C.; Orner, E.; Sy, S.; Chandran, K.; Dziura, J.; Almo, S. C.; Ring, A.; Keller, M. J.; Herold, K. C.; Herold, B. C., Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. *Science Translational Medicine* **2020,** *12* (564), eabd5487. https://stm.sciencemag.org/content/scitransmed/12/564/eabd5487.full.pdf
536. Pigoga, J. L.; Friedman, A.; Broccoli, M.; Hirner, S.; Naidoo, A. V.; Singh, S.; Werner, K.; Wallis, L. A., Clinical and historical features associated with severe COVID-19 infection: a systematic review. *medRxiv*

2020, 2020.04.23.20076653.
https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20076653.full.pdf
537. Pirjani, R.; Hosseini, R.; Soori, T.; Rabiei, M.; Hosseini, L.; Abiri, A.; Moini, A.; Shizarpour, A.; Razani, G.; Sepidarkish, M., Maternal and neonatal outcomes in COVID-19 infected pregnancies: a prospective cohort study. *Journal of Travel Medicine* **2020**. https://doi.org/10.1093/jtm/taaa158
538. Plante, J. A.; Liu, Y.; Liu, J.; Xia, H.; Johnson, B. A.; Lokugamage, K. G.; Zhang, X.; Muruato, A. E.; Zou, J.; Fontes-Garfias, C. R.; Mirchandani, D.; Scharton, D.; Bilello, J. P.; Ku, Z.; An, Z.; Kalveram, B.; Freiberg, A. N.; Menachery, V. D.; Xie, X.; Plante, K. S.; Weaver, S. C.; Shi, P.-Y., Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. *bioRxiv* **2020**, 2020.09.01.278689.
http://biorxiv.org/content/early/2020/09/02/2020.09.01.278689.abstract
539. Plante, J. A.; Liu, Y.; Liu, J.; Xia, H.; Johnson, B. A.; Lokugamage, K. G.; Zhang, X.; Muruato, A. E.; Zou, J.; Fontes-Garfias, C. R.; Mirchandani, D.; Scharton, D.; Bilello, J. P.; Ku, Z.; An, Z.; Kalveram, B.; Freiberg, A. N.; Menachery, V. D.; Xie, X.; Plante, K. S.; Weaver, S. C.; Shi, P. Y., Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* **2020**.
540. Pollán, M.; Pérez-Gómez, B.; Pastor-Barriuso, R.; al., e., Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet* **2020**.
https://doi.org/10.1016/S0140-6736(20)31483-5
541. Poston, D.; Weisblum, Y.; Wise, H.; Templeton, K.; Jenks, S.; Hatziioannou, T.; Bieniasz, P. D., Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection. *medRxiv* **2020**, 2020.10.08.20209650.
https://www.medrxiv.org/content/medrxiv/early/2020/10/11/2020.10.08.20209650.full.pdf
542. Potter, D.; Riffon, M.; Kakamada, S.; Miller, R. S.; Komatsoulis, G. A., Disproportionate impact of COVID-19 disease among racial and ethnic minorities in the U.S. cancer population as seen in CancerLinQ Discovery data. *Journal of Clinical Oncology* **2020,** *38* (29_suppl), 84-84.
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.29_suppl.84
543. Press, A., Finland deploys coronavirus-sniffing dogs at main airport. https://www.msn.com/en-us/news/world/finland-deploys-coronavirus-sniffing-dogs-at-main-airport/ar-BB19li6Z?li=BBnbcA1 (accessed 23 SEP 2020).
544. Price-Haywood, E. G.; Burton, J.; Fort, D.; Seoane, L., Hospitalization and Mortality among Black Patients and White Patients with Covid-19. *New England Journal of Medicine* **2020**.
https://www.nejm.org/doi/full/10.1056/NEJMsa2011686
545. Qin, J.; You, C.; Lin, Q.; Hu, T.; Yu, S.; Zhou, X., Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study. *Science Advances* **2020,** *07 Aug 2020*.
https://advances.sciencemag.org/content/early/2020/08/07/sciadv.abc1202
546. Qiu, H.; Wu, J.; Hong, L.; Luo, Y.; Song, Q.; Chen, D., Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *The Lancet Infectious Diseases*. https://doi.org/10.1016/S1473-3099(20)30198-5
547. Queensland, U. o., An interventional study to evaluate the safety and immune response of a vaccine against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19 infection) when given to healthy adult participants. .
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true.
548. Rabenau, H. F.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Preiser, W.; Doerr, H. W., Stability and inactivation of SARS coronavirus. *Med Microbiol Immunol* **2005,** *194* (1-2), 1-6.
https://link.springer.com/content/pdf/10.1007/s00430-004-0219-0.pdf
549. Rahmani, H.; Davoudi-Monfared, E.; Nourian, A.; Khalili, H.; Hajizadeh, N.; Jalalabadi, N. Z.; Fazeli, M. R.; Ghazaeian, M.; Yekaninejad, M. S., Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. *Int Immunopharmacol* **2020,** *88*, 106903.

550. Rai, B.; Shukla, A.; Dwivedi, L. K., Estimates of serial interval for COVID-19: A systematic review and meta-analysis. *Clinical Epidemiology and Global Health* **2020**. http://www.sciencedirect.com/science/article/pii/S2213398420301895
551. Rajasingham, R.; Bangdiwala, A. S.; Nicol, M. R.; Skipper, C. P.; Pastick, K. A.; Axelrod, M. L.; Pullen, M. F.; Nascene, A. A.; Williams, D. A.; Engen, N. W.; Okafor, E. C.; Rini, B. I.; Mayer, I. A.; McDonald, E. G.; Lee, T. C.; Li, P.; MacKenzie, L. J.; Balko, J. M.; Dunlop, S. J.; Hullsiek, K. H.; Boulware, D. R.; Lofgren, S. M.; team, o. b. o. t. C. P., Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1571
552. Rambaut, A., Phylodynamic analysis of nCoV-2019 genomes - 27-Jan-2020. http://virological.org/t/phylodynamic-analysis-of-ncov-2019-genomes-27-jan-2020/353.
553. Rapid Expert Consultation, *Rapid Expert Consultation Update on SARS-CoV-2 Surface Stability and Incubation for the COVID-19 Pandemic (March 27, 2020)*. The National Academies Press: Washington, DC, 2020. https://www.nap.edu/read/25763/chapter/1
554. Rapkiewicz, A. V.; Mai, X.; Carsons, S. E.; Pittaluga, S.; Kleiner, D. E.; Berger, J. S.; Thomas, S.; Adler, N. M.; Charytan, D. M.; Gasmi, B.; Hochman, J. S.; Reynolds, H. R., Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. *EClinicalMedicine* **2020**, 100434. http://www.sciencedirect.com/science/article/pii/S2589537020301784
555. Rasheed, A. M.; Fatak, D. F.; Hashim, H. A.; Maulood, M. F.; Kabah, K. K.; Almusawi, Y. A.; Abdulamir, A. S., The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. *Infez Med* **2020,** *28* (3), 357-366.
556. Ratnesar-Shumate, S.; Williams, G.; Green, B.; Krause, M.; Holland, B.; Wood, S.; Bohannon, J.; Boydston, J.; Freeburger, D.; Hooper, I.; Beck, K.; Yeager, J.; Altamura, L. A.; Biryukov, J.; Yolitz, J.; Schuit, M.; Wahl, V.; Hevey, M.; Dabisch, P., Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa274
557. Ray, M., Bharat Biotech's Covid-19 vaccine gets nod for Phase 3 trial. Here's how it came through. https://www.hindustantimes.com/india-news/bharat-biotech-s-covid-19-vaccine-gets-nod-for-phase-3-trial-here-s-how-it-came-through/story-Hcxt2OVsWr7gPxw6dnvxKP.html.
558. Reevell, P.; Salzman, S., Russia announces expanded trials for coronavirus vaccine approved 10 days ago. https://abcnews.go.com/International/russia-announces-expanded-trials-coronavirus-vaccine-approved-10/story?id=72497297.
559. Regeneron, REGN-COV2 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS HOLDING ENROLLMENT IN HOSPITALIZED PATIENTS WITH HIGH OXYGEN REQUIREMENTS AND CONTINUING ENROLLMENT IN PATIENTS WITH LOW OR NO OXYGEN REQUIREMENTS. Regeneron: 2020. https://investor.regeneron.com/news-releases/news-release-details/regn-cov2-independent-data-monitoring-committee-recommends
560. Regeneron, Statement on REGN-COV2 Emergency Use Authorization Request. 2020. https://newsroom.regeneron.com/static-files/6feab76b-176d-402d-bf30-d40462e68b7b
561. Regeneron Pharmaceuticals, I., REGENERON'S REGN-COV2 ANTIBODY COCKTAIL REDUCED VIRAL LEVELS AND IMPROVED SYMPTOMS IN NON-HOSPITALIZED COVID-19 PATIENTS. 2020; p 3. https://newsroom.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and
562. Reich, N., Ensemble. https://reichlab.io/.
563. ReiThera, ReiThera, Laukocare, and Univercells announce Pan-European consortium for the fast-track development of a single-dose adenovirus-based Covid-19 vaccine. https://www.reithera.com/2020/04/23/reithera-leukocare-and-univercells-announce-pan-european-consortium-for-the-fast-track-development-of-a-single-dose-adenovirus-based-covid-19-vaccine/.

564. Remuzzi, A.; Remuzzi, G., COVID-19 and Italy: what next? *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)30627-9
565. Ren, L.; Yu, S.; Xu, W.; Overton, J. L.; Chiamvimonvat, N.; Thai, P. N., Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. *J Cardiol* **2020**.
566. Ren, X.; Li, Y.; Yang, X.; Li, Z.; Cui, J.; Zhu, A.; Zhao, H.; Yu, J.; Nie, T.; Ren, M.; Dong, S.; Cheng, Y.; Chen, Q.; Chang, Z.; Sun, J.; Wang, L.; Feng, L.; Gao, G. F.; Feng, Z.; Li, Z., Evidence for pre-symptomatic transmission of coronavirus disease 2019 (COVID-19) in China. *Influenza and Other Respiratory Viruses* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12787
567. Reuters, Frozen food package polluted by living coronavirus could cause infection, China's CDC says. https://www.reuters.com/article/us-health-coronavirus-china-packaging-idUKKBN2720MD (accessed 01 Nov 2020).
568. Reuters, WHO looks at mink farm biosecurity globally after Danish coronavirus cases. Farge, E.; Kelland, K., Eds. 2020. https://in.reuters.com/article/health-coronavirus-who/who-looking-at-biosecurity-in-other-countries-after-danish-covid-19-mink-outbreak-idINKBN27M1F4?il=0
569. RIBSP, Randomized, Blind, Placebo-controlled I/II Phase QAZCOVID-IN®- COVID-19 Inactivated Vaccine. https://clinicaltrials.gov/ct2/show/NCT04530357?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1.
570. Rice, K.; Wynne, B.; Martin, V.; Ackland, G. J., Effect of school closures on mortality from coronavirus disease 2019: old and new predictions. *BMJ* **2020,** *371*, m3588. https://www.bmj.com/content/bmj/371/bmj.m3588.full.pdf
571. Richard, M.; Kok, A.; de Meulder, D.; Bestebroer, T. M.; Lamers, M. M.; Okba, N. M. A.; Fentener van Vlissingen, M.; Rockx, B.; Haagmans, B. L.; Koopmans, M. P. G.; Fouchier, R. A. M.; Herfst, S., SARS-CoV-2 is transmitted via contact and via the air between ferrets. *Nature Communications* **2020,** *11* (1), 3496. https://doi.org/10.1038/s41467-020-17367-2
572. Richter, W.; Hofacre, K.; Willenberg, Z., *Final Report for the Bioquell Hydrogen Peroxide Vapor (HPV) Decontamination for Reuse of N95 Respirators*; Battelle Memorial Institute: 2016. http://wayback.archive-it.org/7993/20170113034232/http://www.fda.gov/downloads/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMRegulatoryScience/UCM516998.pdf
573. Rickman, H. M.; Rampling, T.; Shaw, K.; Martinez-Garcia, G.; Hail, L.; Coen, P.; Shahmanesh, M.; Shin, G. Y.; Nastouli, E.; Houlihan, C. F., Nosocomial transmission of COVID-19: a retrospective study of 66 hospital-acquired cases in a London teaching hospital. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa816
574. Riddell, S.; Goldie, S.; Hill, A.; Eagles, D.; Drew, T. W., The effect of temperature on persistence of SARS-CoV-2 on common surfaces. *Virology Journal* **2020,** *17* (1), 145. https://doi.org/10.1186/s12985-020-01418-7
575. Riou, J.; Althaus, C. L., Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance* **2020,** *25* (4), 2000058. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.4.2000058
576. Riphagen, S.; Gomez, X.; Gonzalez-Martinez, C.; Wilkinson, N.; Theocharis, P., Hyperinflammatory shock in children during COVID-19 pandemic. *The Lancet*. https://doi.org/10.1016/S0140-6736(20)31094-1
577. Robertson, L. J.; Moore, J. S.; Blighe, K.; Ng, K. Y.; Quinn, N.; Jennings, F.; Warnock, G.; Sharpe, P.; Clarke, M.; Maguire, K.; Rainey, S.; Price, R.; Burns, W.; Kowalczyk, A.; Awuah, A.; McNamee, S.; Wallace, G.; Sager, S.; Chao Shern, C.; Nesbit, M. A.; McLaughlin, J.; Moore, T., SARS-CoV-2 antibody testing in a UK population: detectable IgG for up to 20 weeks post infection. *medRxiv* **2020**, 2020.09.29.20201509. https://www.medrxiv.org/content/medrxiv/early/2020/10/01/2020.09.29.20201509.full.pdf

578. Rockx, B.; Kuiken, T.; Herfst, S.; Bestebroer, T.; Lamers, M. M.; Oude Munnink, B. B.; de Meulder, D.; van Amerongen, G.; van den Brand, J.; Okba, N. M. A.; Schipper, D.; van Run, P.; Leijten, L.; Sikkema, R.; Verschoor, E.; Verstrepen, B.; Bogers, W.; Langermans, J.; Drosten, C.; Fentener van Vlissingen, M.; Fouchier, R.; de Swart, R.; Koopmans, M.; Haagmans, B. L., Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. *Science* **2020**, eabb7314. https://science.sciencemag.org/content/sci/early/2020/04/16/science.abb7314.full.pdf
579. Rodda, L. B.; Netland, J.; Shehata, L.; Pruner, K. B.; Morawski, P. M.; Thouvenel, C.; Takehara, K. K.; Eggenberger, J.; Hemann, E. A.; Waterman, H. R.; Fahning, M. L.; Chen, Y.; Rathe, J.; Stokes, C.; Wrenn, S.; Fiala, B.; Carter, L. P.; Hamerman, J. A.; King, N. P.; Gale, M.; Campbell, D. J.; Rawlings, D.; Pepper, M., Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. *medRxiv* **2020**, 2020.08.11.20171843. https://www.medrxiv.org/content/medrxiv/early/2020/08/15/2020.08.11.20171843.full.pdf
580. Rokkas, T., Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis. *Annals of Gastroenterology* **2020,** *33* (4), 355-365. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315709/
581. Roschewski, M.; Lionakis, M. S.; Sharman, J. P.; Roswarski, J.; Goy, A.; Monticelli, M. A.; Roshon, M.; Wrzesinski, S. H.; Desai, J. V.; Zarakas, M. A.; Collen, J.; Rose, K.; Hamdy, A.; Izumi, R.; Wright, G. W.; Chung, K. K.; Baselga, J.; Staudt, L. M.; Wilson, W. H., Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Science Immunology* **2020,** *5* (48), eabd0110. http://immunology.sciencemag.org/content/5/48/eabd0110.abstract
582. Rothe, C.; Schunk, M.; Sothmann, P.; Bretzel, G.; Froeschl, G.; Wallrauch, C.; Zimmer, T.; Thiel, V.; Janke, C.; Guggemos, W.; Seilmaier, M.; Drosten, C.; Vollmar, P.; Zwirglmaier, K.; Zange, S.; Wölfel, R.; Hoelscher, M., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2001468 https://www.nejm.org/doi/10.1056/NEJMc2001468
583. Ruktanonchai, N. W.; Floyd, J. R.; Lai, S.; Ruktanonchai, C. W.; Sadilek, A.; Rente-Lourenco, P.; Ben, X.; Carioli, A.; Gwinn, J.; Steele, J. E.; Prosper, O.; Schneider, A.; Oplinger, A.; Eastham, P.; Tatem, A. J., Assessing the impact of coordinated COVID-19 exit strategies across Europe. *Science* **2020**, eabc5096. https://science.sciencemag.org/content/sci/early/2020/07/16/science.abc5096.full.pdf
584. Rundle, A., Severe COVID-19 Risk Mapping. https://columbia.maps.arcgis.com/apps/webappviewer/index.html?id=ade6ba85450c4325a12a5b9c09ba796c.
585. Russell, T. W.; Hellewell, J.; Abbott, S.; Golding, N.; Gibbs, H.; Jarvis, C. I.; van Zandvoort, K.; group, C. n. w.; Flasche, S.; Eggo, R. M.; Edmunds, W. J.; Kucharski, A. J., Using a delay-adjusted case fatality ratio to estimate under-reporting. CMMID: 2020. https://cmmid.github.io/topics/covid19/severity/global_cfr_estimates.html
586. RUSSO, R.; Levine, C.; Veilleux, C.; Peixoto, B.; McCormick-Ell, J.; Block, T.; Gresko, A.; Delmas, G.; Chitale, P.; Frees, A.; Ruiz, A.; Alland, D., Decontaminating N95 respirators during the Covid-19 pandemic: simple and practical approaches to increase decontamination capacity, speed, safety and ease of use. *medRxiv* **2020**, 2020.08.17.20177022. https://www.medrxiv.org/content/medrxiv/early/2020/08/21/2020.08.17.20177022.full.pdf
587. Ryan, D. J.; Toomey, S.; Madden, S. F.; Casey, M.; Breathnach, O. S.; Morris, P. G.; Grogan, L.; Branagan, P.; Costello, R. W.; De Barra, E.; Hurley, K.; Gunaratnam, C.; McElvaney, N. G.; OBrien, M. E.; Sulaiman, I.; Morgan, R. K.; Hennessy, B. T., Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19). *Thorax* **2020**, thoraxjnl-2020-215705. https://thorax.bmj.com/content/thoraxjnl/early/2020/10/23/thoraxjnl-2020-215705.full.pdf
588. Ryan, K. A.; Bewley, K. R.; Fotheringham, S. A.; Brown, P.; Hall, Y.; Marriott, A. C.; Tree, J. A.; Allen, L.; Aram, M. J.; Brunt, E.; Buttigieg, K. R.; Cavell, B. E.; Carter, D. P.; Cobb, R.; Coombes, N. S.; Godwin, K.

J.; Gooch, K. E.; Gouriet, J.; Halkerston, R.; Harris, D. J.; Humphries, H. E.; Hunter, L.; Ho, C. M. K.; Kennard, C. L.; Leung, S.; Ngabo, D.; Osman, K. L.; Paterson, J.; Penn, E. J.; Pullan, S. T.; Rayner, E.; Slack, G. S.; Steeds, K.; Taylor, I.; Tipton, T.; Thomas, S.; Wand, N. I.; Watson, R. J.; Wiblin, N. R.; Charlton, S.; Hallis, B.; Hiscox, J. A.; Funnell, S.; Dennis, M. J.; Whittaker, C. J.; Catton, M. G.; Druce, J.; Salguero, F. J.; Carroll, M. W., Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge. *bioRxiv* **2020**, 2020.05.29.123810. https://www.biorxiv.org/content/biorxiv/early/2020/05/29/2020.05.29.123810.full.pdf

589. Saeed, O.; Castagna, F.; Agalliu, I.; Xue, X.; Patel, S. R.; Rochlani, Y.; Kataria, R.; Vukelic, S.; Sims, D. B.; Alvarez, C.; Rivas-Lasarte, M.; Garcia, M. J.; Jorde, U. P., Statin Use and In-Hospital Mortality in Diabetics with COVID-19. *J Am Heart Assoc* **2020**, e018475.

590. Safewell, SafeSpace. https://www.safewellsolutions.co.uk/products/safespace/ (accessed 10 Oct 2020).

591. Salazar, E.; Christensen, P. A.; Graviss, E. A.; Nguyen, D. T.; Castillo, B.; Chen, J.; Lopez, B. V.; Eagar, T. N.; Yi, X.; Zhao, P.; Rogers, J.; Shehabeldin, A.; Joseph, D.; Masud, F.; Leveque, C.; Olsen, R. J.; Bernard, D. W.; Gollihar, J.; Musser, J. M., Significantly decreased mortality in a large cohort of COVID-19 patients transfused early with convalescent plasma containing high titer anti-SARS-CoV-2 spike protein IgG. *The American Journal of Pathology* **2020**. http://www.sciencedirect.com/science/article/pii/S0002944020304892

592. Sanchez, G. V.; Biedron, C.; Fink, L. R.; al., e., Initial and Repeated Point Prevalence Surveys to Inform SARS-CoV-2 Infection Prevention in 26 Skilled Nursing Facilities — Detroit, Michigan, March–May 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 1 July 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6927e1.htm?s_cid=mm6927e1_w#suggestedcitation

593. Sandhu, T.; Tieng, A.; Chilimuri, S.; Franchin, G., A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. *Can J Infect Dis Med Microbiol* **2020,** *2020*, 8865954.

594. Sanofi, Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older. https://clinicaltrials.gov/ct2/show/NCT04537208.

595. Santarpia, J. L.; Rivera, D. N.; Herrera, V.; Morwitzer, M. J.; Creager, H.; Santarpia, G. W.; Crown, K. K.; Brett-Major, D.; Schnaubelt, E.; Broadhurst, M. J.; Lawler, J. V.; Reid, S. P.; Lowe, J. J., Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center. *medRxiv* **2020**, 2020.03.23.20039446. https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.23.20039446.1.full.pdf

596. Schlottau, K.; Rissmann, M.; Graaf, A.; Schön, J.; Sehl, J.; Wylezich, C.; Höper, D.; Mettenleiter, T. C.; Balkema-Buschmann, A.; Harder, T.; Grund, C.; Hoffmann, D.; Breithaupt, A.; Beer, M., SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. *The Lancet Microbe* **2020**. https://doi.org/10.1016/S2666-5247(20)30089-6

597. Schnirring, L., New coronavirus infects health workers, spreads to Korea. http://www.cidrap.umn.edu/news-perspective/2020/01/new-coronavirus-infects-health-workers-spreads-korea.

598. Schuit, M.; Ratnesar-Shumate, S.; Yolitz, J.; Williams, G.; Weaver, W.; Green, B.; Miller, D.; Krause, M.; Beck, K.; Wood, S.; Holland, B.; Bohannon, J.; Freeburger, D.; Hooper, I.; Biryukov, J.; Altamura, L. A.; Wahl, V.; Hevey, M.; Dabisch, P., Airborne SARS-CoV-2 is Rapidly Inactivated by Simulated Sunlight. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa334

599. Sciences, C. A. o. M., Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19. Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19.

600. Self, W. H.; Semler, M. W.; Leither, L. M.; Casey, J. D.; Angus, D. C.; Brower, R. G.; Chang, S. Y.; Collins, S. P.; Eppensteiner, J. C.; Filbin, M. R.; Files, D. C.; Gibbs, K. W.; Ginde, A. A.; Gong, M. N.; Harrell,

F. E., Jr; Hayden, D. L.; Hough, C. L.; Johnson, N. J.; Khan, A.; Lindsell, C. J.; Matthay, M. A.; Moss, M.; Park, P. K.; Rice, T. W.; Robinson, B. R. H.; Schoenfeld, D. A.; Shapiro, N. I.; Steingrub, J. S.; Ulysse, C. A.; Weissman, A.; Yealy, D. M.; Thompson, B. T.; Brown, S. M.; National Heart, L.; Network, B. I. P. C. T., Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.22240
601. Seow, J.; Graham, C.; Merrick, B.; Acors, S.; Steel, K. J. A.; Hemmings, O.; O'Bryne, A.; Kouphou, N.; Pickering, S.; Galao, R.; Betancor, G.; Wilson, H. D.; Signell, A. W.; Winstone, H.; Kerridge, C.; Temperton, N.; Snell, L.; Bisnauthsing, K.; Moore, A.; Green, A.; Martinez, L.; Stokes, B.; Honey, J.; Izquierdo-Barras, A.; Arbane, G.; Patel, A.; OConnell, L.; O Hara, G.; MacMahon, E.; Douthwaite, S.; Nebbia, G.; Batra, R.; Martinez-Nunez, R.; Edgeworth, J. D.; Neil, S. J. D.; Malim, M. H.; Doores, K., Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. *medRxiv* **2020**, 2020.07.09.20148429. https://www.medrxiv.org/content/medrxiv/early/2020/07/11/2020.07.09.20148429.full.pdf
602. sermet, i.; temmam, s.; huon, c.; behillil, s.; gadjos, v.; bigot, t.; lurier, t.; chretien, d.; backovick, m.; Moisan-Delaunay, A.; donati, f.; albert, m.; foucaud, e.; Mesplees, B.; benoist, g.; fayes, a.; duval-arnould, m.; cretolle, c.; charbit, m.; aubart, m.; Auriau, J.; lorrot, m.; Kariyawasam, D.; fertita, l.; Orliaguet, G.; pigneur, b.; Bader-Meunier, B.; briand, c.; toubiana, j.; Guilleminot, T.; van der werf, s.; leruez-ville, m.; eloit, m., Prior infection by seasonal coronaviruses does not prevent SARS-CoV-2 infection and associated Multisystem Inflammatory Syndrome in children. *medRxiv* **2020**, 2020.06.29.20142596. https://www.medrxiv.org/content/medrxiv/early/2020/06/30/2020.06.29.20142596.full.pdf
603. Services, I. o. M. a. L., REALM Project Releases Results from Latest Tests of Coronavirus on Leather, Summary of Research. https://www.imls.gov/news/realm-project-releases-results-latest-tests-coronavirus-leather-summary-research.
604. Shacham, E.; Scroggins, S.; Ellis, M.; Garza, A., Association of County-Wide Mask Ordinances with Reductions in Daily CoVID-19 Incident Case Growth in a Midwestern Region Over 12 Weeks. *medRxiv* **2020**, 2020.10.28.20221705. https://www.medrxiv.org/content/medrxiv/early/2020/10/30/2020.10.28.20221705.full.pdf
605. Shan, B.; Broza, Y. Y.; Li, W.; Wang, Y.; Wu, S.; Liu, Z.; Wang, J.; Gui, S.; Wang, L.; Zhang, Z.; Liu, W.; Zhou, S.; Jin, W.; Zhang, Q.; Hu, D.; Lin, L.; Zhang, Q.; Li, W.; Wang, J.; Liu, H.; Pan, Y.; Haick, H., Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath. *ACS Nano* **2020**. https://doi.org/10.1021/acsnano.0c05657
606. Shea, K.; Borchering, R. K.; Probert, W. J. M.; Howerton, E.; Bogich, T. L.; Li, S.; van Panhuis, W. G.; Viboud, C.; Aguás, R.; Belov, A.; Bhargava, S. H.; Cavany, S.; Chang, J. C.; Chen, C.; Chen, J.; Chen, S.; Chen, Y.; Childs, L. M.; Chow, C. C.; Crooker, I.; Del Valle, S. Y.; España, G.; Fairchild, G.; Gerkin, R. C.; Germann, T. C.; Gu, Q.; Guan, X.; Guo, L.; Hart, G. R.; Hladish, T. J.; Hupert, N.; Janies, D.; Kerr, C. C.; Klein, D. J.; Klein, E.; Lin, G.; Manore, C.; Meyers, L. A.; Mittler, J.; Mu, K.; Núñez, R. C.; Oidtman, R.; Pasco, R.; Piontti, A. P. y.; Paul, R.; Pearson, C. A. B.; Perdomo, D. R.; Perkins, T. A.; Pierce, K.; Pillai, A. N.; Rael, R. C.; Rosenfeld, K.; Ross, C. W.; Spencer, J. A.; Stoltzfus, A. B.; Toh, K. B.; Vattikuti, S.; Vespignani, A.; Wang, L.; White, L.; Xu, P.; Yang, Y.; Yogurtcu, O. N.; Zhang, W.; Zhao, Y.; Zou, D.; Ferrari, M.; Pannell, D.; Tildesley, M.; Seifarth, J.; Johnson, E.; Biggerstaff, M.; Johansson, M.; Slayton, R. B.; Levander, J.; Stazer, J.; Salerno, J.; Runge, M. C., COVID-19 reopening strategies at the county level in the face of uncertainty: Multiple Models for Outbreak Decision Support. *medRxiv* **2020**, 2020.11.03.20225409. https://www.medrxiv.org/content/medrxiv/early/2020/11/05/2020.11.03.20225409.full.pdf
607. Shekerdemian, L. S.; Mahmood, N. R.; Wolfe, K. K.; Riggs, B. J.; Ross, C. E.; McKiernan, C. A.; Heidemann, S. M.; Kleinman, L. C.; Sen, A. I.; Hall, M. W.; Priestley, M. A.; McGuire, J. K.; Boukas, K.; Sharron, M. P.; Burns, J. P.; Collaborative, f. t. I. C.-P., Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatrics* **2020**. https://doi.org/10.1001/jamapediatrics.2020.1948

608. Shen, M.; Zu, J.; Fairley, C. K.; Pagán, J. A.; An, L.; Du, Z.; Guo, Y.; Rong, L.; Xiao, Y.; Zhuang, G.; Li, Y.; Zhang, L., Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use. *medRxiv* **2020**, 2020.10.28.20221234.
https://www.medrxiv.org/content/medrxiv/early/2020/10/30/2020.10.28.20221234.full.pdf
609. Shepardson, D., U.S. CDC issues 'strong recommendation' for mask mandate on airplanes, trains. *Reuters* 2020. https://ca.reuters.com/article/instant-article/idUSL1N2HA24V
610. Sherina, N.; Piralla, A.; Du, L.; Wan, H.; Kumagai-Braesh, M.; Andrell, J.; Braesch-Andersen, S.; Cassaniti, I.; Percivalle, E.; Sarasini, A.; Bergami, F.; Di Martino, R.; Colaneri, M.; Vecchia, M.; Sambo, M.; Zuccaro, V.; Bruno, R.; Oggionni, T.; Meloni, F.; Abolhassani, H.; Bertoglio, F.; Schubert, M.; Byrne-Steele, M.; Han, J.; Hust, M.; Xue, Y.; Hammarstrom, L.; Baldanti, F.; Marcotte, H.; Pan-Hammarstrom, Q., Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection. *bioRxiv* **2020**, 2020.11.06.371617.
https://www.biorxiv.org/content/biorxiv/early/2020/11/06/2020.11.06.371617.full.pdf
611. Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; Zhao, Y.; Liu, P.; Liang, L.; Cui, P.; Wang, J.; Zhang, X.; Guan, Y.; Tan, W.; Wu, G.; Chen, H.; Bu, Z., Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. *Science* **2020**, eabb7015.
https://science.sciencemag.org/content/sci/early/2020/04/07/science.abb7015.full.pdf
612. Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; Huang, H.; Yang, B.; Huang, C., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology* **2020**. https://doi.org/10.1001/jamacardio.2020.0950
613. Sia, S. F.; Yan, L. M.; Chin, A. W. H.; Fung, K.; Choy, K. T.; Wong, A. Y. L.; Kaewpreedee, P.; Perera, R.; Poon, L. L. M.; Nicholls, J. M.; Peiris, M.; Yen, H. L., Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* **2020**.
614. Silcott, D.; Kinahan, S.; Santarpia, J.; Silcott, B.; Silcott, R.; Silcott, P.; Silcott, B.; Distelhorst, S.; Herrera, V.; Rivera, D.; Crown, K.; Lucero, G.; Bryden, W.; McLoughlin, M.; Cetta, M.; Accardi, R., *TRANSCOM/AMC Commercial Aircraft Cabin Aerosol Dispersion Tests*; USATRANSCOM and AMC: 2020.
https://www.ustranscom.mil/cmd/docs/TRANSCOM%20Report%20Final.pdf
615. Silverman, J. D.; Hupert, N.; Washburne, A. D., Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States. *Science Translational Medicine* **2020**, eabc1126.
https://stm.sciencemag.org/content/scitransmed/early/2020/06/22/scitranslmed.abc1126.full.pdf
616. Simmons, S.; Carrion, R.; Alfson, K.; Staples, H.; Jinadatha, C.; Jarvis, W.; Sampathkumar, P.; Chemaly, R. F.; Khawaja, F.; Povroznik, M.; Jackson, S.; Kaye, K. S.; Rodriguez, R. M.; Stibich, M., Deactivation of SARS-CoV-2 with Pulsed Xenon Ultraviolet: implications for environmental COVID-19 control. *Infection Control & Hospital Epidemiology* **2020**, 1-19.
https://www.cambridge.org/core/article/deactivation-of-sarscov2-with-pulsed-xenon-ultraviolet-implications-for-environmental-covid19-control/AD5CF52419E27E86E0114059FBA78D4C
617. Singh, K.; Mittal, S.; Gollapudi, S.; Butzmann, A.; Kumar, J.; Ohgami, R. S., A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity. *International Journal of Laboratory Hematology n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/ijlh.13354
618. Sinovac, Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV).
https://clinicaltrials.gov/ct2/show/NCT04456595?term=vaccine&cond=covid-19&draw=2&rank=1.
619. Sit, T. H. C.; Brackman, C. J.; Ip, S. M.; Tam, K. W. S.; Law, P. Y. T.; To, E. M. W.; Yu, V. Y. T.; Sims, L. D.; Tsang, D. N. C.; Chu, D. K. W.; Perera, R.; Poon, L. L. M.; Peiris, M., Infection of dogs with SARS-CoV-2. *Nature* **2020**.

620. Skalina, K. A.; Goldstein, D. Y.; Sulail, J.; Hahm, E.; Narlieva, M.; Szymczak, W.; Fox, A. S., Extended Storage of SARS-CoV2 Nasopharyngeal Swabs Does Not Negatively Impact Results of Molecular-Based Testing. *medRxiv* **2020**, 2020.05.16.20104158. https://www.medrxiv.org/content/medrxiv/early/2020/05/20/2020.05.16.20104158.full.pdf
621. Song, J.-Y.; Yun, J.-G.; Noh, J.-Y.; Cheong, H.-J.; Kim, W.-J., Covid-19 in South Korea — Challenges of Subclinical Manifestations. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2001801
622. Ssentongo, A. E.; Ssentongo, P.; Heilbrunn, E. S.; Lekoubou, A.; Du, P.; Liao, D.; Oh, J. S.; Chinchilli, V. M., Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. *Open Heart* **2020,** *7* (2), e001353. http://openheart.bmj.com/content/7/2/e001353.abstract
623. Stadnytskyi, V.; Bax, C. E.; Bax, A.; Anfinrud, P., The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. *Proceedings of the National Academy of Sciences* **2020**, 202006874. https://www.pnas.org/content/pnas/early/2020/05/12/2006874117.full.pdf
624. Staff, CanSino's COVID-19 vaccine candidate approved for military use in China. *Reuters* 2020. https://www.reuters.com/article/us-health-coronavirus-china-vaccine/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china-idUSKBN2400DZ
625. Staff, G. B., Originally Built for Bioterrorism Agents, This Decontamination System Now Clears SARS-CoV-2 from Military Aircraft. *Global Biodefense* 2020. https://globalbiodefense.com/2020/11/05/military-aircraft-sars-cov-2-sanitization-with-hot-air-system/
626. Sterne, J. A. C.; Murthy, S.; Diaz, J. V.; Slutsky, A. S.; Villar, J.; Angus, D. C.; Annane, D.; Azevedo, L. C. P.; Berwanger, O.; Cavalcanti, A. B.; Dequin, P. F.; Du, B.; Emberson, J.; Fisher, D.; Giraudeau, B.; Gordon, A. C.; Granholm, A.; Green, C.; Haynes, R.; Heming, N.; Higgins, J. P. T.; Horby, P.; Jüni, P.; Landray, M. J.; Le Gouge, A.; Leclerc, M.; Lim, W. S.; Machado, F. R.; McArthur, C.; Meziani, F.; Møller, M. H.; Perner, A.; Petersen, M. W.; Savovic, J.; Tomazini, B.; Veiga, V. C.; Webb, S.; Marshall, J. C., Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *Jama* **2020**. https://jamanetwork.com/journals/jama/fullarticle/2770279
627. Stubblefield, W. B.; Talbot, H. K.; Feldstein, L.; Tenforde, M. W.; Rasheed, M. A. U.; Mills, L.; Lester, S. N.; Freeman, B.; Thornburg, N. J.; Jones, I. D.; Ward, M. J.; Lindsell, C. J.; Baughman, A.; Halasa, N.; Grijalva, C. G.; Rice, T. W.; Patel, M. M.; Self, W. H.; Investigators, I. V. E. i. t. C. I., Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for COVID-19 Patients — Nashville, Tennessee. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa936
628. Su, H.; Yang, M.; Wan, C.; Yi, L.-X.; Tang, F.; Zhu, H.-Y.; Yi, F.; Yang, H.-C.; Fogo, A. B.; Nie, X.; Zhang, C., Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney International*. https://doi.org/10.1016/j.kint.2020.04.003
629. Suarez, D. L.; Pantin-Jackwood, M. J.; Swayne, D. E.; Lee, S. A.; DeBlois, S. M.; Spackman, E., Lack of susceptibility of poultry to SARS-CoV-2 and MERS-CoV. *bioRxiv* **2020**, 2020.06.16.154658. http://biorxiv.org/content/early/2020/06/16/2020.06.16.154658.abstract
630. Sugano, N.; Ando, W.; Fukushima, W., Cluster of SARS-CoV-2 infections linked to music clubs in Osaka, Japan: asymptomatically infected persons can transmit the virus as soon as 2 days after infection. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa542
631. Sukhyun, R.; Seikh Taslim, A.; Cheolsun, J.; Baekjin, K.; Benjamin, J. C., Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020. *Emerging Infectious Disease journal* **2020,** *26* (10). https://wwwnc.cdc.gov/eid/article/26/10/20-1886_article
632. Sun, J.; Zhu, A.; Li, H.; Zheng, K.; Zhuang, Z.; Chen, Z.; Shi, Y.; Zhang, Z.; Chen, S. B.; Liu, X.; Dai, J.; Li, X.; Huang, S.; Huang, X.; Luo, L.; Wen, L.; Zhuo, J.; Li, Y.; Wang, Y.; Zhang, L.; Zhang, Y.; Li, F.; Feng, L.;

Chen, X.; Zhong, N.; Yang, Z.; Huang, J.; Zhao, J.; Li, Y. M., Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient. *Emerg Microbes Infect* **2020**, 1-8.
633. Sun, S.; Cai, X.; Wang, H.; He, G.; Lin, Y.; Lu, B.; Chen, C.; Pan, Y.; Hu, X., Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clinica Chimica Acta* **2020,** *507*, 174-180. http://www.sciencedirect.com/science/article/pii/S0009898120301790
634. Sun, S. H.; Chen, Q.; Gu, H. J.; Yang, G.; Wang, Y. X.; Huang, X. Y.; Liu, S. S.; Zhang, N. N.; Li, X. F.; Xiong, R.; Guo, Y.; Deng, Y. Q.; Huang, W. J.; Liu, Q.; Liu, Q. M.; Shen, Y. L.; Zhou, Y.; Yang, X.; Zhao, T. Y.; Fan, C. F.; Zhou, Y. S.; Qin, C. F.; Wang, Y. C., A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. *Cell Host Microbe* **2020**.
635. Suthar, M. S.; Zimmerman, M. G.; Kauffman, R. C.; Mantus, G.; Linderman, S. L.; Hudson, W. H.; Vanderheiden, A.; Nyhoff, L.; Davis, C. W.; Adekunle, S.; Affer, M.; Sherman, M.; Reynolds, S.; Verkerke, H. P.; Alter, D. N.; Guarner, J.; Bryksin, J.; Horwath, M.; Arthur, C. M.; Saakadze, N.; Smith, G. H.; Edupuganti, S.; Scherer, E. M.; Hellmeister, K.; Cheng, A.; Morales, J. A.; Neish, A. S.; Stowell, S. R.; Frank, F.; Ortlund, E.; Anderson, E.; Menachery, V. D.; Rouphael, N.; Mehta, A.; Stephens, D. S.; Ahmed, R.; Roback, J. D.; Wrammert, J., Rapid generation of neutralizing antibody responses in COVID-19 patients. *Cell Reports Medicine* **2020**. https://doi.org/10.1016/j.xcrm.2020.100040
636. Szablewski, C. M.; Chang, K. T.; Brown, M. M.; al., e., SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 31 July 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6931e1.htm
637. Tabata, S.; Imai, K.; Kawano, S.; Ikeda, M.; Kodama, T.; Miyoshi, K.; Obinata, H.; Mimura, S.; Kodera, T.; Kitagaki, M.; Sato, M.; Suzuki, S.; Ito, T.; Uwabe, Y.; Tamura, K., Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis. *The Lancet Infectious Diseases*. https://doi.org/10.1016/S1473-3099(20)30482-5
638. Taboada, B.; Vazquez-Perez, J. A.; Muñoz Medina, J. E.; Ramos Cervantes, P.; Escalera-Zamudio, M.; Boukadida, C.; Sanchez-Flores, A.; Isa, P.; Mendieta Condado, E.; Martínez-Orozco, J. A.; Becerril-Vargas, E.; Salas-Hernández, J.; Grande, R.; González-Torres, C.; Gaytán-Cervantes, F. J.; Vazquez, G.; Pulido, F.; Araiza Rodríguez, A.; Garcés Ayala, F.; González Bonilla, C. R.; Grajales Muñiz, C.; Borja Aburto, V. H.; Barrera Badillo, G.; López, S.; Hernández Rivas, L.; Perez-Padilla, R.; López Martínez, I.; Ávila-Ríos, S.; Ruiz-Palacios, G.; Ramírez-González, J. E.; Arias, C. F., Genomic Analysis of Early SARS-CoV-2 Variants Introduced in Mexico. *Journal of Virology* **2020**, JVI.01056-20. https://jvi.asm.org/content/jvi/early/2020/07/02/JVI.01056-20.full.pdf
639. Takahashi, T.; Ellingson, M. K.; Wong, P.; Israelow, B.; Lucas, C.; Klein, J.; Silva, J.; Mao, T.; Oh, J. E.; Tokuyama, M.; Lu, P.; Venkataraman, A.; Park, A.; Liu, F.; Meir, A.; Sun, J.; Wang, E. Y.; Casanovas-Massana, A.; Wyllie, A. L.; Vogels, C. B. F.; Earnest, R.; Lapidus, S.; Ott, I. M.; Moore, A. J.; Anastasio, K.; Askenase, M. H.; Batsu, M.; Beatty, H.; Bermejo, S.; Bickerton, S.; Brower, K.; Bucklin, M. L.; Cahill, S.; Campbell, M.; Cao, Y.; Courchaine, E.; Datta, R.; DeIuliis, G.; Geng, B.; Glick, L.; Handoko, R.; Kalinich, C.; Khoury-Hanold, W.; Kim, D.; Knaggs, L.; Kuang, M.; Kudo, E.; Lim, J.; Linehan, M.; Lu-Culligan, A.; Malik, A. A.; Martin, A.; Matos, I.; McDonald, D.; Minasyan, M.; Mohanty, S.; Muenker, M. C.; Naushad, N.; Nelson, A.; Nouws, J.; Nunez-Smith, M.; Obaid, A.; Ott, I.; Park, H.-J.; Peng, X.; Petrone, M.; Prophet, S.; Rahming, H.; Rice, T.; Rose, K.-A.; Sewanan, L.; Sharma, L.; Shepard, D.; Silva, E.; Simonov, M.; Smolgovsky, M.; Song, E.; Sonnert, N.; Strong, Y.; Todeasa, C.; Valdez, J.; Velazquez, S.; Vijayakumar, P.; Wang, H.; Watkins, A.; White, E. B.; Yang, Y.; Shaw, A.; Fournier, J. B.; Odio, C. D.; Farhadian, S.; Dela Cruz, C.; Grubaugh, N. D.; Schulz, W. L.; Ring, A. M.; Ko, A. I.; Omer, S. B.; Iwasaki, A.; Yale, I. r. t., Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2700-3
640. Tan, C. W.; Ho, L. P.; Kalimuddin, S.; Cherng, B. P. Z.; Teh, Y. E.; Thien, S. Y.; Wong, H. M.; Tern, P. J. W.; Chandran, M.; Chay, J. W. M.; Nagarajan, C.; Sultana, R.; Low, J. G. H.; Ng, H. J., Cohort study to evaluate effect of vitamin D, magnesium, and vitamin B12 in combination on severe outcome

progression in older patients with coronavirus (COVID-19). *Nutrition* **2020,** *79-80*, 111017. http://www.sciencedirect.com/science/article/pii/S0899900720303002
641. Tan, F.; Wang, K.; Liu, J.; Liu, D.; Luo, J.; Zhou, R., Viral Transmission and Clinical Features in Asymptomatic Carriers of SARS-CoV-2 in Wuhan, China. *Frontiers in Medicine* **2020,** *7* (547). https://www.frontiersin.org/article/10.3389/fmed.2020.00547
642. Tan, W.; Lu, Y.; Zhang, J.; Wang, J.; Dan, Y.; Tan, Z.; He, X.; Qian, C.; Sun, Q.; Hu, Q.; Liu, H.; Ye, S.; Xiang, X.; Zhou, Y.; Zhang, W.; Guo, Y.; Wang, X.-H.; He, W.; Wan, X.; Sun, F.; Wei, Q.; Chen, C.; Pan, G.; Xia, J.; Mao, Q.; Chen, Y.; Deng, G., Viral Kinetics and Antibody Responses in Patients with COVID-19. *medRxiv* **2020**, 2020.03.24.20042382. https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.24.20042382.full.pdf
643. Taquet, M.; Luciano, S.; Geddes, J. R.; Harrison, P. J., Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. *The Lancet Psychiatry* **2020**. https://doi.org/10.1016/S2215-0366(20)30462-4
644. Tass, Russia's Chumakov Center begins clinical trials of its COVID-19 vaccine in St. Petersburg. https://tass.com/society/1213793.
645. Team, D. W., 'Covaxin': Bharat Biotech to begin Phase-III trials of COVID-19 vaccine in UP from October. https://www.dnaindia.com/india/report-covaxin-bharat-biotech-covid-19-vaccine-phase-3-trials-uttar-pradesh-october-2845194.
646. Tenforde, M. W.; Kim, S. S.; Lindsell, C. J.; al., e., Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 24 July 2020*.
647. The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T., The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly* **2020,** *2*, 1-10. http://weekly.chinacdc.cn//article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51
648. Thomas, P.; Alexander, P. E.; Ahmed, U.; Elderhorst, E.; El-Khechen, H.; Mammen, M. J.; Debono, V. B.; Aponte Torres, Z.; Aryal, K.; Brocard, E.; Sagastuy, B.; Alhazzani, W., Vertical transmission risk of SARS-CoV-2 infection in the third trimester: a systematic scoping review. *The Journal of Maternal-Fetal & Neonatal Medicine* **2020**, 1-8. https://doi.org/10.1080/14767058.2020.1786055
649. Thomas, P. R.; Karriker, L. A.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Crawford, K. K.; Bates, J. L.; Hammen, K. J.; Holtkamp, D. J., Evaluation of time and temperature sufficient to inactivate porcine epidemic diarrhea virus in swine feces on metal surfaces. *Journal of Swine Health and Production* **2015,** *23* (2), 84.
650. Thomas, P. R.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Myers, J. N., Methods for inactivating PEDV in Hog Trailers. *Animal Industry Report* **2015,** *661* (1), 91.
651. Thomson, E. C.; Rosen, L. E.; Shepherd, J. G.; Spreafico, R.; da Silva Filipe, A.; Wojcechowskyj, J. A.; Davis, C.; Piccoli, L.; Pascall, D. J.; Dillen, J.; Lytras, S.; Czudnochowski, N.; Shah, R.; Meury, M.; Jesudason, N.; De Marco, A.; Li, K.; Bassi, J.; Toole, A.; Pinto, D.; Colquhoun, R. M.; Culap, K.; Jackson, B.; Zatta, F.; Rambaut, A.; Jaconi, S.; Sreenu, V. B.; Nix, J.; Jarrett, R. F.; Beltramello, M.; Nomikou, K.; Pizzuto, M.; Tong, L.; Cameroni, E.; Johnson, N.; Wickenhagen, A.; Ceschi, A.; Mair, D.; Ferrari, P.; Smollett, K.; Sallusto, F.; Carmichael, S.; Garzoni, C.; Nichols, J.; Galli, M.; Hughes, J.; Riva, A.; Ho, A.; Semple, M. G.; Openshaw, P. J. M.; Baillie, K.; Rihn, S. J.; Lycett, S. J.; Virgin, H. W.; Telenti, A.; Corti, D.; Robertson, D. L.; Snell, G., The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity. *bioRxiv* **2020**, 2020.11.04.355842. http://biorxiv.org/content/early/2020/11/05/2020.11.04.355842.abstract
652. TILLETT, R.; SEVINSKY, J.; HARTLEY, P.; KERWIN, H.; CRAWFORD, N.; GORZALSKI, A.; LAVERDURE, C.; VERMA, S.; ROSSETTO, C.; FARRELL, M.; JACKSON, D.; Pandori, M.; VAN HOOSER, S., Genomic Evidence

for a Case of Reinfection with SARS-CoV-2. *The Lancet* **2020**.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3681489
653. To, K. K.-W.; Tsang, O. T.-Y.; Leung, W.-S.; Tam, A. R.; Wu, T.-C.; Lung, D. C.; Yip, C. C.-Y.; Cai, J.-P.; Chan, J. M.-C.; Chik, T. S.-H., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases* **2020**.
654. Tomazini, B. M.; Maia, I. S.; Cavalcanti, A. B.; Berwanger, O.; Rosa, R. G.; Veiga, V. C.; Avezum, A.; Lopes, R. D.; Bueno, F. R.; Silva, M.; Baldassare, F. P.; Costa, E. L. V.; Moura, R. A. B.; Honorato, M. O.; Costa, A. N.; Damiani, L. P.; Lisboa, T.; Kawano-Dourado, L.; Zampieri, F. G.; Olivato, G. B.; Righy, C.; Amendola, C. P.; Roepke, R. M. L.; Freitas, D. H. M.; Forte, D. N.; Freitas, F. G. R.; Fernandes, C. C. F.; Melro, L. M. G.; Junior, G. F. S.; Morais, D. C.; Zung, S.; Machado, F. R.; Azevedo, L. C. P., Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *Jama* **2020**.
https://jamanetwork.com/journals/jama/fullarticle/2770277
655. Tortajada, C.; Colomer, E.; Andreu-Ballester, J. C.; Esparcia, A.; Oltra, C.; Flores, J., Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and Intensive Care Unit admission in patients with COVID-19 according to patients' oxygen requirements. *J Med Virol* **2020**.
656. Treibel, T. A.; Manisty, C.; Burton, M.; McKnight, Á.; Lambourne, J.; Augusto, J. B.; Couto-Parada, X.; Cutino-Moguel, T.; Noursadeghi, M.; Moon, J. C., COVID-19: PCR screening of asymptomatic health-care workers at London hospital. *The Lancet*. https://doi.org/10.1016/S0140-6736(20)31100-4
657. Tsay, C.; Lejarza, F.; Stadtherr, M. A.; Baldea, M., Modeling, state estimation, and optimal control for the US COVID-19 outbreak. *Scientific Reports* **2020,** *10* (1), 10711. https://doi.org/10.1038/s41598-020-67459-8
658. Tso, F. Y.; Lidenge, S. J.; Peña, P. B.; Clegg, A. A.; Ngowi, J. R.; Mwaiselage, J.; Ngalamika, O.; Julius, P.; West, J. T.; Wood, C., High prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-Sahara Africa. *International Journal of Infectious Diseases* **2020**.
https://doi.org/10.1016/j.ijid.2020.10.104
659. Tuebingen, U. H., Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC).
https://clinicaltrials.gov/ct2/show/NCT04546841?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2.
660. Twin FM, NHS Trials "Unique" New Decontamination Tech to Reduce COVID Transmission Indoors.
https://www.twinfm.com/article/nhs-trials-unique-new-decontamination-tech-to-reduce-covid-transmission-indoors (accessed 19 Oct 2020).
661. UCLA, COVID-19 Cases in the United States. https://covid19.uclaml.org/model.html.
662. Ueki, H.; Furusawa, Y.; Iwatsuki-Horimoto, K.; Imai, M.; Kabata, H.; Nishimura, H.; Kawaoka, Y., Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2. *mSphere* **2020,** *5* (5), e00637-20. https://msphere.asm.org/content/msph/5/5/e00637-20.full.pdf
663. Ulrich, L.; Wernike, K.; Hoffmann, D.; Mettenleiter, T. C.; Beer, M., Experimental infection of cattle with SARS-CoV-2. *bioRxiv* **2020**, 2020.08.25.254474.
http://biorxiv.org/content/early/2020/08/25/2020.08.25.254474.abstract
664. University of Washington Medicine, Researchers seek cost-effective way to decontaminate PPE.
https://newsroom.uw.edu/postscript/researchers-seek-cost-effective-way-decontaminate-ppe (accessed 05 Oct 2020).
665. Urigo, C.; Soin, S.; Sahu, A., Spontaneous pneumomediastinum as a complication of a COVID-19 related pneumonia: case report and review of literature. *Radiology Case Reports* **2020,** *15* (12), 2577-2581. http://www.sciencedirect.com/science/article/pii/S1930043320305148

666. van de Veerdonk, F. L.; Kouijzer, I. J. E.; de Nooijer, A. H.; van der Hoeven, H. G.; Maas, C.; Netea, M. G.; Brüggemann, R. J. M., Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19. *JAMA Network Open* **2020,** *3* (8), e2017708-e2017708. https://doi.org/10.1001/jamanetworkopen.2020.17708
667. van der Sande, M.; Teunis, P.; Sabel, R., Professional and Home-Made Face Masks Reduce Exposure to Respiratory Infections among the General Population. *Plos One* **2008,** *3* (7). <Go to ISI>://WOS:000264065800020
668. van Doorn, A. S.; Meijer, B.; Frampton, C. M. A.; Barclay, M. L.; de Boer, N. K. H., Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. *Alimentary Pharmacology & Therapeutics n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.16036
669. van Doremalen, N.; Bushmaker, T.; Morris, D. H.; Holbrook, M. G.; Gamble, A.; Williamson, B. N.; Tamin, A.; Harcourt, J. L.; Thornburg, N. J.; Gerber, S. I.; Lloyd-Smith, J. O.; de Wit, E.; Munster, V. J., Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New England Journal of Medicine* **2020**. https://doi.org/10.1056/NEJMc2004973
670. van Dorp, L.; Acman, M.; Richard, D.; Shaw, L. P.; Ford, C. E.; Ormond, L.; Owen, C. J.; Pang, J.; Tan, C. C. S.; Boshier, F. A. T.; Ortiz, A. T.; Balloux, F., Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. *Infection, Genetics and Evolution* **2020**, 104351. http://www.sciencedirect.com/science/article/pii/S1567134820301829
671. Varga, Z.; Flammer, A. J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A. S.; Mehra, M. R.; Schuepbach, R. A.; Ruschitzka, F.; Moch, H., Endothelial cell infection and endotheliitis in COVID-19. *The Lancet* **2020,** *395* (10234), 1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5
672. Vaxart, Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults. https://clinicaltrials.gov/ct2/show/NCT04563702.
673. Vaxine, Monovalent Recombinant COVID19 Vaccine (COVAX19). https://clinicaltrials.gov/ct2/show/NCT04453852?term=NCT04453852&draw=2&rank=1.
674. Vector, Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona). https://clinicaltrials.gov/ct2/show/NCT04527575.
675. Verdict, Cepheid to develop automated molecular test for coronavirus. Verdict Medical Devices: 2020. https://www.medicaldevice-network.com/news/cepheid-automated-test-coronavirus/
676. Verma, S.; Dhanak, M.; Frankenfield, J., Visualizing droplet dispersal for face shields and masks with exhalation valves. *arXiv preprint arXiv:2008.00125* **2020**.
677. Vilke, G. M.; Brennan, J. J.; Cronin, A. O.; Castillo, E. M., Clinical features of covid-19 patients: is temperature screening useful? *The Journal of Emergency Medicine* **2020**. http://www.sciencedirect.com/science/article/pii/S073646792030977X
678. Viner, R. M.; Mytton, O. T.; Bonell, C.; Melendez-Torres, G. J.; Ward, J.; Hudson, L.; Waddington, C.; Thomas, J.; Russell, S.; van der Klis, F.; Koirala, A.; Ladhani, S.; Panovska-Griffiths, J.; Davies, N. G.; Booy, R.; Eggo, R. M., Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. *JAMA Pediatrics* **2020**. https://doi.org/10.1001/jamapediatrics.2020.4573
679. Viola, I. M.; Peterson, B.; Pisetta, G.; Pavar, G.; Akhtar, H.; Menolascina, F.; Mangano, E.; Dunn, K.; Gabl, R.; Nila, A.; Molinari, E.; Cummins, C.; Thompson, G.; Lo, M.; Denison, F.; Digard, P.; Malik, O.; Dunn, M. J. G.; Mehendale, F., Face Coverings, Aerosol Dispersion and Mitigation of Virus Transmission Risk. arXiv.org: 2020.
680. Vivanti, A. J.; Vauloup-Fellous, C.; Prevot, S.; Zupan, V.; Suffee, C.; Do Cao, J.; Benachi, A.; De Luca, D., Transplacental transmission of SARS-CoV-2 infection. *Nature Communications* **2020,** *11* (1), 3572. https://doi.org/10.1038/s41467-020-17436-6
681. Vlaar, A. P. J.; de Bruin, S.; Busch, M.; Timmermans, S.; van Zeggeren, I. E.; Koning, R.; Ter Horst, L.; Bulle, E. B.; van Baarle, F.; van de Poll, M. C. G.; Kemper, E. M.; van der Horst, I. C. C.; Schultz, M. J.;

Horn, J.; Paulus, F.; Bos, L. D.; Wiersinga, W. J.; Witzenrath, M.; Rueckinger, S.; Pilz, K.; Brouwer, M. C.; Guo, R. F.; Heunks, L.; van Paassen, P.; Riedemann, N. C.; van de Beek, D., Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. *Lancet Rheumatol* **2020**.
682. Volz, E. M.; Hill, V.; McCrone, J. T.; Price, A.; Jorgensen, D.; Toole, A.; Southgate, J. A.; Johnson, R.; Jackson, B.; Nascimento, F. F.; Rey, S. M.; Nicholls, S. M.; Colquhoun, R. M.; da Silva Filipe, A.; Shepherd, J. G.; Pascall, D. J.; Shah, R.; Jesudason, N.; Li, K.; Jarrett, R.; Pacchiarini, N.; Bull, M.; Geidelberg, L.; Siveroni, I.; Goodfellow, I. G.; Loman, N. J.; Pybus, O.; Robertson, D. L.; Thomson, E. C.; Rambaut, A.; Connor, T. R., Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity. *medRxiv* **2020**, 2020.07.31.20166082.
http://medrxiv.org/content/early/2020/09/01/2020.07.31.20166082.abstract
683. Wajnberg, A.; Amanat, F.; Firpo, A.; Altman, D. R.; Bailey, M. J.; Mansour, M.; McMahon, M.; Meade, P.; Mendu, D. R.; Muellers, K.; Stadlbauer, D.; Stone, K.; Strohmeier, S.; Simon, V.; Aberg, J.; Reich, D. L.; Krammer, F.; Cordon-Cardo, C., Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* **2020**, eabd7728.
https://science.sciencemag.org/content/sci/early/2020/10/27/science.abd7728.full.pdf
684. Walsh, K. A.; Jordan, K.; Clyne, B.; Rohde, D.; Drummond, L.; Byrne, P.; Ahern, S.; Carty, P. G.; O'Brien, K. K.; O'Murchu, E.; O'Neill, M.; Smith, S. M.; Ryan, M.; Harrington, P., SARS-CoV-2 Detection, Viral Load and Infectivity over the Course of an Infection: SARS-CoV-2 Detection, Viral Load and Infectivity. *The Journal of infection* **2020**, S0163-4453(20)30449-7.
https://pubmed.ncbi.nlm.nih.gov/32615199
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323671/
685. Walsh, K. A.; Spillane, S.; Comber, L.; Cardwell, K.; Harrington, P.; Connell, J.; Teljeur, C.; Broderick, N.; de Gascun, C. F.; Smith, S. M.; Ryan, M.; O'Neill, M., The duration of infectiousness of individuals infected with SARS-CoV-2. *Journal of Infection*. https://doi.org/10.1016/j.jinf.2020.10.009
686. Wambier, C. G.; Vaño-Galván, S.; McCoy, J.; Gomez-Zubiaur, A.; Herrera, S.; Hermosa-Gelbard, Á.; Moreno-Arrones, O. M.; Jiménez-Gómez, N.; González-Cantero, A.; Pascual, P. F.; Segurado-Miravalles, G.; Shapiro, J.; Pérez-García, B.; Goren, A., Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients – the “Gabrin sign&#x201d. *Journal of the American Academy of Dermatology*. https://doi.org/10.1016/j.jaad.2020.05.079
687. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* **2020**.
https://doi.org/10.1001/jama.2020.1585
https://jamanetwork.com/journals/jama/articlepdf/2761044/jama_wang_2020_oi_200019.pdf
688. Wang, D.; Li, R.; Wang, J.; Jiang, Q.; Gao, C.; Yang, J.; Ge, L.; Hu, Q., Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. *BMC Infectious Diseases* **2020,** *20* (1), 519. https://doi.org/10.1186/s12879-020-05242-w
689. Wang, D.; You, Y.; Zhou, X.; Zong, Z.; Huang, H.; Zhang, H.; Yong, X.; Cheng, Y.; Yang, L.; Guo, Q.; Long, Y.; Liu, Y.; Huang, J.; Du, L., Selection of homemade mask materials for preventing transmission of COVID-19: a laboratory study. *medRxiv* **2020**.
690. Wang, K.; Zhao, S.; Li, H.; Song, Y.; Wang, L.; Wang, M. H.; Peng, Z.; Li, H.; He, D., Real-time estimation of the reproduction number of the novel coronavirus disease (COVID-19) in China in 2020 based on incidence data. *Annals of Translational Medicine* **2020,** *8* (11), 689.
http://atm.amegroups.com/article/view/43447

691. Wang, L.; Didelot, X.; Yang, J.; Wong, G.; Shi, Y.; Liu, W.; Gao, G. F.; Bi, Y., Inference of person-to-person transmission of COVID-19 reveals hidden super-spreading events during the early outbreak phase. *Nature Communications* **2020,** *11* (1), 5006. https://doi.org/10.1038/s41467-020-18836-4
692. Wang, R.; Qian, C.; Pang, Y.; Li, M.; Yang, Y.; Ma, H.; Zhao, M.; Qian, F.; Yu, H.; Liu, Z.; Ni, T.; Zheng, Y.; Wang, Y., opvCRISPR: One-pot visual RT-LAMP-CRISPR platform for SARS-cov-2 detection. *Biosensors and Bioelectronics* **2021,** *172*, 112766.
http://www.sciencedirect.com/science/article/pii/S0956566320307533
693. Wang, S.; Ma, P.; Zhang, S.; Song, S.; Wang, Z.; Ma, Y.; Xu, J.; Wu, F.; Duan, L.; Yin, Z.; Luo, H.; Xiong, N.; Xu, M.; Zeng, T.; Jin, Y., Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. *Diabetologia* **2020**. https://doi.org/10.1007/s00125-020-05209-1
694. Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G.; Tan, W., Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.3786
695. Wang, X.; Ferro, E. G.; Zhou, G.; Hashimoto, D.; Bhatt, D. L., Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. *JAMA* **2020**.
https://doi.org/10.1001/jama.2020.12897
696. Wang, X.; Pan, Y.; Zhang, D.; Chen, L.; Jia, L.; Li, X.; Yang, P.; Wang, Q.; Macintyre, C. R., Basic epidemiological parameter values from data of real-world in mega-cities: the characteristics of COVID-19 in Beijing, China. *BMC Infectious Diseases* **2020,** *20* (1), 526. https://doi.org/10.1186/s12879-020-05251-9
697. Wang, Y.; Chen, B.; Li, Y.; Zhang, L.; Wang, Y.; Yang, S.; Xiao, X.; Qin, Q., The Use of Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19 Patients: A Systematic Review and Meta-analysis. *J Med Virol* **2020**.
698. Wang, Y.; Tian, H.; Zhang, L.; Zhang, M.; Guo, D.; Wu, W.; Zhang, X.; Kan, G. L.; Jia, L.; Huo, D.; Liu, B.; Wang, X.; Sun, Y.; Wang, Q.; Yang, P.; MacIntyre, C. R., Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Global Health* **2020,** *5* (5), e002794.
https://gh.bmj.com/content/bmjgh/5/5/e002794.full.pdf
699. Wang, Y.; Xu, G.; Huang, Y.-W., Modeling the load of SARS-CoV-2 virus in human expelled particles during coughing and speaking. *PLOS ONE* **2020,** *15* (10), e0241539.
https://doi.org/10.1371/journal.pone.0241539
700. Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet* **2020,** *395* (10236), 1569-1578.
http://www.sciencedirect.com/science/article/pii/S0140673620310229
701. Wantai, B., A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DeINS1-2019-nCoV-RBD-OPT1). http://www.chictr.org.cn/showprojen.aspx?proj=55421.
702. Ward, H.; Cooke, G.; Atchison, C.; Whitaker, M.; Elliott, J.; Moshe, M.; Brown, J. C.; Flower, B.; Daunt, A.; Ainslie, K.; Ashby, D.; Donnelly, C.; Riley, S.; Darzi, A.; Barclay, W.; Elliott, P., Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults *Preprint* **2020**.
https://www.imperial.ac.uk/media/imperial-college/institute-of-global-health-innovation/MEDRXIV-2020-219725v1-Elliott.pdf
703. WCS, A Tiger at Bronx Zoo Tests Positive for COVID-19; The Tiger and the Zoo's Other Cats Are Doing Well at This Time. https://newsroom.wcs.org/News-

Releases/articleType/ArticleView/articleId/14010/A-Tiger-at-Bronx-Zoo-Tests-Positive-for-COVID-19-The-Tiger-and-the-Zoos-Other-Cats-Are-Doing-Well-at-This-Time.aspx (accessed April 6, 2020).
704. Webb, B. J.; Peltan, I. D.; Jensen, P.; Hoda, D.; Hunter, B.; Silver, A.; Starr, N.; Buckel, W.; Grisel, N.; Hummel, E.; Snow, G.; Morris, D.; Stenehjem, E.; Srivastava, R.; Brown, S. M., Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. *The Lancet Rheumatology* **2020**. http://www.sciencedirect.com/science/article/pii/S266599132030343X
705. Wei, W. E.; Li, Z.; Chiew, C. J.; Yong, S. E.; Toh, M. P.; Lee, V. J., Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23 - March 16, 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub* (1 April 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e1.htm
706. Wei, Y.; Wei, L.; Liu, Y.; Huang, L.; Shen, S.; Zhang, R.; Chen, J.; Zhao, Y.; Shen, H.; Chen, F., A systematic review and meta-analysis reveals long and dispersive incubation period of COVID-19. *medRxiv* **2020**, 2020.06.20.20134387. https://www.medrxiv.org/content/medrxiv/early/2020/06/22/2020.06.20.20134387.full.pdf
707. Weill, J. A.; Stigler, M.; Deschenes, O.; Springborn, M. R., Social distancing responses to COVID-19 emergency declarations strongly differentiated by income. *Proceedings of the National Academy of Sciences* **2020**, 202009412. https://www.pnas.org/content/pnas/early/2020/07/28/2009412117.full.pdf
708. Weisberg, S. P.; Connors, T. J.; Zhu, Y.; Baldwin, M. R.; Lin, W.-H.; Wontakal, S.; Szabo, P. A.; Wells, S. B.; Dogra, P.; Gray, J.; Idzikowski, E.; Stelitano, D.; Bovier, F. T.; Davis-Porada, J.; Matsumoto, R.; Poon, M. M. L.; Chait, M.; Mathieu, C.; Horvat, B.; Decimo, D.; Hudson, K. E.; Zotti, F. D.; Bitan, Z. C.; La Carpia, F.; Ferrara, S. A.; Mace, E.; Milner, J.; Moscona, A.; Hod, E.; Porotto, M.; Farber, D. L., Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nature Immunology* **2020**. https://doi.org/10.1038/s41590-020-00826-9
709. Weissman, D.; Alameh, M.-G.; Silva, T. d.; Collini, P.; Hornsby, H.; Brown, R.; LaBranche, C. C.; Edwards, R. J.; Sutherland, L.; Santra, S.; Mansouri, K.; Gobeil, S.; McDanal, C.; Pardi, N.; Hengartner, N.; Lin, P. J. C.; Tam, Y.; Shaw, P. A.; Lewis, M. G.; Boesler, C.; Şahin, U.; Acharya, P.; Haynes, B. F.; Korber, B.; Montefiori, D. C., D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2.full.pdf.
710. Weissman, D. N.; de Perio, M. A.; Radonovich, L. J., Jr, COVID-19 and Risks Posed to Personnel During Endotracheal Intubation. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.6627
711. Wellinghausen, N.; Plonné, D.; Voss, M.; Ivanova, R.; Frodl, R.; Deininger, S., SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. *Journal of Clinical Virology* **2020,** *130*, 104542. http://www.sciencedirect.com/science/article/pii/S1386653220302845
712. Wende, W., Israel to initiate human trials of potential Covid-19 vaccine. https://www.clinicaltrialsarena.com/news/israel-human-covid-19-trial/.
713. Westblade, L. F.; Brar, G.; Pinheiro, L. C.; Paidoussis, D.; Rajan, M.; Martin, P.; Goyal, P.; Sepulveda, J. L.; Zhang, L.; George, G.; Liu, D.; Whittier, S.; Plate, M.; Small, C. B.; Rand, J. H.; Cushing, M. M.; Walsh, T. J.; Cooke, J.; Safford, M. M.; Loda, M.; Satlin, M. J., SARS-CoV-2 Viral Load Predicts Mortality in Patients with and Without Cancer Who Are Hospitalized with COVID-19. *Cancer Cell* **2020**. http://www.sciencedirect.com/science/article/pii/S1535610820304815
714. Whitman, J. D.; Hiatt, J.; Mowrey, C. T.; al., e., Test performance evaluation of SARS-CoV-2 serological assays. *Unpublished Preprint* **2020**. https://www.dropbox.com/s/cd1628cau09288a/SARS-CoV-2_Serology_Manuscript.pdf?dl=0
715. Whitworth, C.; Mu, Y.; Houston, H.; Martinez-Smith, M.; Noble-Wang, J.; Coulliette-Salmond, A.; Rose, L., Persistence of Bacteriophage Phi 6 on Porous and Nonporous Surfaces and the Potential for Its Use as an Ebola Virus or Coronavirus Surrogate. *Applied and Environmental Microbiology* **2020,** *86* (17), e01482-20. https://aem.asm.org/content/aem/86/17/e01482-20.full.pdf

716. Whitworth, J., U.S. FDA 'aware' of China testing food for coronavirus. https://www.foodsafetynews.com/2020/06/u-s-fda-aware-of-china-testing-food-for-coronavirus/ (accessed 06/22/2020).
717. WHO, *Advice on the use of masks on the context of COVID-19. Interim Guidance. 5 June 2020.*; World Health Organization: 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks
718. WHO, *"Immunity passports" in the context of COVID-19*; World Health Organization: 2020. https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19
719. WHO, *Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected*; 2020. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125
720. WHO, Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.
721. WHO, Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. World Health Organization: 2020. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
722. WHO, *Transmission of SARS-CoV-2: implications for infection prevention precautions*; World Health Organization: 2020. https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions
723. Wiersinga, W. J.; Rhodes, A.; Cheng, A. C.; Peacock, S. J.; Prescott, H. C., Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.12839
724. Wölfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M. A.; Niemeyer, D.; Jones, T. C.; Vollmar, P.; Rothe, C.; Hoelscher, M.; Bleicker, T.; Brünink, S.; Schneider, J.; Ehmann, R.; Zwirglmaier, K.; Drosten, C.; Wendtner, C., Virological assessment of hospitalized patients with COVID-2019. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2196-x
725. Wong, F.; Collins, J. J., Evidence that coronavirus superspreading is fat-tailed. *Proceedings of the National Academy of Sciences* **2020**, 202018490. https://www.pnas.org/content/pnas/early/2020/10/30/2018490117.full.pdf
726. Wong, M. C.; Javornik Cregeen, S. J.; Ajami, N. J.; Petrosino, J. F., Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. *bioRxiv* **2020**, 2020.02.07.939207. https://www.biorxiv.org/content/biorxiv/early/2020/02/13/2020.02.07.939207.full.pdf
727. Wong, Y. C.; Lau, S. Y.; Wang To, K. K.; Mok, B. W. Y.; Li, X.; Wang, P.; Deng, S.; Woo, K. F.; Du, Z.; Li, C.; Zhou, J.; Woo Chan, J. F.; Yuen, K. Y.; Chen, H.; Chen, Z., Natural transmission of bat-like SARS-CoV-2PRRA variants in COVID-19 patients. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa953
728. Woodworth, K. R.; Olsen, E. O. M.; Neelam, V.; Lewis, E. L.; Galang, R. R.; Oduyebo, T.; Aveni, K.; Yazdy, M. M.; Harvey, E.; Longcore, N. D.; Barton, J.; Fussman, C.; Siebman, S.; Lush, M.; Patrick, P. H.; Halai, U.-A.; Valencia-Prado, M.; Orkis, L.; Sowunmi, S.; Schlosser, L.; Khuwaja, S.; Read, J. S.; Hall, A. J.; Meaney-Delman, D.; Ellington, S. R.; Gilboa, S. M.; Tong, V. T., Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy
SET-NET, 16 Jurisdictions, March 29–October 14, 2020.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e2.htm?s_cid=mm6944e2_w.
729. Woolf, S. H.; Chapman, D. A.; Sabo, R. T.; Weinberger, D. M.; Hill, L., Excess Deaths From COVID-19 and Other Causes, March-April 2020. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.11787
730. Woolsey, C. B.; Borisevich, V.; Prasad, A. N.; Agans, K. N.; Deer, D. J.; Dobias, N. S.; Heymann, J. C.; Foster, S. L.; Levine, C. B.; Medina, L.; Melody, K.; Geisbert, J. B.; Fenton, K. A.; Geisbert, T. W.; Cross, R.

W., Establishment of an African green monkey model for COVID-19. *bioRxiv* **2020**, 2020.05.17.100289. http://biorxiv.org/content/early/2020/05/17/2020.05.17.100289.abstract
731. Worobey, M.; Pekar, J.; Larsen, B. B.; Nelson, M. I.; Hill, V.; Joy, J. B.; Rambaut, A.; Suchard, M. A.; Wertheim, J. O.; Lemey, P., The emergence of SARS-CoV-2 in Europe and the US. *bioRxiv* **2020**, 2020.05.21.109322. https://www.biorxiv.org/content/biorxiv/early/2020/05/23/2020.05.21.109322.full.pdf
732. Worthham, J. M.; Lee, J. T.; Althomsons, S.; al., e., Characteristics of Persons Who Died with COVID-19 — United States, February 12–May 18, 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: July 10, 2020* (69). https://www.cdc.gov/mmwr/volumes/69/wr/mm6928e1.htm
733. Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S., Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. *bioRxiv* **2020**, 2020.02.11.944462. https://www.biorxiv.org/content/biorxiv/early/2020/02/15/2020.02.11.944462.full.pdf
734. Wright, E. S.; Lakdawala, S. S.; Cooper, V. S., SARS-CoV-2 genome evolution exposes early human adaptations. *bioRxiv* **2020**, 2020.05.26.117069. https://www.biorxiv.org/content/biorxiv/early/2020/05/26/2020.05.26.117069.full.pdf
735. Wu, C.; Hou, D.; Du, C.; Cai, Y.; Zheng, J.; Xu, J.; Chen, X.; Chen, C.; Hu, X.; Zhang, Y.; Song, J.; Wang, L.; Chao, Y. C.; Feng, Y.; Xiong, W.; Chen, D.; Zhong, M.; Hu, J.; Jiang, J.; Bai, C.; Zhou, X.; Xu, J.; Song, Y.; Gong, F., Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. *Crit Care* **2020,** *24* (1), 643.
736. Wu, F.; Wang, A.; Liu, M.; Wang, Q.; Chen, J.; Xia, S.; Ling, Y.; Zhang, Y.; Xun, J.; Lu, L.; Jiang, S.; Lu, H.; Wen, Y.; Huang, J., Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv* **2020**, 2020.03.30.20047365. https://www.medrxiv.org/content/medrxiv/early/2020/04/06/2020.03.30.20047365.full.pdf
737. Wu, G.; Yang, P.; Xie, Y.; Woodruff, H. C.; Rao, X.; Guiot, J.; Frix, A.-N.; Louis, R.; Moutschen, M.; Li, J.; Li, J.; Yan, C.; Du, D.; Zhao, S.; Ding, Y.; Liu, B.; Sun, W.; Albarello, F.; D'Abramo, A.; Schininà, V.; Nicastri, E.; Occhipinti, M.; Barisione, G.; Barisione, E.; Halilaj, I.; Lovinfosse, P.; Wang, X.; Wu, J.; Lambin, P., Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study. *European Respiratory Journal* **2020**, 2001104. https://erj.ersjournals.com/content/erj/early/2020/06/25/13993003.01104-2020.full.pdf
738. Wu, H.; Zhu, H.; Yuan, C.; Yao, C.; Luo, W.; Shen, X.; Wang, J.; Shao, J.; Xiang, Y., Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China. *JAMA Network Open* **2020,** *3* (6), e2010895-e2010895. https://doi.org/10.1001/jamanetworkopen.2020.10895
739. Wu, J. T.; Leung, K.; Leung, G. M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet* **2020**. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext
740. Wu, L.-P.; Wang, N.-C.; Chang, Y.-H.; Tian, X.-Y.; Na, D.-Y.; Zhang, L.-Y.; Zheng, L.; Lan, T.; Wang, L.-F.; Liang, G.-D., Duration of antibody responses after severe acute respiratory syndrome. *Emerging infectious diseases* **2007,** *13* (10), 1562. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851497/pdf/07-0576_finalD.pdf
741. Xiao, K.; Zhai, J.; Feng, Y.; Zhou, N.; Zhang, X.; Zou, J. J.; Li, N.; Guo, Y.; Li, X.; Shen, X.; Zhang, Z.; Shu, F.; Huang, W.; Li, Y.; Zhang, Z.; Chen, R. A.; Wu, Y. J.; Peng, S. M.; Huang, M.; Xie, W. J.; Cai, Q. H.; Hou, F. H.; Chen, W.; Xiao, L.; Shen, Y., Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. *Nature* **2020**.
742. Xinhua, China detects large quantity of novel coronavirus at Wuhan seafood market http://www.xinhuanet.com/english/2020-01/27/c_138735677.htm.

743. Xinhua, COVID-19 vaccine candidate produced from insect cells to enter human trials. http://en.nhc.gov.cn/2020-08/26/c_81483.htm.
744. Xu, X. K.; Liu, X. F.; Wu, Y.; Ali, S. T.; Du, Z.; Bosetti, P.; Lau, E. H. Y.; Cowling, B. J.; Wang, L., Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection. *Clin Infect Dis* **2020**.
745. Yan, C. H.; Faraji, F.; Prajapati, D. P.; Boone, C. E.; DeConde, A. S., In *Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms*, International Forum of Allergy & Rhinology, Wiley Online Library: 2020.
746. Yan, L.; Shu, K.; Guan, J.; Shanchang, H., Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route. *Zenodo* **2020**. https://zenodo.org/record/4028830#.X3JdatpKiUn
747. Yang, C.; Jiang, M.; Wang, X.; Tang, X.; Fang, S.; Li, H.; Zuo, L.; Jiang, Y.; Zhong, Y.; Chen, Q.; Zheng, C.; Wang, L.; Wu, S.; Wu, W.; Liu, H.; Yuan, J.; Liao, X.; Zhang, Z.; Shi, X.; Geng, Y.; Zhang, H.; Zheng, H.; Wan, M.; Lu, L.; Ren, X.; Cui, Y.; Zou, X.; Feng, T.; Xia, J.; Yang, R.; Liu, Y.; Mei, S.; Li, B.; Yang, Z.; Hu, Q., Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study. *Emerging Microbes & Infections* **2020,** *9* (1), 2368-2378. https://doi.org/10.1080/22221751.2020.1837018
748. Yang, L.; Dai, J.; Zhao, J.; Wang, Y.; Deng, P.; Wang, J., Estimation of incubation period and serial interval of COVID-19: analysis of 178 cases and 131 transmission chains in Hubei province, China. *Epidemiology and Infection* **2020,** *148*, e117. https://www.cambridge.org/core/article/estimation-of-incubation-period-and-serial-interval-of-covid19-analysis-of-178-cases-and-131-transmission-chains-in-hubei-province-china/C1B194C01268F005AAFBE8D50CB5F945
749. Yang, P.; Qi, J.; Zhang, S.; Bi, G.; Wang, X.; Yang, Y.; Sheng, B.; Mao, X., Feasibility of Controlling COVID-19 Outbreaks in the UK by Rolling Interventions. *medRxiv* **2020**, 2020.04.05.20054429. https://www.medrxiv.org/content/medrxiv/early/2020/04/07/2020.04.05.20054429.full.pdf
750. Yap, T. F.; Liu, Z.; Shveda, R. A.; Preston, D. J., A predictive model of the temperature-dependent inactivation of coronaviruses. *Applied Physics Letters* **2020,** *117* (6), 060601. https://aip.scitation.org/doi/abs/10.1063/5.0020782
751. Yehya, N.; Venkataramani, A.; Harhay, M. O., Statewide Interventions and Covid-19 Mortality in the United States: An Observational Study. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa923
752. Yonker, L. M.; Neilan, A. M.; Bartsch, Y.; Patel, A. B.; Regan, J.; Arya, P.; Gootkind, E.; Park, G.; Hardcastle, M.; St. John, A.; Appleman, L.; Chiu, M. L.; Fialkowski, A.; De la Flor, D.; Lima, R.; Bordt, E. A.; Yockey, L. J.; D'Avino, P.; Fischinger, S.; Shui, J. E.; Lerou, P. H.; Bonventre, J. V.; Yu, X. G.; Ryan, E. T.; Bassett, I. V.; Irimia, D.; Edlow, A. G.; Alter, G.; Li, J. Z.; Fasano, A., Pediatric SARS-CoV-2: Clinical Presentation, Infectivity, and Immune Responses. *The Journal of Pediatrics* **2020**. https://doi.org/10.1016/j.jpeds.2020.08.037
753. Young, B. E.; Fong, S.-W.; Chan, Y.-H.; Mak, T.-M.; Ang, L. W.; Anderson, D. E.; Lee, C. Y.-P.; Amrun, S. N.; Lee, B.; Goh, Y. S.; Su, Y. C. F.; Wei, W. E.; Kalimuddin, S.; Chai, L. Y. A.; Pada, S.; Tan, S. Y.; Sun, L.; Parthasarathy, P.; Chen, Y. Y. C.; Barkham, T.; Lin, R. T. P.; Maurer-Stroh, S.; Leo, Y.-S.; Wang, L.-F.; Renia, L.; Lee, V. J.; Smith, G. J. D.; Lye, D. C.; Ng, L. F. P., Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)31757-8
754. Yu, W.-B.; Tang, G.-D.; Zhang, L.; Corlett, R. T., Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. *ChinaXiv* **2020**. http://www.chinaxiv.org/abs/202002.00033

755. Yuki, F.; Eiichiro, S.; Naho, T.; Reiko, M.; Ikkoh, Y.; Yura, K. K.; Mayuko, S.; Konosuke, M.; Takeaki, I.; Yugo, S.; Shohei, N.; Kazuaki, J.; Tadatsugu, I.; Tomimasa, S.; Motoi, S.; Hiroshi, N.; Hitoshi, O., Clusters of Coronavirus Disease in Communities, Japan, January–April 2020. *Emerging Infectious Disease journal* **2020,** *26* (9). https://wwwnc.cdc.gov/eid/article/26/9/20-2272_article
756. Zangmeister, C. D.; Radney, J. G.; Vicenzi, E. P.; Weaver, J. L., Filtration Efficiencies of Nanoscale Aerosol by Cloth Mask Materials Used to Slow the Spread of SARS CoV-2. *ACS Nano* **2020**. https://doi.org/10.1021/acsnano.0c05025
757. Zeng, H.-L.; Lu, Q.-B.; Yang, Q.; Wang, X.; Yue, D.-Y.; Zhang, L.-K.; Li, H.; Liu, W.; Li, H.-J., Longitudinal Profile of Laboratory Parameters and Their Application in the Prediction for Fatal Outcome Among Patients Infected With SARS-CoV-2: A Retrospective Cohort Study. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa574
758. Zhang, J.; Wu, J.; Sun, X.; Xue, H.; Shao, J.; Cai, W.; Jing, Y.; Yue, M.; Dong, C., Associations of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. *Epidemiology and Infection* **2020**, 1-19. https://www.cambridge.org/core/article/associations-of-hypertension-with-the-severity-and-fatality-of-sarscov2-infection-a-metaanalysis/4116FAD7D866737099F976E7E7FAEB15
759. Zhang, L.; Jackson, C. B.; Mou, H.; Ojha, A.; Rangarajan, E. S.; Izard, T.; Farzan, M.; Choe, H., The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. *bioRxiv* **2020**, 2020.06.12.148726. http://biorxiv.org/content/early/2020/06/12/2020.06.12.148726.abstract
760. Zhang, Q.; Zhang, H.; Huang, K.; Yang, Y.; Hui, X.; Gao, J.; He, X.; Li, C.; Gong, W.; Zhang, Y.; Peng, C.; Gao, X.; Chen, H.; Zou, Z.; Shi, Z.; Jin, M., SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation. *bioRxiv* **2020**, 2020.04.01.021196. http://biorxiv.org/content/early/2020/04/03/2020.04.01.021196.abstract
761. Zhang, T.; Wu, Q.; Zhang, Z., Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. *Current Biology* **2020,** *30* (7), 1346-1351.e2. http://www.sciencedirect.com/science/article/pii/S0960982220303602
762. Zhang, X.; Tan, Y.; Ling, Y.; Lu, G.; Liu, F.; Yi, Z.; Jia, X.; Wu, M.; Shi, B.; Xu, S.; Chen, J.; Wang, W.; Chen, B.; Jiang, L.; Yu, S.; Lu, J.; Wang, J.; Xu, M.; Yuan, Z.; Zhang, Q.; Zhang, X.; Zhao, G.; Wang, S.; Chen, S.; Lu, H., Viral and host factors related to the clinical outcome of COVID-19. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2355-0
763. Zhang, Y.; Muscatello, D.; Tian, Y.; Chen, Y.; Li, S.; Duan, W.; Ma, C.; Sun, Y.; Wu, S.; Ge, L.; Yang, P.; Jia, L.; Wang, Q.; MacIntyre, C. R., Role of presymptomatic transmission of COVID-19: evidence from Beijing, China. *Journal of Epidemiology and Community Health* **2020**, jech-2020-214635. https://jech.bmj.com/content/jech/early/2020/08/26/jech-2020-214635.full.pdf
764. Zhao; Musa; Lin; Ran; Yang; Wang; Lou; Yang; Gao; He; Wang, Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. *Journal of Clinical Medicine* **2020,** *9* (2), 388.
765. Zhao, G.; Jiang, Y.; Qiu, H.; Gao, T.; Zeng, Y.; Guo, Y.; Yu, H.; Li, J.; Kou, Z.; Du, L.; Tan, W.; Jiang, S.; Sun, S.; Zhou, Y., Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. *PLoS One* **2015,** *10* (12), e0145561. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689477/pdf/pone.0145561.pdf
766. Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; Qian, S.; Hong, C.; Wang, F.; Liu, Y.; Wang, Z.; He, Q.; He, B.; Zhang, T.; Ge, S.; Liu, L.; Zhang, J.; Xia, N.; Zhang, Z., Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546052#
767. Zhao, L.; Qi, Y.; Luzzatto-Fegiz, P.; Cui, Y.; Zhu, Y., COVID-19: Effects of Environmental Conditions on the Propagation of Respiratory Droplets. *Nano Letters* **2020,** *20* (10), 7744-7750. https://doi.org/10.1021/acs.nanolett.0c03331

768. Zhen-Dong, T.; An, T.; Ke-Feng, L.; Peng, L.; Hong-Ling, W.; Jing-Ping, Y.; Yong-Li, Z.; Jian-Bo, Y., Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerging Infectious Disease journal* **2020,** *26* (5). https://wwwnc.cdc.gov/eid/article/26/5/20-0198_article
769. Zhongchu, L., The sixth press conference of "Prevention and Control of New Coronavirus Infected Pneumonia". Hubei Provincial Government: 2020.
http://www.hubei.gov.cn/hbfb/xwfbh/202001/t20200128_2015591.shtml
770. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*.
https://doi.org/10.1016/S0140-6736(20)30566-3
771. Zhou, H.; Chen, X.; Hu, T.; Li, J.; Song, H.; Liu, Y.; Wang, P.; Liu, D.; Yang, J.; Holmes, E. C.; Hughes, A. C.; Bi, Y.; Shi, W., A novel bat coronavirus reveals natural insertions at the S1/S2 cleavage site of the Spike protein and a possible recombinant origin of HCoV-19. *bioRxiv* **2020**, 2020.03.02.974139.
https://www.biorxiv.org/content/biorxiv/early/2020/03/11/2020.03.02.974139.full.pdf
772. Zhou, L.; Yao, M.; Zhang, X.; Hu, B.; Li, X.; Chen, H.; Zhang, L.; Liu, Y.; Du, M.; Sun, B.; Jiang, Y.; Zhou, K.; Hong, J.; Yu, N.; Ding, Z.; Xu, Y.; Hu, M.; Morawska, L.; Grinshpun, S. A.; Biswas, P.; Flagan, R. C.; Zhu, B.; Liu, W.; Zhang, Y., Breath-, air- and surface-borne SARS-CoV-2 in hospitals. *Journal of Aerosol Science* **2020**, 105693. http://www.sciencedirect.com/science/article/pii/S0021850220301786
773. Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.; Shi, Z.-L., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv* **2020**, 2020.01.22.914952.
https://www.biorxiv.org/content/biorxiv/early/2020/01/23/2020.01.22.914952.1.full.pdf
774. Zhu, F.-C.; Guan, X.-H.; Li, Y.-H.; Huang, J.-Y.; Jiang, T.; Hou, L.-H.; Li, J.-X.; Yang, B.-F.; Wang, L.; Wang, W.-J.; Wu, S.-P.; Wang, Z.; Wu, X.-H.; Xu, J.-J.; Zhang, Z.; Jia, S.-Y.; Wang, B.-S.; Hu, Y.; Liu, J.-J.; Zhang, J.; Qian, X.-A.; Li, Q.; Pan, H.-X.; Jiang, H.-D.; Deng, P.; Gou, J.-B.; Wang, X.-W.; Wang, X.-H.; Chen, W., Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)31605-6
775. Zhu, J.; Wu, C.; Wu, L., Associations between genetically predicted protein levels and COVID-19 severity. *J Infect Dis* **2020**.
776. Zhu, S.; Zong, Z., Why did so few healthcare workers in China get COVID-19 infection. *QJM: An International Journal of Medicine* **2020**.
777. Zietz, M.; Zucker, J.; Tatonetti, N. P., Associations between blood type and COVID-19 infection, intubation, and death. *Nature Communications* **2020,** *11* (1), 5761. https://doi.org/10.1038/s41467-020-19623-x
778. Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H.-L.; Peiris, M.; Wu, J., SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* **2020**.
https://www.nejm.org/doi/full/10.1056/NEJMc2001737
779. Zuo, J.; Dowell, A.; Pearce, H.; Verma, K.; Long, H.; Begum, J.; Aiano, F.; Amin-Chowdhury, Z.; Hallis, B.; Stapley, L.; Borrow, R.; Linley, E.; Ahmad, S.; Parker, B.; Horsley, A.; Amirthalingam, G.; Brown, K.; Ramsay, M. E.; Ladhani, S.; Moss, P., Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection. *bioRxiv* **2020**, 2020.11.01.362319.
https://www.biorxiv.org/content/biorxiv/early/2020/11/02/2020.11.01.362319.full.pdf
780. Zuo, Y.; Estes, S. K.; Ali, R. A.; Gandhi, A. A.; Yalavarthi, S.; Shi, H.; Sule, G.; Gockman, K.; Madison, J. A.; Zuo, M.; Yadav, V.; Wang, J.; Woodard, W.; Lezak, S. P.; Lugogo, N. L.; Smith, S. A.; Morrissey, J. H.;

Kanthi, Y.; Knight, J. S., Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. *Science Translational Medicine* **2020**, eabd3876. https://stm.sciencemag.org/content/scitransmed/early/2020/11/02/scitranslmed.abd3876.full.pdf
781. Zydus, Novel Corona Virus-2019-nCov vaccine by intradermal route in healthy subjects. . http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306&EncHid=&userName=vaccine.